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Toxicology, once said to be the science of poisons, is presently defined by The 
Society of Toxicology as “the study of the adverse effects of chemical, physical or 
biological agents on living organisms and the ecosystem, including the prevention and 
amelioration of such adverse effects”. It is therefore an inherently multidisciplinary 
subject that encompasses many areas, such as chemistry, biology and pharmacology. 
Free radical toxicology is a very relevant and emerging field in Toxicology. 
During the past three decades, a remarkable rise of new information implicating reactive 
species in the mechanisms of action of many toxicants and pathological phenomena has 
driven an increasing interest of this scientific area. This thesis, by aiming at developing 
and studying antioxidant compounds, gathers concepts of chemistry and biology 
towards the discovery of novel approaches to overcome toxicity of oxidative stress-
related conditions. Carrying out my PhD thesis in such a multidisciplinary area of 
research was very motivating, absorbing and challenging since the very beginning. The 
results presented herein contribute to the understanding of superoxide dismutase 
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Superoxide anion, along with other reactive species, is involved in many 
toxicological processes, as well as in a number of pathophysiological phenomena. 
Superoxide dismutase mimetics (SODm), i.e., synthetic compounds that mimic the 
functional properties of superoxide dismutase converting O2
•–
 to H2O2 and O2, have thus 
emerged as prospective pharmaceutical candidates to overcome toxicity in oxidative 
stress-related conditions. Several metal-containing compounds were previously shown 
to possess SOD-like activity. This thesis is focused on two promising classes of 
macrocyclic complexes: manganese(III) porphyrins (MnPs) and macrocyclic copper(II) 
complexes. 
The effects of MnTM-4-PyP, a para-substituted MnP, against the cell injury 
induced by three different oxidants were evaluated in V79 cells. This MnP protected 
against the cytotoxicity and increase in intracellular O2
•–
 levels induced by the xanthine-
xanthine oxidase system (XXO; an extracellular O2
•–
 generator) and by tert-
butylhydroperoxide (TBHP; an analogue of lipid hydroperoxides). However, MnTM-4-
PyP did not show considerable protection against the anticancer drug doxorubicin (Dox) 
that, among other mechanisms of cytotoxicity, generates O2
•–
 intracellularly. The effects 
of MnTM-4-PyP were not observed at the cell division level, as shown by the mitotic 
index analysis. The results of this well established SODm in XXO- and TBHP-treated 
cells permitted the validation of cell-based models of oxidative stress to be used in the 
evaluation of the macrocyclic copper(II) complexes developed within the scope of this 
thesis. 
Two optimized ortho-substituted MnPs, MnTE-2-PyP and MnTnHex-2-PyP, 
were also studied in this thesis and their role against TBHP-induced cell injury was 
evaluated. The two MnPs, even at low concentrations, counteracted remarkably the 
effects of TBHP in cell viability and intracellular O2
•–
 levels. While the exposure of V79 
cells to TBHP resulted in a significant depletion of total and reduced glutathione and in 
an increase in GSSG, MnPs augmented markedly the total and reduced glutathione 
contents in TBHP-treated cells. 
 Two sets of macrocyclic copper(II) complexes, without (CuL1-CuL5) or with a 
pyridine ring in the macrocyclic backbone (CuL6-CuL9), were synthesized and 
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evaluated in vitro for their O2
•–
 scavenging ability. The complexes were chemically 
characterized in order to correlate their biochemical activity with thermodynamic, 
structural and electrochemical features. The complexes CuL3, CuL4 and CuL8 were 
selected to be further evaluated in cell-based assays since they presented high 
thermodynamic stability and effective ability to scavenge O2
•–
, and were devoid of 
significant cytotoxicity. These complexes did not show considerable antioxidant 
activities in the oxidative stress models previously validated (XXO and TBHP). CuL3, 
CuL4 and CuL8 were also studied as redox modulators of anticancer drugs. The three 
complexes were shown to undergo Fenton chemistry in vitro. However, CuL3 and 
CuL4 did not potentiate the cytotoxicity of Dox in breast carcinoma (MCF7) cells. 
Conversely, CuL8 was shown to improve the therapeutic window of Dox, and 
especially of oxaliplatin, by both protecting non-tumoral human mammary cells 
(MCF10A) and boosting the cytotoxic effects in breast carcinoma cells. 
The results presented in this thesis contribute to the comprehension of SODm as 
promising pharmaceutical agents both for antioxidant and cancer therapies, reinforcing 
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A produção de espécies reactivas, nomeadamente de O2
•–
, está associada a 
diversos fenómenos toxicológicos e fisiopatológicos. Entre estes, destacam-se os 
processos de lesão tecidular e inflamação, os quais são factores etiológicos chave num 
grande número de patologias, incluindo isquémia-reperfusão, aterosclerose, cancro, 
lesão por radiação, doenças neurodegenerativas, doenças inflamatórias pulmonares, 
intestinais e cardiovasculares, entre outras. A remoção de O2
•–
 pode ser assim uma via 
importante para modular um vasto número de fenómenos patológicos. As enzimas 
superóxido dismutases (SOD), que catalizam a reacção de dismutação do O2
•–
 em H2O2 
e O2, são metaloproteínas com um papel fulcral na defesa contra o excesso de espécies 
reactivas. Estudos pré-clínicos e clínicos com SOD têm demonstrado protecção contra 
os efeitos nocivos de várias situações de stress oxidativo. No entanto, a utilização 
clínica da enzima nativa apresenta diversas limitações. Tendo em conta que a remoção 
de O2
•–
 permite minorar fenómenos inflamatórios, e de modo a ultrapassar as limitações 
do uso da SOD nativa, têm sido desenvolvidos nos últimos anos compostos de baixo 
peso molecular com a capacidade de mimetizar as propriedades funcionais da SOD. 
Estes compostos designam-se usualmente por SOD miméticos (SODm). Várias classes 
de SODm têm sido desenvolvidas, tendo demonstrado efeitos benéficos notáveis em 
diferentes modelos de stress oxidativo, quer em cultura de células, quer em modelos 
animais. A maioria destes compostos contém um ião metálico no seu centro activo, 
habitualmente Mn(III), Mn(II), Cu(II) ou Fe(III), o qual é estabilizado por coordenação 
com um ligando. A utilização de ligandos macrocíclicos tem revelado vantagens em 
termos de estabilidade termodinâmica e actividade catalítica. Neste âmbito, a presente 
tese incide sobre duas classes de complexos macrocíclicos com actividade mimética da 
SOD: porfirinas de Mn(III) (MnPs) e complexos macrocíclicos de Cu(II). 
A classe das MnPs contém os SODm mais potentes e estáveis desenvolvidos até 
ao momento. Apesar de serem amplamente estudados, os efeitos ao nível celular destes 
compostos ainda não são totalmente conhecidos. A porfirina para-substituída MnTM-4-
PyP é um SODm de eficácia bem estabelecida, disponível comercialmente, que tem 
vindo a ser estudado em vários modelos de situações fisiopatológicas. Os papel deste 
SODm face à toxicidade induzida por três oxidantes, cujos mecanismos de toxicidade 
diferem nas espécies reactivas envolvidas e no local de formação destas, foi avaliado em 
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células V79, uma linha celular de fibroblastos de pulmão de hamster chinês. Os 
sistemas oxidantes estudados foram: xantina-xantina oxidase (XXO), um gerador 
extracellular de O2
•–
;  tert-butilhidroperóxido (TBHP), um análogo de cadeia curta dos 
hidroperóxidos lipídicos; e o fármaco citotóxico Doxorrubicina (Dox) que, entre outros 
mecanismos, gera O2
•–
 intracelularmente. A porfirina MnTM-4-PyP demonstrou efeitos 
protectores muito significativos face à XXO e ao TBHP, quer em termos de viabilidade 
celular (avaliada através dos ensaios MTT e Violeta cristal), quer no que respeita aos 
níveis intracelulares de O2
•–
 (avaliados por fluorimetria, com a sonda dihidroetídio - 
DHE). No entanto, a análise do índice mitótico demonstrou que o efeito protector da 
MnP não foi observado ao nível da divisão celular. Relativamente à Dox, não se 
verificaram efeitos protectores consideráveis na presença de MnTM-4-PyP. Através dos 
resultados obtidos para os sistemas TBHP e XXO, estabeleceram-se protocolos para 
avaliar os possíveis efeitos antioxidantes dos complexos macrocíclicos de cobre(II) 
desenvolvidos no âmbito desta tese. 
Estudos de relação estrutura-actividade anteriormente realizados na Duke 
University deram origem aos compostos MnTE-2-PyP e MnTnHex-2-PyP, duas MnPs 
optimizadas substituídas na posição orto, que apresentam uma elevada actividade 
catalítica. O efeito destas MnPs em células V79 expostas a TBHP foi avaliado. Ambas 
as MnPs, mesmo em concentrações muito baixas, revelaram uma capacidade notável 
para reverter o decréscimo de viabilidade celular induzido por este oxidante. Em relação 
aos níveis intracelulares de O2
•–
, o efeito protector das MnPs foi também muito 
significativo. Foram ainda estudados os efeitos destas MnPs ao nível do glutationo. Em 
células expostas a TBHP observou-se uma depleção acentuada de glutationo total 
(quantificado pelo ensaio DTNB) e reduzido (avaliada por fluorimetria, usando a sonda 
monoclorobimano). Observou-se ainda um aumento considerável da proporção de 
glutationo na forma oxidada (pelo método DTNB). Em culturas simultaneamente 
tratadas com TBHP e MnTE-2-PyP ou MnTnHex-2-PyP, registou-se um aumento muito 
significativo nos níveis de glutationo total, assim como da forma reduzida, 
restabelecendo-se o equilíbrio do estado redox das células. 
A segunda parte da presente tese é dedicada ao desenvolvimento e estudo de 
complexos macrocíclicos de cobre(II) com actividade mimética da SOD. Apesar de 
terem sido já estudados muitos complexos de Cu(II) para este fim, a descoberta de 
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novos complexos com elevada estabilidade e actividade, juntamente com baixa 
toxicidade constitui ainda um desafio. Foram assim sintetizados dois tipos de 
complexos macrocíclicos de cobre(II), contendo ou não um grupo piridínico no anel 
macrocíclico. Para o primeiro grupo de complexos (CuL1-CuL5), os respectivos 
ligandos foram sintetizados pelo método de Richman e Atkins, seguido da remoção dos 
grupos protectores por cisão reductiva. No caso do segundo tipo de complexos (CuL6-
CuL9), contendo um grupo piridínico no anel macrocíclico, recorreu-se a um processo 
de ciclização assistida por ião metálico para a obtenção dos ligandos. Os ligandos 





RMN). A estabilidade termodinâmica dos respectivos complexos de cobre(II) foi 
avaliada por técnicas potenciométricas. Foram ainda realizados estudos estruturais 
(ressonância paramagnética electrónica e absorção na região do visível) e 
electroquímicos (por voltametria cíclica), com o objectivo de correlacionar as 
propriedades químicas dos complexos com a respectiva capacidade de degradar O2
•–
. A 
avaliação desta actividade sequestradora de O2
•–
 dos complexos foi realizada in vitro, 
por dois métodos diferentes: a redução do NBT e a oxidação do DHE. Com base nestes 
estudos seleccionaram-se os complexos com elevada estabilidade termodinâmica, 
actividade sequestradora de O2
•–
 efectiva e baixa citotoxicidade, para serem estudados 
mais aprofundadamente em ensaios celulares. As capacidades antioxidantes dos 
complexos CuL4, CuL5 e CuL8, foram então avaliadas nos dois modelos de stress 
oxidativo previamente validados (XXO e TBHP). No entanto, não se observaram efeitos 
protectores consideráveis face a estes sistemas oxidantes. 
Os compostos com actividade mimética da SOD têm-se também revelado 
promissores adjuvantes em quimio- e radioterapia, quer por poderem potenciar a acção 
antitumoral destes regimes, quer pela possibilidade de protegerem o tecido não tumoral 
dos seus efeitos adversos. Assim, foram realizados estudos no sentido de avaliar uma 
possível utilização dos complexos CuL3, CuL4 e CuL8 no contexto do cancro da mama. 
Muitos dos complexos de cobre(II), para além de dismutarem o O2
•–
, podem reagir com 
o H2O2 formado produzindo HO
•
, o que poderá ter vantagens na supressão da 
proliferação de células tumorais. Os três complexos foram assim avaliados pelo ensaio 
de clivagem do DNA plasmídico, tendo demonstrado capacidade de gerar HO
•
. No 
entanto, os complexos CuL3 e CuL4 não potenciaram a citotoxicidade da Dox em 
células humanas de carcinoma da mama (MCF7). Por outro lado, o complexo CuL8 
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revelou a capacidade de modulação redox dos efeitos da Dox e, sobretudo da 
oxaliplatina, em células mamárias humanas. Este complexo exerceu um efeito 
citoprotector em células mamárias não tumorais (MCF10A) e potenciou o efeitos dos 
fármacos citotóxicos nas células tumorais MCF7. O complexo CuL8, ao melhorar a 
janela terapêutica dos fármacos antitumorais Dox e oxaliplatina, poderá ser útil como 
adjuvante em regimes quimioterápicos e deverá ser mais estudado neste sentido. 
Em suma, o desenvolvimento de SODm é uma área em grande expansão, dadas 
as múltiplas oportunidades terapêuticas destes compostos. Os resultados descritos na 
presente tese contribuem para um conhecimento mais aprofundados dos efeitos dos 
SODm quer em terapêutica antioxidante, quer em terapêutica antitumoral, reforçando o 
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1.1. Oxidative stress and reactive oxygen species 
The term “oxidative stress” can be defined as an imbalance between oxidants and 
antioxidants in favor of the oxidants, potentially leading to damage [1]. Oxidants are 
formed as normal products of aerobic metabolism and their production is balanced by 
the antioxidant defenses [1]. Under pathophysiological conditions, due to an increased 
production of oxidants or to a failure of antioxidant defenses, oxidative damage may 
occur [2]. Oxidative damage seems to be implicated in several pathological processes 
including tissue injury, inflammatory disorders, cardiovascular diseases, pulmonary 
diseases, neurodegenerative diseases, and cancer [3, 4]. 
The collective term reactive species (RS) includes oxygen, nitrogen, chlorine, 
bromine and sulphur transient species with high chemical reactivity [4, 5]. These 
include free radicals, i.e., species containing one or more unpaired electrons, and non-
radical derivatives [4]. Reactive oxygen species (ROS) encompass a variety of diverse 
chemical species including superoxide anion (O2
•–
), hydroxyl radical (HO
•
), hydrogen 
peroxide (H2O2), singlet oxygen (
1
O2), alkoxyl radicals (RO
•
), and peroxyl radicals 
(ROO
•




, are extremely unstable and reactive. In 
contrast, other ROS like H2O2 or ROO
• 
are relatively stable, with half-lives in the range 
of seconds. These species may diffuse away from their site of generation, transporting 
the radical or oxidant function to other target sites [1, 6]. Reactive nitrogen species 
(RNS), such as peroxynitrite (ONOO
-
), are also relevant in numerous 
pathophysiological phenomena [7, 8]. Fig. 1.1 shows the generation pathways of ROS. 
Superoxide anion is formed in biological systems by the partial reduction of molecular 
oxygen. Reduction of O2
•– 
with a second electron, as well as a two-electron reduction of 
O2, generates O2
2-
, which leads to H2O2. The one-electron reduction of H2O2, that 
occurs in the presence of reduced transition metals like Cu(I) and Fe(II), originates HO
• 
[9, 10]. Other reactive species can be generated by the reaction of ROS with biological 
molecules (e.g. polyunsaturated lipids, thiols and nitric oxide (NO)) [3]. For example, 
the reaction between O2
•–
 and NO originates ONOO
-
, which is unstable at physiological 
pH and rapidly decomposes to form potent nitrating and oxidizing species [3, 4]. Other 
species that result from the reaction of RS with biomolecules are the radicals alkoxyl 
and peroxyl [11]. These can be generated by a variety of routes, including the reaction 
3 
 
of lipid peroxides with HO2
•
, the breakdown of organic peroxides, and the reaction of 
RS with lipids or amino acid radicals [4, 11].  
 
Fig. 1.1 – Generation of the most relevant reactive oxygen species (adapted from [3]). 
 
ROS can be generated as a result of normal intracellular metabolism. The 
majority of intracellular ROS production is derived from the mitochondria [6]. In fact, 
O2
•–
 is formed from the uncoupling of the mitochondrial electron transport chain during 
oxidative phosphorylation [3, 10]. Also, the catalytic action of a variety of intracellular 
and extracellular oxidases like NADPH oxidase, xanthine oxidase or lipooxygenase, as 
well as the metabolism of arachidonic acid, gives rise to O2
•–
 [4, 7]. Superoxide can also 
be produced by the phagocytic NADPH oxidase, during host defense responses, where 
O2
•–
 is thought to act in cell-signaling and in the killing of foreign bacteria [3, 8, 10]. 
Other ROS are also generated in peroxisomes, as well as from a variety of cytosolic 
enzyme systems [6, 10]. Other process closely related with ROS formation is the lipid 
peroxidation (LPO), i.e., the oxidative deterioration of polynsaturated lipids (Fig. 1.2)  








) to an unsaturated 
lipid or by hydrogen abstraction from a methylene group by a RS, forming a carbon 
radical. Carbon radicals often stabilize by molecular rearrangement generating 



















). These radicals can abstract H
•
 from an adjacent lipid, propagating the process. 




 generates a lipid hydroperoxide (LOOH). The 





that may also abstract H
•
 from unsaturated lipids, continuing the 
propagation of LPO. These phenomena may occur in biological membranes, leading to 
oxidative damage. In fact, the continued oxidation of fatty-acid side chains and their 
fragmentation to produce aldehydes and hydrocarbons may lead to loss of membrane 
integrity. In addition, products of lipid peroxidation (e.g. isoprostanes, 
malondialdehyde, 4-hydroxynonenal) may exert themselves deleterious effects [4], 
namely DNA damage and inhibition of proteins, leading to cytotoxicity, allergy, 







Fig. 1.2 – Basic reaction 
sequence of lipid 
peroxidation (adapted from 



















































Despite the endogeneous sources of ROS, a number of external agents can trigger 
ROS production [6]. Different types of radiation, like X-rays, ultraviolet, ultrasound, 
microwave, and ionizing radiation are known to generate ROS [1, 6]. Also, 
chemotherapeutic agents, hyperthermia, inflammatory cytokines and environmental 
toxins can shift cells into a state of oxidative stress [6]. 
Although high concentrations of ROS trigger oxidative damage, low concentrations 
of ROS are needed to regulate several key physiological processes [9, 10, 15]. These 
include cell differentiation, cell proliferation and apoptosis that are regulated by redox-
sensitive signal transduction pathways [9, 10, 15]. 
 
1.1.1. Antioxidant defences 
The production of ROS is counteracted by an intricate antioxidant defense system 
[6, 9]. An antioxidant has been defined as a substance that, when present at low 
concentrations compared with those of an oxidizable substrate, significantly delays or 
prevents oxidation of that substrate [2, 4, 11]. More recently, Halliwell and Gutteridge 
[4] altered this definition in order to account chaperones, repair systems and inhibitors 
of RS generation. An antioxidant is presently defined as any substance that delays, 
prevents or removes oxidative damage to a target molecule [4]. This concept includes 
non-enzymatic compounds, as well as antioxidant enzymes [1]. 
Non-enzymatic antioxidant defenses comprise a number of low molecular weight 
molecules with the ability to scavenge ROS [6, 10]. These include compounds 
synthesized in vivo (e.g. glutathione, bilirubin, pyruvate, melatonin, coenzyme Q, uric 
acid), as well as agents obtained from the diet (e.g. ascorbate, tocopherol, carotenoids, 
flavonoids) [4]. 
Eukaryotic cells possess an efficient antioxidant enzymatic network, as depicted in 
Fig. 1.3. The three major classes of antioxidant enzymes are the superoxide dismutases 





Fig. 1.3 – Enzymatic antioxidant defenses: role of superoxide dismutases (SOD), 
catalases (CAT), glutathione peroxidases (GPx), glutathione reductase (GR), glucose-6-
phosphate dehydrogenase (G-6-PDH), and NADP
+
-dependent isocitrate dehydrogenase 
(ICD) on ROS detoxification (adapted from [9, 15]). 
 
Superoxide dismutase (SOD) 
Superoxide dismutases, which enzymatic activity was discovered in 1969 by 
McCord and Fridovich, are metalloproteins with oxido-reductase capacity that catalyze 
the dismutation of O2
•–
 [16]. A dismutation reaction is defined as a reaction in which 
two like-molecules react to produce two different products (i.e. A + A → B + C) [3]. In 
the case of SOD, oxygen and H2O2 are formed from two O2
•–






 → O2 + M
n +







 → H2O2 + M
(n+1)+
  (Eq 2) 
Net reaction: 2O2
•–
 → O2 + H2O2 
O2


















The oxidized form of the metalloenzyme SOD (M
(n+1)+
) reacts with one O2
•–
 to 
form O2 and generate the reduced form of the enzyme (M
n+
) (Eq 1). In the second step 
of the dismutation reaction, the reduced enzyme reacts with another O2
•–
 and two 
protons to form H2O2, regenerating the oxidized form of the enzyme (Eq 2). 
Three different isoforms of SOD have been characterized in mammals. The SOD 
enzymes have a distinct genomic structure and are well compartmentalized [8]. Table 
I.1 summarizes the differences between the three SOD isoforms. 
 
Table I.1 – Types of SOD enzymes in mammals [4, 5, 8]. 
 SOD1 SOD2 SOD3 (EC-SOD) 
Active center Cu(II)/(I) and Zn(II) Mn(III)/(II) Cu(II)/(I) and Zn(II) 
Protein 
Structure 
Homodimer Homotetramer Tetrameric glycoprotein 










lymph, synovial fluid) 
 
 
The involvement of the three SOD isoforms in several pathological conditions 
has been unraveled by modulating the expression of the enzymes using knockout and 
transgenic models [8]. Down-regulation of SOD1 has been associated with neuronal 
death, reduced fertility and increased susceptibility to paraquat toxicity [5, 8]. On the 
other hand, the overexpression of this enzyme in transgenic mice was shown to protect 
the cerebral tissue in pathological conditions such as ischemia or Parkinson’s disease 
[8]. Loss or reduction of the SOD2 activity has been associated with neurodegeneration, 
heart failure, and dilated cardiomyopathy [5, 8, 12]. The importance of SOD2 is also 
highlighted by the fact that, in contrast to SOD1 and SOD3, the SOD2 knock-out mice 
do not survive past 3 weeks of age [5, 12]. Furthermore, SOD2 gene has several 
polymorphisms which result in a reduction of the enzyme activity and were shown to be 
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associated with an increased risk of sporadic motor neuron disease, nonfamilial 
idiopathic cardiomyopathy, breast cancer and reduction of the tumour-suppressive effect 
of SOD2 [8, 17]. Studies with SOD3 knockout mice have shown that the loss of this 
enzyme activity is related to an impaired spatial learning and an increased sensitivity to 
hyperoxia exposure [8] 
Further classes of SOD have been identified, namely nickel-containing SODs in 
Streptomyces sp. and some cyanobacteria, and iron-containing SODs in bacteria, algae, 
trypanosomes and higher plants [4, 5]. 
 
Catalase (CAT) 
CAT enzymes are present in the peroxisomes of most aerobes and catalyze the 
direct decomposition of H2O2 to ground-state O2 [4]. In animals, CAT is present in all 
organs and it is most concentrated in liver, kidney and erythrocytes [4, 18]. Human 
CAT is a tetrameric haemin-enzyme consisting of four identical subunits of 60 kDa, 
each containing Fe(III)-haem at its active site [4, 5, 18]. Its gene is located in 
chromosome 11, band p13 [18]. 
CAT enzymes catalyze the dismutation of H2O2. In fact, H2O2 oxidizes the heme 
iron of the resting enzyme to form an oxyferryl group with a π-cationic porphyrin 
radical, termed Compound I (Eq 3). This step is followed by oxidation of a second 
molecule of H2O2 by Compound I (Eq 4) [19]. The catalatic rate of mammalian CAT is 
among the highest of known enzymatic rates, and it is simply proportional to H2O2 













=O)  + H2O2 → CAT (Por-Fe
III
) + H2O + O2 (Eq 4) 




Glutathione peroxidases (GPx) 
Peroxidases remove H2O2 by using it to oxidize another substrate [4]. GPx 
are selenium-containing peroxidases that degrade a variety of peroxides, namely H2O2 
(Eq 5) and ROOH (Eq 6), by coupling their reduction with the oxidation of reduced 
glutathione (GSH) [4, 5]. 
2 H2O2 + 2 GSH → GSSG + 2 H2O   (Eq 5) 
ROOH + 2 GSH → GSSG + H2O + ROH  (Eq 6) 
 
GPx enzymes are widely distributed in animal tissues [4]. Four isoenzymes have 
been identified in humans, being the level of each isoform dependent of the tissue type 
[4, 5]. The classical GPx (GPx1) is cytosolic. GPx2 is an isoform present in the gastro-
intestinal tract. In plasma and other extracellular fluids, a different isoenzyme (GPx3) is 
found. The fourth type is the phospholipid hydroperoxide glutathione peroxidase 
(PHGPx or GPx4), which has the ability to act upon peroxidized fatty acid residues 
within membranes and lipoproteins [4]. GPx4 is a monomer, while GPx1, GPx2 and 
GPx3 are tetramers. Each protein unit contains a selenium atom in the active site, in the 
form of selenocysteine. The catalytic activity of GPx is schematized in Fig. 1.4. During 
GPx catalysis, the selenol form of the enzyme is oxidized to selenenic acid by 
peroxides. This form reacts with reduced glutathione (GSH) to give H2O and a 
selenosulphide adduct. A second GSH molecule then regenerates the active form of the 





Fig. 1.4 – Catalytic cycle 
of glutathione peroxidase 














The catalytic activity of GPx involves the oxidation of GSH in GSSG. However, 
in physiological conditions, the cellular ratio GSH/GSSG is high, because GSSG is 
reduced back to GSH by glutathione reductase (GR) [1, 4]. The catalytic activity of this 
enzyme requires NADPH, according to the following reaction (Eq 7): 
GSSG + NADPH + H
+
 → 2 GSH + NADP
+  
(Eq 7) 
Cellular NADPH can be provided by different sources, including Glucose-6-
phosphate dehydrogenase (G-6-PDH) and NADP
+
-dependent isocitrate dehydrogenase 
(ICD) (Fig. 1.3) [4]. 
In addition to being a cofactor for GPx enzymes, GSH plays other important 





O2 [10, 21]. Moreover, it is used by glutathione S-transferases (GSTs) 
to conjugate and eliminate reactive compounds, including products formed in vivo 
during oxidative stress [1, 4, 10, 21, 22]. Glutathione is also able to regenerate 
important antioxidants (e.g. Vitamins C and E) back to their active forms, being this 
capacity linked with the redox state of the glutathione disulphide-glutathione couple 
(GSSG/2GSH) [10]. This redox couple is a major contributor to the redox state of the 
cellular milieu. In a non-stressed cell, glutathione is present in the cytosol at a 
concentration between 1 and 10 mM, being ~99% in the form of GSH and ~1% as 




1.1.2. Consequences of oxidative stress 
A situation of oxidative stress, due to diminished antioxidant defenses or to an 
increase in the production of RS, may induce different cellular responses. These 
responses depend on the cell type and the severity of oxidative stress. As summarized in 
Fig. 1.5 mild oxidative stress may induce cell proliferation, while intense oxidation will 
result in cell injury and can even trigger cell death [4]. 
 
 
Fig. 1.5 – Cellular responses to oxidative stress. Many cells respond to mild oxidative 
stress by proliferating. As oxidative stress increases, cells may up-regulate their defense 
systems as an adaptive response. Greater oxidative stress will lead to damage in 
biomolecules such as DNA, proteins, lipids, or carbohydrates, resulting in oxidative cell 
injury. Cells may recover from this damage by repairing it or displacing the damaged 
molecules, or they can survive with persistent lesions. In case of intense oxidative 
stress, cells may become senescent, i.e., they survive but are no longer able to divide. 
Under highly oxidizing conditions, mechanisms of cell death (apoptosis and necrosis) 



























Activation of transcription factors
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Pro-inflammatory action of superoxide 
Under physiological circumstances, the levels of O2
•–
 are kept under tight control by 
endogenous SOD [7]. However, in acute and chronic inflammation, the production of 
O2
•–
 is increased at a rate that may overwhelm the capacity of the endogenous SOD to 
remove it. This imbalance results in superoxide-mediated damage [7, 8]. Some 
important pro-inflammatory roles for O2
•–
 have been described [5, 7, 8] (Fig. 1.6), 
namely: 
 endothelial cell damage and increased microvascular permeability; 
 formation of chemotactic factors; 
 recruitment of neutrophils at sites of inflammation; 
 auto-catalytic destruction of neurotransmitters and hormones; 
 lipid peroxidation and oxidation; 
 DNA single-strand damage and activation of poly-ADP-ribose polymerase (PARP); 
 formation of peroxynitrite, a potent cytotoxic RS that can nitrate and deactivate SOD 
and that causes the inactivation of nitric oxide; 
 reduction of Fe(III) to Fe(II) with its consequent release from storage sites, so that it 





Fig. 1.6 – Different roles of O2
•–
 in inflammation. Excessive production of O2
•–
 can lead 
to inflammation through various pathways, including the depletion of beneficial NO and 
the generation of deleterious ONOO
-




















These phenomena lead to tissue injury and inflammation that are involved in 
many diseases. Table I.2 presents some pathological conditions in which the 
involvement of superoxide anion has been suggested. 
 
Table I.2 – Clinical conditions in which the involvement of superoxide anion has been 
suggested [7, 8, 23]. 
Category Examples 
Inflammatory conditions Pain, Crohn’s disease, osteoarthritis, dermatitis, psoriasis  
Cardiovascular diseases Ischemia-reperfusion injury, shock, atherosclerosis, 
stroke 
Neurodegenerative diseases Parkinson’s, Alzheimer, amiotrophic lateral sclerosis  
Pulmonary diseases Asthma, hyperoxic lung damage, chronic obstructive 
pulmonary disease  
Oncology Side effects of chemotherapy and radiotherapy 
Reproductive system Erectile dysfunction, infertility 
 
Additionally to the phenomena described above, O2
•–
 also seems to be involved in 
the processes of cell transformation, metastasis and angiogenesis [16]. 
The exposure to a number of xenobiotics may also result in the release and/or 
generation of O2
•–
, being their toxic effects related with oxidative stress. This O2
•–
 
generation from xenobiotics can occur directly or upon metabolization, redox reactions, 
redox cycling processes, via lipid peroxidation or by stimulation of endogenous 
production of O2
•–
. Examples of xenobiotics whose effects seem to be somehow related 
with O2
•– 
are the pesticides paraquat and pentachlorophenol, and the transition metal 
vanadium, pointing out a role for O2
•–
 in occupational toxicology. There are also several 
drugs (e.g. gentamicin, anthracyclines and rifamycin) whose action and toxic effects 
are, at least partially, related to O2
•–
 generation [4, 24]. 
The removal of O2
•–
 provides thus a unique strategy to manipulate numerous 
pathological processes, being a very promising approach to the treatment of a variety of 
diseases and intoxications in which O2
•–




1.2. Superoxide dismutase mimetics 
Some therapeutic approaches have emerged based on the fact that the removal of 
O2
•–
 modulates the course of numerous pathological processes. Efforts have been made 
towards a clinical use of SOD. A different strategy, that has shown very promising 
results, relies on the development of synthetic compounds with the capacity to mimic 
the native enzyme - SOD mimetics (SODm). 
Protective and beneficial roles of SOD have been demonstrated in a broad range of 
diseases, both in preclinical and in clinical studies [8, 16]. Preclinical studies have 
revealed a protective role of SOD in animal models of a variety of pathological 
conditions, including: ischemia-reperfusion injury, transplant-induced reperfusion 
injury, inflammation, cancer, AIDS and pulmonary disorders [7]. Moreover, the 
overexpression of SOD in animal models has provided protection against the deleterious 
effects of a wide range of oxidative stress paradigms, such as stroke or Parkinson's 
disease [3, 7]. 
In terms of clinical data, a Cu,Zn-SOD prepared from bovine tissues – Orgotein, 
used to be applied as a human therapy in inflammatory conditions, namely in 
rheumatoid arthritis, osteoarthritis, and against the side effects associated with 
chemotherapy and radiotherapy [7]. Despite the encouraging anti-inflammatory 
properties demonstrated, Orgotein was responsible for immunological problems and 
was withdrawn from the market [7]. Besides this problem of antigenicity, the use of 
native SOD as a therapeutic agent presents high-manufacturing costs and limitations 
related with the large size of these proteins that limit their cell permeability and 
circulating half-life [3]. Moreover, SOD presents a bell-shaped dose-response curve, 
making difficult the precise restoration of optimal balance between O2
•–
 and SOD [16]. 
Various attempts at modifying the SOD enzymes have been performed in order to 
improve their properties. These include the delivery of SOD by liposomes, the 
development of SOD conjugates, and the genetic engineering of the human proteins [4, 
5, 16].  
 SOD mimetics constitute a different and promising strategy to remove of O2
•–
, 
overcoming the limitations of the clinical use of native SOD. A SODm can be defined 
as a small synthetic molecule that achieve the destruction of O2
•–
 at a rate of tens of 
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millions of times per second per molecule, mechanistically similar to endogenous SOD 
[7]. Taking into account that the ultimate goal is pharmaceutical use, these small 
molecules could have a number of advantages over the native enzyme. They are more 
likely to access inter- and intracellular spaces, are devoid of immunogenicity, exhibit 
longer half-lives, might be capable of oral administration, and they are easier to produce 
in large amounts and with lower costs than the enzymes [25, 26]. 
 The very first studies on SODm begun in the late 1970s and early 1980s. Since 
then, a growing number of low molecular-weight catalytic antioxidants with the 
capacity to mimic SOD has been developed [3, 7, 27-30]. Nowadays, this is still an 
emergent field as can be confirmed by the increasing number of publications on this 
subject, and also by the expanding list of possible therapeutic applications of these 
compounds. In fact, SODm have shown very promising results in in vitro and in vivo 
models of a variety of pathological phenomena (e.g. inflammation, neurodegenerative 
diseases, cardiovascular diseases, pulmonary diseases and cancer), as well as in 
toxicological conditions (e.g. exposure to paraquat and to beryllium). This topic will be 
described in section 1.2.3. 
 
1.2.1. Considerations for drug design 
SODm should exhibit high rates of reaction with O2
•–  
[3]. For a relevant SOD 
activity in vivo, the catalytic activity of SODm should be comparable or even superior 
to that of the native enzyme [7]. Most of the catalytic antioxidants are designed with 
redox-active metal centers that catalyze the dismutation reaction by a mechanism 
similar to that of the active-site metals of SOD [3, 4]. Only a few metals, namely Cu, 
Mn, Fe, and perhaps Ni, have the ability to form complexes with this activity [25]. To 
therapeutically use this property, these metals must be enclosed in a stable ligand. The 
number and type of donor atoms of the ligand, as well as the proper shape of the 
complex formed, must be taken into account in the rational design of novel SODm, in 
order to achieve antioxidants with fast catalytic rates [7]. Also the ligand charges can 
have a major effect in terms of catalytic rate, since the appropriate placement of positive 
charges may provide electrostatic guidance for the approach of O2
•– 
to the active site of 
the SODm [28, 31]. The design of SODm with high catalytic rates leads to compounds 
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that are efficacious at very low concentrations, allowing therapeutic regimens with low 
inherent side effect probability [25]. 
 In order to react as a true catalyst, rather than as a stoichiometric superoxide 
scavenger, it is required that a SODm presents a reversible redox behaviour. The SODm 
has to undergo a reduction in the presence of O2
•–
 and its reduced form should be 
reoxidized by O2
•– 
[32]. This capacity to allow both half-reactions of the catalytic cycle 
(Eq 8 and 9) depends on the half wave potential (E1/2) of the metal site [28], being 
possible when this value is between -0.3 and +0.9 V [33]. 
O2
•–
 → O2 + e
-







 → H2O2  E1/2 = +900 mV (Eq 9) 
All the natural SOD enzymes, regardless of the type of metal, exhibit redox 
potentials close to +300 mV vs NHE, which is the halfway between the redox potentials 
of the two half reactions of the catalytic cycle [26, 28]. Thus, a metal-centered redox 
potential of ~300 mV provides equal thermodynamically facilitation for both processes, 
driving energy to both half reactions and avoiding one or the other from becoming rate-
limiting [26]. The determination of the redox potential of a SODm is therefore a very 
important parameter to be evaluated when developing novel catalytic antioxidants. Fig. 
1.7 illustrates this point and shows the location in terms of E1/2 of some of the SODm 
developed so far. 
 
 
Fig. 1.7 - Redox diagram for O2
•–
 oxidation and reduction and the placement of some 
SODm on it (adapted from [33]). 
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Since many SODm are metal complexes, it is crucial that they present high 
stability to be used as pharmaceuticals [25]. The metal must be bound tightly to the 
ligand, to avoid ligand exchange and loss of activity [26]. Moreover, the release of a 
potentially harmful metal ion from the complex in an inappropriate biological 
compartment must be avoided [25]. When addressing a pharmaceutical application, 
several aspects of stability should be considered. Not only the inherent chemical, 
thermodynamic and kinetic stabilities of a complex are important [7, 25], but also the 
characteristics of the biological milieus and the pharmacokinetics of the SODm should 
be considered [7, 25, 26]. 
One important aspect of the stability issue is the thermodynamic stability of a 
complex, which can be evaluated by the determination of its stability constant [25]. 
Complexes with high values of stability constants are required to avoid dissociation. 
Other important parameter is the kinetic stability or dissociation rate of the complex.  
Ideally, the kinetics of excretion after an in vivo administration should be faster than the 
kinetics of complex dissociation [25]. Macrocycles, i.e. polydentate ligands whose 
structure consists of a ring with a minimum of nine atoms and containing at least three 
donor atoms [34], usually provide enhanced kinetic stability as compared to non-cyclic 
ligands [7]. 
In terms of biological stability, it is crucial that the complex is stably formed at 
physiological pH values. This includes not only pH 7.4, but also more acidic conditions, 
depending on the application of the SODm. Since metal complexes are susceptible to 
proton-assisted dissociation, this can constitute a problem in the acid pH of the stomach, 
in case of an oral administration. Also, if the target of a complex is an ischemic tissue, 
the complex must be stable at the lowered pH value (~5) of oxygen-deprived tissues 
[25]. The development of a stable SODm should also consider the biological redox 
environment. Most complexes are susceptible to oxidative ligand degradation. This may 
be a problem if a complex gets to the liver, due to the strong oxidizing environment of 
this organ [25]. Additionally, many complexes dissociate via reduction of the metal. In 
the reducing environment of most cells, the reduction of the metal center can lead to the 
decomposition of the complex [25]. Furthermore, when studying the stability of a 
complex it is also important to take into account the presence of endogenous chelators 
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(e.g. albumin, glutathione) in the biological milieus that can compete for the metal [7, 
26]. 
Another significant aspect of drug design is the optimization of the 
bioavailability. Bioavailability greatly affects the in vivo efficacy and safety of a SODm 
and is dependent upon its size, charge, shape (conformational flexibility and overall 
geometry), and lipophilicity [28, 35]. When designing a novel SODm, chemical 
modifications on its structure to modify lipophilicity should be performed according to 
the target organ and final goal of the compound. For example, highly lipophilic drugs, 
with the ability to cross the blood/brain barrier, would be desired to treat 
neurodegenerative diseases [25, 35]. On the other hand, an SODm to be used in 
reperfusion injury following a myocardial infarct should be more hydrophilic, so that it 
can stay longer in circulation (water phase) [25]. The lipophilicity of a SODm may be 
assessed using thin-layer chromatography or by the determination of the partition 
coefficient between n-octanol and water [28]. 
The size and charge of a SODm can be exploited to target crucial cellular 
compartments [3]. Since mitochondria are the major source of O2
•–
, many efforts have 
been made to obtain mitochondrially targeted catalytic antioxidants [28]. One successful 
approach to obtain mitochondria-targeted compounds is the attachment of the lipophilic 
cation triphenylphosphonium to antioxidants [36]. Because of its positive charge, this 
strategy also allows an accumulation of several-hundredfold within mitochondria driven 
by the membrane potential, enhancing the protection of mitochondria from oxidative 
damage. This approach has been applied to obtain mitochondria-targeted versions of 
SODm, namely with M40403 and tempol [36]. Other strategies that have been used to 
target antioxidants to mitochondria include the attachment of a cationic N-arylpyridyl 
group or of specific oligopeptides [28, 37]. 
Other characteristics should also be addressed in the development of novel 
SODm. The non-peptidic nature of these small molecules is important to avoid 
immunogenic reactions and degradation by proteases [7]. It is also important that a 
SODm compound could not be deactivated by peroxynitrite [7]. Finally, the purity of a 
SODm should be established very carefully, since even small-trace impurities might 
modify the SOD-like activity, affecting the therapeutic and/or mechanistic evaluations 
of the compound [28]. 
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1.2.2. Classes of SODm 
Most of the catalytic antioxidants contain a redox-active metal on their active 
center. The metal-containing SODm more extensively studied are manganese(III) 
metalloporphyrins (a), manganese(III) salen complexes (b) and manganese(II) cyclic 
polyamines (c) [3, 28]. Also, copper(II) (d) and iron(III) (e) complexes have been 
developed. A different class of SODm is constituted by nitroxides (f), a group of 
compounds that do not have a metal center in their structure. Many other compounds, 
with different chemical structures, have also been reported to possess SOD-like activity 
(g). These classes of SODm are briefly described below. 
 
a) Manganese(III) porphyrins 
This class of SODm is constituted by manganese(III) complexes in which the 
metal ion in enclosed in a porphyrin ligand. Porphyrins are naturally occurring 
macrocyclic compounds, which structure consists of a 16-atoms ring containing four 
nitrogen atoms, obtained by linking four tetrapyrrolic subunits with four methine 
bridges. The cavity of these macrocycle can properly accommodate a number of metal 
ions, forming metalloporphyrins [38]. Nature has developed natural metalloporphyrins 
as major prosthetic groups embedded in a variety of biomolecules (e.g. hemoglobin, 
myoglobin, nitric oxide synthase, cytochrome oxidase, cyt P450 systems, 
cycloxygenase) [28]. Synthetic metalloporphyrins appeared as a natural choice for 
developing SODm because these agents: (i) have chemical accessibility, (ii) are not 
antigenic, (iii) have a porphyrin core structure that can be chemically modified; (iv) are 
extremely stable; and (v) possess low molecular weight and can penetrate the cellular 
and subcellular membranes [28]. Metalloporphyrins were therefore the first compounds 
considered as SODm. Two scientists deeply influenced the design of metalloporphyrins 
as SODm, Irwin Fridovich, known for its outstanding work in free radical biology and 
medicine, and Peter Hambright, a pioneer in the water-soluble porphyrins’ field [28]. 
The most stable and effective SODm developed so far are manganese-containing 
synthetic meso-substituted porphyrins [28]. 
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 and peroxyl radicals [39]. The SOD-like activity of the 
MnPs involves the alternate reduction and oxidation of the Mn center, which results in 
changes in valence between Mn(III) and Mn(II), much like native SODs [27]. The 
ability of MnPs to scavenge ONOO
-
 is related to the formation of an oxo–Mn(IV) 
complex that is reduced to Mn(III) by endogenous antioxidants [40]. The mechanism of 
lipid peroxidation inhibition by MnPs is thought to be analogous to that mentioned for 
ONOO
-
 scavenging [3, 39]. MnPs also have the ability to degrade H2O2 due to their 
extensive conjugated ring system that undergoes reversible one-electron oxidations. 
However, this CAT-like activity is negligible, being less than 1% of that of native 
enzymes [3]. The mitigation of oxidative stress injury by MnPs seems to involve not 
only the direct scavenging of ROS/RNS, but also the modulation of redox-active 
transcription factors, such as HIF-1α, NF-kB, and AP-1 [41-45].  
Porphyrin ligands allow for a considerable range of redox potentials and 
lipophilicities, which are important features in the development of SODm for 
pharmaceutical purposes [25, 35]. Examples of some representative compounds of this 
class are depicted in Fig. 1.8. 



























This class of SODm is currently being developed by Aeolus Pharmaceuticals, 
which is a subsidiary of Incara Pharmaceuticals. The MnP AEOL 10150 (MnTDE-2-
ImP) (Fig. 1.8) is currently undergoing clinical trials. Two phase I clinical trials to 
evaluate the safety, tolerability and pharmacokinetics of this compound administered by 
subcutaneous injection to patients with amyotrophic lateral sclerosis were successfully 
completed and no serious adverse effects were reported. A new clinical trial with AEOL 
10150 is being prepared to evaluate its safety and efficacy in radiation protection [46]. 
 
b) Manganese(III) salen complexes 
Other relevant Mn-containing SODm are the Mn(III)-salens complexes (salen = 














Fig. 1.9 – Chemical structures of four representative salen-manganese complexes. 
 
These compounds were previously developed by the Eukarion, Inc. company, 
being usually named as EUKs [3, 25]. Two compounds of the Eukarion portfolio 
achieved later stages of development: a topical formulation of EUK189 was studied in 
phase I clinical trials for radiotherapy-induced dermatitis, and EUK134 is currently used 





Ltd. This company recently announced that it will cease the research in therapeutics and 
will focus its strengths on diagnostic products and changed its name to Tyrian 
Diagnostics [49]. 
The Mn moiety of these complexes is coordinated by four axial ligands that can 
be either N or O atoms [3, 4, 47]. The tetracoordination of Mn allows several possible 
valence states, which are thought to be important in the scavenging of a wide variety of 
ROS and, thus, contribute to the non-selective nature of these antioxidants [3]. In fact, 
Mn(III)-salens have been reported to have two key antioxidant properties – the 
scavenging of O2
•–
and H2O2 [3, 25]. Moreover, their capacity to react with ONOO
-
 and 
lipid peroxides has also been suggested [3, 4]. 
Mechanistic details on the SOD-like of these complexes activity have not been 
reported [3, 25, 48]. However, the Mn(III)-salens undergo quasi-reversible reductions in 
cyclic voltammetry experiments, what establishes that reduction of Mn(III) to Mn(II) is 
a thermodynamically viable step in the SOD activity of these complexes [25, 48]. 
Mn(III)-salens have been reported to have lower catalytic activity when 
compared to other classes of SODm. It is therefore possible that the protective effects 
observed in biological studies (Tables I.3 and I.4) are due to a combination of 
antioxidant reactions, rather than a true catalytic SOD activity [25]. This class of SODm 
presents other drawbacks, namely very low water solubility and limited stability [25, 48, 
50]. 
 
c) Mn(II) cyclic polyamines  
A third class of SODm includes the Mn(II)-pentaazamacrocyclic complexes 
[48]. In these compounds, the Mn(II) is held by five coordination points and is only 
available for one-electron transfers [3, 4]. Thus, these complexes can transfer one 
electron to and from O2
•–
 catalyzing its dismutation, but they are not reactive towards 
H2O2 or ONOO
-
 [4]. Such specificity is desirable for mechanistic studies, but it would 
be disadvantageous for therapeutic purposes [28]. However, although these complexes 
are specific for O2
•–
 in test tube reactions, this selectivity may not occur in more 
complex biological systems [3, 4]. During the dismutation of O2
•–
, the Mn(II) at the 
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active center of the macrocyclic complex undergoes alternate oxidation and reduction, 
which results in an interchanging valence state between Mn(II) and Mn(III) [3, 28]. 
These compounds present reasonable thermodynamic stability, but excellent 
kinetic stability [25]. The chemical stability of Mn(II)pentaazacyclopentadecane 
complexes can be improved by increasing the number of substituents on the carbons of 
the inner ring of the macrocycle, while substituents on the nitrogens destroy activity 
[25]. Structure-activity studies revealed that a trans-cyclohexane substitution improves 
stability (thermodynamic and kinetic) and activity [25], and allowed the development of 
optimised compounds. M40403 and M40401 (Fig. 1.10) are pentaazacyclopentadecane 
analogues containing bis(cyclohexylpyridine) functionalities, that are very kinetically 








Fig. 1.10 – Chemical structure of four representative Mn(II) cyclic polyamines. 
 
Mn(II) cyclic polyamines have been developed at MetaPhore Pharmaceuticals 
and then at ActivBiotics. The most studied SODm of this class is M40403 (Fig. 1.10), 
which was introduced into human clinical testing in 2001. This complex has 
successfully completed a Phase I safety clinical trial in healthy human subjects [48]. 
Also, different phase II clinical trials have demonstrated the efficacy and safety of 





or bunionectomy) and in cancer pain. Two phase II clinical trials are now in preparation, 
to evaluate the effects of this SODm in oral mucositis and post-operative ileus. By 
removing O2
•–
, M40403 was proposed to exert protective actions at three different 
pathways: the inhibition of ONOO
-
 formation, sparing NO; the inhibition of neutrophil 
infiltration at the site of inflammation; and the inhibition of pro-inflammatory cytokine 
release (e.g. TNFα, IL-1β and IL-6) [48]. 
 
d) Copper(II) complexes 
Many copper(II)-based SODm have been proposed, either as binuclear or 
mononuclear complexes, with different classes of ligands, including derivatives of 
imidazoles, amines,  pyridines, anti-inflammatory drugs (salicylates, indomethacin), 
amino acids, sulfonamides, peptides, imines, cyclodextrin,  curcumin, triazines, 
quinoline and others [4, 51, 52]. Copper(II) complexes have been studied in different 
models of oxidative stress-related pathologies, as will be shown in section 1.2.3. Among 
these complexes, copper(II) 3',5'-diisopropylsalicylate (CuDIPs) is widely studied and is 
used as a cosmetic ingredient to protect skin from UV light-induced damage, boosting 
the Sun Protection Factor in sunscreens. 
Although many Cu(II) complexes are efficient SODm in vitro, they tend to lose 
their activity in vivo, especially in the case of acyclic complexes. Many of the Cu(II) 
chelates described in the literature probably dissociate to release copper ions in vivo [4]. 
This can raise toxicity concerns due to the possible production of HO• radical via Fenton 
chemistry [28]. Moreover, since many proteins and other biological chelators have high 
affinity for Cu(II) (e.g. albumin, copper chaperones, glutathione and metallothioneins) 
[53], the SODm complex can be inactivated in the biological milieu [51]. High stability 
constants are thus required to avoid the dissociation of the complex in vivo. This could 
be achieved by using macrocyclic ligands [25, 54]. The macrocyclic nature of the ligand 
seems important for the SOD mimetic activity of the corresponding complexes as well 
as for their stability in the presence of proteins, even if the metal ion does not lie inside 
the cavity [54]. Several macrocyclic copper complexes have been reported to scavenge 
superoxide anion [54-59]. Based on the structure of Cu,Zn-SOD active site, 
imidazolate-bridged binuclear Cu(II) complexes have been prepared and characterized 
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as SODm. Also in this type of complexes, the use of macrocyclic ligands has shown 
advantages, namely in terms of stability in a larger pH range [51]. 
Some studies on Cu(II) porphyrins (CuPs) as potential SODm have also been 
reported. Although some CuPs do not possess catalytic SOD activity (e.g. CuTM-4-
PyP), other derivatives, namely CuBr8TM-4-PyP, have significant SOD-like activity 
along with a very high stability. The occurrence of Fenton chemistry on Cu(II) site 
within porphyrins has not been explored [28]. 
In the development of Cu(II) complexes with SOD-like activity, it is necessary 
to find a balance between a sufficient stability for the complex to survive in in vivo 
conditions, and a certain flexibility that allows the change of metal coordination during 
the catalytic process [51]. Although many copper(II) complexes have been studied, 
most of them are not thermodynamically stable or highly active at the range of 
physiological pH [60]. For this reason, the identification of novel complexes with high 
stability and activity, together with low toxicity, is still a challenging issue in 
bioinorganic chemistry. 
 
e) Iron(III) complexes 
Iron(III) complexes would be attractive SODm since they exhibit high kinetic 
and thermodynamic stability. However, iron ions are prone to react with H2O2 via 
Fenton reaction, generating the highly toxic HO
•
 radical [25]. This reaction can occur 
both with iron complexes and with free aquo iron ions that can be released from the 
complex during redox cycle [25, 28]. Since H2O2 is one of the products of the O2
•–
dismutation, the possible occurrence of Fenton reaction may limit the application of iron 
complexes as SODm [25, 28]. 
A number of iron(III) complexes with non-macrocyclic polydentate ligands (e.g. 
aminopolycarboxylates and tripodal ligands) have been reported to possess SOD 
activity. However, it is not clear whether these complexes have true catalytic activity. 
Moreover, some of these complexes were shown to damage DNA due to HO
•
 
generation [25]. Iron(III) complexes with pentaazacyclopentadecane derivatives have 
also been studied. However, their catalytic activities are considerable lower than those 
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of the Mn(II) analogues. Furthermore, their ability to produce HO
•
 radical makes these 
complexes considerably toxic [25]. Also some Fe(III) porphyrins (FePs) (e.g. FeTBAP 
and FeTMPyP) were shown to dismutate O2
•–
 [4, 25, 28]. Along with the SOD-like 
activity, FePs can also react with ONOO
-
 [4, 28]. Although some reports on the 
protective effects of FePs have been published, these compounds promote the Fenton 
reaction being their therapeutic potential, at least as catalytic antioxidants, limited by 
their inherent toxicity [25, 28, 61]. 
 
f) Nitroxides 
A number of compounds initially developed as free radical spin traps have been 
shown to have antioxidant properties, namely the capacity of reacting with O2
•– 
[4, 62]. 
If a spin trap intercepts a biologically damaging radical, then it may protect against 
oxidative injury [4]. Nitroxides react with free radicals and form more stable free radical 
products. However, the rate of reaction with O2
•–
 of most nitroxides is low, and thus 
large amounts (often millimolar levels) of these compounds are required for an effective 
activity [62]. Furthermore, many nitroxides are inefficient SODm at physiological pH 
[28]. During the O2
•–
 dismutation, nitroxides (RNO
•
) cycle between the oxidized 
oxoammonium cation (RNO
+
), and the reduced form hydroxylamine (RNOH). The 
oxoammonium cations have also the ability to react rapidly with ONOO
-
 [28]. In the 
absence of a reducing agent, RNO
+ 
can oxidize various biomolecules including DNA. 
Under reducing conditions, the antioxidant activity of hydroxylamine occurs 
presumably through hydrogen atom donation and may account for the in vivo protective 
effects of nitroxides [28]. Also, many nitroxides can be metabolized to release NO and 
can inhibit enzymes that are endogenous sources of ROS [62]. 
These compounds are well tolerated in animals and can achieve high tissue 
levels [62]. Some examples of SODm of this class are oxano, 3-nitratomethyl-PROXYL 
and Tempol (Fig. 1.11) [4]. Also, the nitrone α-phenyl-tert-butylnitrone (PBN, Fig. 
1.11), which reacts with radicals to give a nitroxide, has shown good results in oxidative 










Fig. 1.11 – Chemical structures of Tempol and PBN. 
 
Tempol is the most studied compound of this class and has shown protective 
effects in a number of oxidative damage models (Table I.4). Moreover, Tempol is being 
studied in clinical trials to prevent radiation-induced alopecia. A phase I trial has 
demonstrated that the topical application of Tempol to the scalp before whole brain 
radiation is safe and well tolerated. A phase II study using a gel formulation of Tempol 
has been initiated [63]. 
 
g) Other compounds with SOD-like activity 
A new class of SODm has been developed by the company PledPharma AB and 
contains the manganese(II) complexes of dipyridoxyl ethylenediamine diacetate 
derivatives (PLED-derivatives). Among these compounds, mangafodipir (PP-095), 
which is already clinically approved as a magnetic resonance imaging contrast agent, 
has completed a phase II clinical trial in 2010. This study was conducted in patients 
operated for colon cancer and has shown that the pre-treatment with mangafodipir 
lowers the frequency and severity of adverse effects of FOLFOX (folinate, oxaliplatin, 
5-fluorouracil) chemotherapy regimen. In addition, a phase II clinical study was started 
in 2009 using the PLED-derivative PP-099, to study whether this SODm reduces 
myocardial infarct size in patients undergoing primary percutaneous coronary 
intervention [64]. 
A number of porphyrin-related compounds, such as phthalocyanines, 
porphyrazines, biliverdins, corroles and texaphyrins, have also been explored as SOD 




activity. In the case of Mn corroles, the Mn(IV)/Mn(III) redox couple is responsible for 
the O2
•–
 dismutation. These complexes have also the ability to scavenge ONOO
-
 and 
H2O2, which may account for the suppression of oxidative stress [28]. 
Cerium(IV) oxide (CeO2) nanoparticles have also been investigated as SODm. 
The SOD activity of these nanoparticles was shown to depend on the size of the 
nanoparticles, as well as on the Ce (IV)/Ce(III) ratio in these materials [28]. Osmium 
tetraoxide (OsO4), which is used in the treatment of arthritic joints, was also shown to 
exhibit a relevant SOD-like activity. The dismutation cycle is dependent on the 
Os(VIII)/Os(VII) redox couple [28]. 
SOD-like catalytic activity was also reported for some water-soluble fullerenes. 
In addition, some compounds of this class are able to directly react with hydroxyl, 
alkoxyl, alkylperoxyl and benzyl radicals. However the mechanism is not fully 
understood, the highly conjugated double bond system seems to be responsible for the 
antioxidant actions of these compounds [28]. Finally, some natural antioxidants of the 
polyphenol type were shown to possess SOD-like activity, namely honokiol, curcumin 





1.2.3. Therapeutic opportunities of SODm 
SODm have been shown to protect against oxidative damage in a wide range of 
cell and animal model systems. Tables I.3 and 1.4 summarize some of the studies 
reported in the literature. 
 
 Table I.3 – Examples of protective effects reported using SODm in cell-based models. 
Model system Cell type SODm found to be protective 
Hydrogen peroxide Fibroblasts MnTBAP [65] 
 Endothelial MnTM-4-PyP [66] 
Oxygen and/or glucose 
deprivation 
Neuronal MnTBAP [67], MnTE-2-PyP 
[67, 68], MnTDE-2-ImP [68] 
Paraquat Epithelial MnBr8TBAP [69] 
 Neuronal MnTDM [70], EUK134 [71], 
EUK189 [71] 
Staurosporin Neuronal EUK134 [72], EUK189 [50], 
EUK207 [50] 
6-Hydroxydopamine Neuronal EUK134 [72], MnTBAP [73] 
Hyperoxia Epithelial EUK134 [74] 
UVB radiation Keratinocytes EUK134 [75] 
Diesel exhaust particles  Epithelial EUK8 [76] 
Gentamicin Cochlear cultures M40403 [77] 
HIV infection Astrocytes M40401 [78] 





Pancreatic cells MnTM-4-PyP [80] 
Endotoxin Macrophages MnTPPS [81], FeTMPS [81], 
FeTM-4-PyP [82] 







Table I.4 – Examples of protective effects reported using SODm in animal models. 
Model system Species SODm found to be protective 
Lung   
Cigarette smoke injury Rat MnTDE-2-ImP [83] 
Antigen-induced asthma Mouse MnTE-2-PyP [84] 
Bronchopulmonary dysplasia Baboon MnTE-2-PyP [85] 
Paraquat pneumotoxicity Mouse MnTBAP [86] 
Cardiovascular   
Heart ischemia–reperfusion Rat  M40403 [87], EUK8 [88] 
Hemorrhagic shock Rat EUK8, EUK134 [89] 
Nitrate tolerance Rat MnTBAP [90] 
Cardiac transplants Rat MnTM-4-PyP [91] 
Ageing-associated cardiovascular dysfunction Rat Cu(II)-aspirinate [92] 
Interleukin-2-induced hypotension Mouse M40403 [93] 
Central nervous system   
Spinal cord injury  Rat MnTBAP [94] 
Ischemia–reperfusion Rat MnTE-2-PyP [95] 
 Mouse MnTDE-2-ImP [68] 
 Gerbil M40401 [96] 
Paraquat-induced neurotoxicity Mouse EUK189 [71] 
Hyperalgesia Rat M40403 [97] 
6-Hydroxydopamine-induced parkinsonism Mouse Tempol [98] 
Age-induced cognitive impairment Mouse EUK189, EUK207 [99] 
Meningitis-induced hearing loss Rat  MnTBAP [100] 
Liver   
Acetaminophen injury Mouse MnTBAP [101] 
Ischemia–reperfusion  Rat MnTDE-2-ImP [102] 
Gastrointestinal   
Acetic acid-induced colitis Rat MnTEGP [103] 
Cerulein-induced pancreatitis Mouse M40401 [104] 
Renal   
Gentamicin injury Rat M40403 [24] 
Endotoxin Mouse MnTE-2-PyP [105] 







Table I.4 (cont.)   
Other   
Peridontitis Rat M40403 [109] 
Preeclampsia Mouse Tempol [110] 
Collagen-induced arthritis Rat M40403 [111] 
Cataracts Rabbit Tempol [112] 
Diabetes-induced erectile dysfunction Rat Tempol [113] 
Alloxan-induced diabetes Mouse Cu(II) complexes with 6-
(benzylamino)purine 
derivatives [114] 




 is involved in many pathological phenomena (Table I.2), and due to 
the ability of catalytic antioxidants to scavenge the excess ROS restoring the redox 
balance of the tissues, the therapeutic possibilities for these compounds are broad. In 
fact, as shown in Table 1.4, pre-clinical studies suggest the usefulness of these 
antioxidants in a variety of diseases, in multiple organs and systems. 
In addition to the aforementioned oxidative-stress related diseases, a promising 
role for SODm in cancer therapy has also been suggested. Many adverse effects of 
chemotherapy and radiotherapy are related to oxidative stress, namely the doxorubicin-
induced cardiotoxicity [22, 115, 116], bleomycin-induced lung fibrosis [116, 117], 
radiation-induced lung injury (pneumonitis and fibrosis) [118]. SODm may therefore be 
promising antioxidants for the protection of non-tumoral tissues from chemotherapy and 
radiotherapy adverse effects. Some studies have been performed towards this 
application of SODm as exemplified in Table I.5. In addition, as mentioned in the above 
section, a few SODm are currently being tested in clinical trials to evaluate their role 







Table I.5 – Examples of protective effects shown by SODm against adverse effects of 
chemotherapy and radiotherapy. 
Anticancer 
agent 
Adverse effect Cell type or 
Animal species 
SODm found to be 
protective 
Doxorubicin Cardiotoxicity Cardiomyocytes MnTBAP [119] 
Bleomycin Lung fibrosis Mouse MnTBAP [117] 








Lung injury Rat EUK189 [118] 
MnTE-2-PyP [121], 
MnTnHex-2-PyP [121] 
Oral mucositis Hamster M40403 [122] 
Hair loss Guinea pig Tempol [123] 
Salivary hypofunction Mouse Tempol [124] 




MnTM-2-PyP [125, 126] 




The potentialities of SODm in cancer therapy are not limited to the mitigation of 
chemo- and radiotherapy side effects. SODm have also been suggested to inhibit 
malignant transformation processes [17, 43]. Moreover, SODm can exert themselves 
antitumor effects or can potentiate established anticancer treatments, as explained 
below.  
ROS are known to exert different effects in cell proliferation, either promoting 
or reducing it, according to their nature and to their intracellular level [128]. Tumor 
cells are usually under higher oxidative stress than normal cells [128] and use to present 
low MnSOD, Cu,Zn-SOD and CAT activities [15, 17]. Nicco et al [129] have proposed 
the following model describing the relationship between the level of H2O2 and the rate 










Fig. 1.12 - Schematic representation of the relationship between intracellular H2O2 




/H2O2 balance alter the cellular redox state, which in turn affects 
signal transduction pathways modulating cell proliferation [17]. In non-tumoral cells, 
the basal level of H2O2 is low and its increase is associated with cell proliferation. On 
the other hand, the intracellular level of H2O2 in tumor cells is often close to the 
threshold of toxicity and a further increase in H2O2 concentration can trigger apoptotic 
pathways [129]. Compounds with SOD-like activity, while dismutating O2
•–
, increase 
the H2O2 concentration and can thus reduce tumor growth or potentiate anticancer 
agents [128-130]. Moreover, if the complex reacts with the generated H2O2 via Fenton 
reaction originating the highly toxic HO• radical, this can be a further advantage in 
promoting cancer cells’ death [61, 128]. This may constitute an important approach to 
promote selective cell death between cancer and normal cells, since cancer cells usually 
possess lower antioxidant defences, being thus unable to efficiently detoxify H2O2 [17]. 
SODm can be useful in cancer treatment either alone or in combination with 
established antitumor treatments. Many anticancer strategies are known to produce ROS 
(e.g. doxorubicin, bleomycin, oxaliplatin, cisplatin, ionizing radiation) [15, 129]. The 
manipulation of antioxidants systems, and specifically the increase of SOD activity in 
cancer cells by the addition of SODm, may be an approach to potentiate these agents 
[15, 17, 129]. Some studies (Table I.6) have been performed in order to explore this 


















Table I.6 – Examples of studies focusing on the potential of SODm as anticancer agents. 
SODm Model Results observed 
Tempol [131] HL60 leukemia cells Tempol exhibited an antiproliferative 
effect 
Tempol [132] Colon carcinoma 
cells 
Tempol exhibited an antiproliferative 
effect and potentiated doxorubicin 
2-methylami-
nopyridine complexes 
of Cu(II), Fe(III) and 




The complexes decreased cell viability 





Hepa 1-6 hepatoma 
cells; 
Mouse bearing CT26 
and Hepa 1-6 tumors 
SODm decreased cell proliferation and 
tumor volume; 







Mouse bearing CT26 
tumors 
SODm potentiated the cytotoxicity of 
oxaliplatin, paclitaxel and 5-fluorouracil; 
Mangafodipir and CuDIPs abrogated 
tumor growth; 
Mangafodipir enhanced the antitumoral 
effects of paclitaxel  
MnTE-2-PyP [134] Mice bearing 4T1 
mammary carcinoma 
MnTE-2-PyP augmented the effects of 
radiation in terms of tumor growth delay 
and devascularisation 
MnTDE-2-ImP [135] Mouse with prostate 
tumor 
MnTDE-2-ImP increased radiation 
effectiveness 
 
SODm may thus be useful in chemotherapy, either reducing carcinogenesis, 
protecting non-tumoral tissues from the oxidative damage induced by anticancer agents, 
or potentiating their toxic effects in tumoral cells. This potentiation capacity can be a 
useful approach to overcome drug resistance, and some studies have already pointed out 
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The global aim of this thesis is to contribute to the development of the SODm 
field, especially in two promising classes of macrocyclic compounds: a) manganese(III) 
porphyrins and b) macrocyclic copper(II) complexes. 
 
a) Manganese(III) porphyrins 
MnPs have already shown remarkable protective effects in models of oxidative 
stress. However, a thorough knowledge on their effects at the cellular level is still 
lacking. Therefore, this thesis aims to contribute to fill this gap, shedding light on the 
role and potentialities of MnPs as catalytic antioxidants. In this context, the para-
substituted porphyrin MnTM-4-PyP (Chapter 3) and two ortho analogues (Chapter 4) 
were studied. 
 
Para-substituted porphyrin MnTM-4-PyP (Chapter 3) 
In chapter 3, the goal was to evaluate the cellular effects of the well established 
SODm MnTM-4-PyP (commercially available), in V79 Chinese hamster cells, a well-
characterized lung fibroblast cell line widely used for cytotoxicity and cytogenetic 
studies, using the following approaches: 
 The assessment of the antioxidant role of MnTM-4-PyP towards the toxicity of three 
oxidative stress inducers: the xanthine/xanthine oxidase (XXO) system, which is an 
extracellular O2
•– 
generator; tert-butylhydroperoxide (TBHP), a short chain analogue 
of lipid hydroperoxides; and Doxorubicin (Dox), an anticancer drug that undergoes a 
redox-cycling process generating O2
•–
. 
 The characterization of the effects of this MnP per se, as well as its role on the 
protection against the three mentioned oxidants, in terms of cell viability, cell division 
and intracellular levels of O2
•–
.  
With the data obtained within Chapter 3 we aimed not only to provide a better 




validated models, to be used as tools for the study of the novel compounds developed 
within the scope of this thesis (Chapters 5 and 6). 
 
Ortho-substituted MnPs: MnTE-2-PyP and MnTnHex-2-PyP (Chapter 4) 
The establishment of a collaboration between the CBT-iMed.UL and the 
Radiation Oncology Department of Duke University, allowed the study of two 
optimized ortho-substituted MnPs, MnTE-2-PyP and MnTnHex-2-PyP. In Chapter 4 the 
goal was to characterize the effects of these MnPs in different perspectives that include: 
 The evaluation of these MnPs against the TBHP-induced cell injury, assessing 
endpoints of cell viability and intracellular O2
•–
 generation.  
 The study of the effects of these MnPs on the glutathione status, since this is crucial to 
understand the cellular redox balance and so far there are no studies committed to this 
point. 
 
b) Macrocyclic copper(II) complexes  
The second key aim of this thesis is to develop novel macrocyclic copper(II) 
complexes with SODm activity. As mentioned in Chapter 1, most of the Cu(II) 
compounds developed so far are not thermodynamically stable or highly active in 
physiological conditions, and the use of macrocyclic ligands has been pointed out as an 
approach to overcome these limitations. In this regard, nine macrocyclic copper(II) 
complexes were synthesized and characterized in terms of thermodynamic and 
structural properties, biochemical activity and biological effects.  
 
Novel macrocyclic copper(II) complexes with SODm activity (Chapters 5 and 6) 
In this context, the aim of the present thesis was to study two different types of 




cyclization of the ligands was carried out by the Richman and Atkins’ method. A 
second series of compounds (Chapter 6) comprised four pyridine-containing 
macrocyclic copper(II) complexes, and the correspondent ligands were synthesized 
using a templated method for the cyclization reaction. With the obtained complexes, the 
following goals were pursued: 
 To characterize the complexes in terms of thermodynamic stability, structural features 
and electrochemical properties.  
 To evaluate the capacity of the copper(II) complexes to scavenge O2
•–
 in vitro. 
 To evaluate the cytotoxicity of the copper(II) complexes in V79 cells.  
 To select the complexes that presented better chemical and biochemical properties and 
study their potential antioxidant role in the cellular models validated in Chapter 3 
(XXO and TBHP). 
 To assess the potential role in chemotherapy of the most promising macrocyclic 
copper(II) complexes, by evaluating their cytotoxicity profile, as well as their ability to 
modulate the cytotoxicity of the anticancer drugs oxaliplatin and Dox, in tumoral 









Oxidative injury in V79 Chinese hamster cells: protective role of the 









This Chapter was adapted from: 
Oxidative injury in V79 Chinese hamster cells: protective role of the superoxide dismutase 
mimetic MnTM-4-PyP. A.S. Fernandes, J. Serejo, J. Gaspar, M.F. Cabral, A.F. 
Bettencourt, J. Rueff, M. Castro, J. Costa, N.G. Oliveira. Cell Biology and Toxicology 




This Chapter focused on three different models of oxidative stress: the extracellular 
superoxide anion generator XXO; TBHP, an analogue of lipid hydroperoxides; and the 
anticancer drug Dox. Superoxide and peroxyl radicals, among other ROS could be 
effectively scavenged by MnTM-4-PyP, a polyfunctional catalytic antioxidant.  In this 
work, the role of MnTM-4-PyP on the protection against the cytotoxicity induced by the 
three aforementioned oxidants was addressed. The effect of MnTM-4-PyP (0.1-100 µM) 
was evaluated in V79 cells, using the MTT reduction and the crystal violet (CV) assays, as 
well as the mitotic index (MI). Also, the generation of intracellular ROS was studied by the 
fluorescence probe dihydroethidium (DHE). MnTM-4-PyP has shown significant 
protective effects against the cytotoxicity of XXO and TBHP, markedly increasing the cell 
viability and reducing the intracellular level of ROS. However, no considerable protection 
occurred against Dox. The three oxidants caused a MI reduction that was not altered by 
MnTM-4-PyP. In summary, MnTM-4-PyP appears to be a promising agent for the 
protection against oxidative injury. However, it has shown differential responses, 
reinforcing the need to study different experimental models for the adequate evaluation of 








The overproduction of ROS is associated with inflammation and tissue injury, being 
related to a large number of pathophysiological and toxicological conditions [1]. There are 
several available models of oxidative stress inducers varying in the species involved and in 
the site of formation of those species. According to the oxidative pathways involved in 
each model, they could be useful to understand different pathological conditions. 
The XXO system is an efficient extracellular superoxide anion generator that was 
found to be cytotoxic in different mammalian cells [2, 3]. The overload of superoxide 
anion in the extracellular space is implicated in vascular diseases [4], thus justifying the 
study of the extracellular generation of this species. In the XXO system, xanthine (X) is 
oxidized to uric acid by xanthine oxidase (XO), in aerobic conditions, with concomitant 
production of O2
•–
 [5] (Fig. 3.1). Furthermore, while acting upon xanthine, XO can 
produce hydrogen peroxide and cause lipid peroxidation [6].  
 
Fig. 3.1 – Generation of O2
•–
 by the xanthine – xanthine oxidase system.  
 
TBHP (Fig. 3.2) is a short chain analogue of lipid hydroperoxides that mimics the 
toxic effect of peroxidized fatty acids, being thus commonly used as a model of lipid 
peroxidation [7-9]. TBHP penetrates cell membranes easily [10] and generates peroxyl 
radicals in the cytosol [9].The mechanisms of cytotoxicity of this oxidant comprise not 
only the generation of ROS, but also changes in mitochondrial permeability [9], oxidative 












Fig. 3.2 – Chemical structure of tert-butylhydroperoxide. 
 
The anthracycline anticancer drug Dox is a quinone that undergoes a one-electron-
reduction within the cell, originating a semi-quinone free radical. This bioreductive 
activation may be catalyzed by different oxidoreductases, namely the NADPH cytochrome 
P450 reductases of the endoplasmic reticulum and nuclear envelope, the mitochondrial 
NADH dehydrogenase and the cytosolic xanthine oxidase [1, 11, 12]. The generated semi-
quinone radical donates its unpaired electron to oxygen, forming superoxide radicals. By 
reducing oxygen to O2
•–
, the Dox molecule is regenerated [11] (Fig. 3.3). Along with this 
redox-cycling process, ROS can be generated as a response to delayed perturbation of cell 
metabolism and function resulting from the treatment with Dox [13]. The production of 
hydroxyl radical and peroxynitrite by Dox, as well as the occurrence of lipid peroxidation, 
has also been reported [11, 14, 15]. Besides the ROS generation, Dox can hinder DNA 
synthesis by intercalation into the DNA or inhibition of topoisomerase II activity [11, 16]. 
These mechanisms seem to play a major role in the antitumor capacity of Dox. However, 
despite being widely used in a variety of solid tumors and hematological malignancies, the 
clinical use of this drug is limited by the occurrence of cardiotoxic effects, which are 
thought to be mainly due to an increase in oxidative stress [11, 15]. 
 
 
Fig. 3.3 – Doxorubicin redox-
cycling (adapted from [17]). 
Dox undergoes a one-electron 
reduction within the cell, 
originating a semi-quinone free 
radical. This radical donates its 
unpaired electron to oxygen, 
forming O2
•–
 and regenerating 
the Dox molecule [11]. 
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The involvement of ROS in several oxidative stress disorders has justified the study 
of low molecular weight SODm. Among these agents, MnPs have shown promising results 







radicals [18]. As described in Chapter 1 (section 1.2.2.), the SOD-like activity of the MnPs 
depends on changes in valence of the Mn center between Mn(III) and Mn(II) [18, 19]. The 
activity of MnPs over ONOO
-
, as well as their capacity to inhibit lipid peroxidation, is 
related to the formation of an oxo–Mn(IV) complex that is reduced to Mn(III) by 
endogenous antioxidants [18-20]. 
The manganese(III)tetrakis-(1-methyl-4-pyridyl) porphyrin (MnTM-4-PyP) (Fig. 3.4) 
possesses important characteristics for a catalytic antioxidant: cell-permeability, water 
solubility, reversible redox behaviour with an appropriate reduction potential, high 
catalytic rate constant for O2
•–
 dismutation [21] and the ability to inhibit lipid peroxidation 
[18, 19]. In addition, MnTM-4-PyP has shown promising results in different experimental 
models, such as cerebral ischemia [22], cardiac transplants [23], and neurodegeneration 
[24]. Despite these relevant data, only few cell-based studies have been reported and there 





























In this context, the aim of this Chapter was to address the role of MnTM-4-PyP on 
the protection against the cytotoxicity induced by the aforementioned oxidants XXO, 
TBHP and Dox, in V79 cells. Complementary cytotoxicity endpoints, the MTT reduction 
and the CV assays, as well as the MI analysis as a measure of cell division, were studied. 
Moreover, the ROS generation induced by these oxidants and the effect of MnTM-4-PyP 
were assessed with the fluorescence probe DHE. 
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3.2. Materials and Methods 
 
3.2.1. Chemicals 
Phosphate buffered saline (PBS; 0.01 M phosphate buffer, 0.138 M NaCl, 0.0027 M KCl, 
pH 7.4), Ham’s F-10 medium, newborn calf serum, penicillin-streptomycin solution, 
trypsin, thiazolyl blue tetrazolium bromide (MTT), CV, Giemsa dye, xanthine, XO, TBHP, 
and Dox were obtained from Sigma-Aldrich. MnTM-4-PyP was purchased from 
Calbiochem (purity ≥ 95% by TLC). Colchicine was acquired from Fluka. 
Dimethylsulfoxide (DMSO) was obtained from Duchefa Biochimie. Ethanol, methanol and 
acetic acid were obtained from Merck. DHE was purchased from Molecular Probes. A 10 
mM stock solution of DHE was prepared in DMSO, aliquotized and stored under N2, at 
−18 ºC. 
 
3.2.2. V79 Cells culture  
Wild-type V79 Chinese Hamster Cells (MZ), kindly provided by Prof. H.R. Glatt 
(Germany), were routinely maintained in 175 cm
2 
culture flasks (Sarstedt) using Ham’s F-
10 medium, supplemented with 10% newborn calf serum and 1% antibiotic solution 
(penicillin-streptomycin) as the cell culture medium. The cells were kept at 37°C, under an 
atmosphere containing 5% CO2.  
 
3.2.3. Cytotoxicity assays 
For the cytotoxicity evaluation, two assays were performed. Due to the limitations 
inherent to each method and since the assessment of an effect on cellular viability may 
depend on the assay chosen, it is usually recommended the use of mechanistically different 
endpoints for a correct evaluation of xenobiotic cytotoxicity [25]. Therefore, the MTT 
assay, which is a measure of mitochondrial function [26], was primarily used. The CV 




3.2.3.1. MTT Reduction assay 
In this method, MTT (yellow salt) is converted by the mitochondrial enzymes of 
viable cells into a purple formazan (Fig. 3.5) which can be measured at 595 nm. The 
absorbance is proportional to the number of viable cells [28]. 
 
 
Fig. 3.5 – MTT reduction in live cells by mitochondrial reductase results in the formation 
of a formazan derivative. 
 
Approximately 6  10
3 
cells were cultured in 200 L of culture medium per well in 
96-well plates and incubated for 24 hours at 37 °C under a 5% CO2 atmosphere. The cells 
were then treated for a further 24 h period with each of the oxidants: X (240 µM)/XO (20 
U/L), TBHP (100 µM) or Dox (2.5 µM) in the presence or absence of MnTM-4-PyP (0.1-
100 µM). The concentrations of the oxidants were chosen so that a near equitoxic effect 
was achieved, with a decrease of ~50% in cell viability. Further concentrations were 
studied for TBHP (25, 50 and 200 µM) and Dox (5, 10 and 20 µM). The cytotoxicity 
induced by MnTM-4-PyP per se was also evaluated in the same experimental conditions. 
After the treatments, the cells were washed with culture medium and MTT (0.5 mg/mL in 
culture medium) was added to each well [29]. The cells were grown for a further period of 
2.5 h and then carefully washed with PBS. DMSO (200 L) was added to each well to 
solubilize the formazan crystals and absorbance was read at 595 nm. Two to eight 
independent experiments were performed and eight replicate cultures were used for each 
concentration in each independent experiment. 
 63 
3.2.3.2. Crystal Violet assay 
Approximately 3.5  10
3 
cells were cultured in 200 L of culture medium per well in 
96-well plates and incubated at 37°C under a 5% CO2 atmosphere. As in the MTT assay, 
the cells were grown for 24 h and then exposed to the oxidants described above with or 
without MnTM-4-PyP for a 24 h period. After the incubation, the cells were washed with 
PBS to remove non-adherent cells. The adherent cells were fixed with 96% ethanol for 10 
min and then stained with 0.1% crystal violet in 10% ethanol for 5 min at room 
temperature. After staining, the extracellular dye was removed by rinsing thoroughly the 
cell monolayers with tap water. The remaining cell-attached dye was dissolved in 200 L 
of 96% ethanol with 1% acetic acid, and the absorbance was measured at 595 nm. Two to 
four independent experiments were performed, each one comprising eight replicate 
cultures.  
 
3.2.4. Evaluation of the Mitotic Index 
Approximately 4  10
5
 cells were cultured in 25 cm
2 
culture flasks for 24 h. 
Afterwards, cells were exposed for 15 h to MnTM-4-PyP (2.5 and 100 μM), and/or to the 
oxidants: X (240 μM)/XO (40 U/L), TBHP (50 μM) or Dox (50 nM). These concentrations 
of the oxidants led to an evident MI reduction, yet to measurable values, thus allowing the 
detection of the possible effects of MnTM-4-PyP. A 15 h incubation period was chosen 
since it corresponds roughly to the duration of one cell cycle of V79 cells. After the 
exposure to the aforementioned agents, the culture medium was replaced by fresh medium 
and colchicine (0.7 µg/ml) was added. Cells were incubated for a further period of 2.5 h, 
and harvested by trypsinization. After a 3 min hypotonic treatment with 75 mM KCl at  
37 ºC, the cells were fixed with methanol/acetic acid (3:1), and slides were prepared and 
stained with Giemsa (4% (v/v) in 0.01 M phosphate buffer, pH 6.8) for 10 min. Two to 
four independent experiments were performed for each sample. For each individual 
experiment, at least 1000 cells were scored using a 400  magnification on a light 




3.2.5. DHE fluorimetric assay 
DHE is a cell permeable probe that reacts with O2
•–
 to form the fluorescent product 2-
hydroxyethidium (Fig. 3.6) [30]. Although its reaction with other ROS may interfere with 
the fluorescence peak, the oxidation of DHE is mostly superoxide dependent [31, 32]. 




Fig. 3.6 – Reaction of dihydroethidium with O2
•–
, originating the fluorescent product  
2-hydroxyethidium. 
 
In this assay, approximately 2  10
4
 cells/well were cultured for 24 hours in 96-well 
plates (black-wall/clear-bottom - Costar 3603). Afterwards, the cells were exposed for 3 h 
to the oxidant systems in the presence or absence of MnTM-4-PyP and to DHE at a final 
concentration of 10 M. The concentrations of the oxidants were: X (240 μM)/XO (100 
and 200 U/L), TBHP (1 and 2 mM) and Dox (2.5, 5 and 10 μM). These concentrations of 
the oxidants allowed a marked increase in the fluorescence intensity. A  
3 h incubation period was chosen due to the instability of ROS and also to avoid a 
pronounced cell death. Otherwise, changes in fluorescence intensity could result from 
differences in the number of cells and not necessarily in the level of ROS. After the 
treatments, the cells were carefully washed with PBS. 200 L of PBS were then added to 
each well and the fluorescence was determined in a Zenyth 3100 microplate reader, using 
excitation = 485 nm and emission = 595 nm. The results were expressed as percentages of 





independent experiments were performed, each comprising six replicate cultures for each 
experimental point.  
 
3.2.6. Statistical analysis 
The Kolmogorov-Smirnov test was used to assess the normality of continuous 
variables. For the variables with a normal distribution the homogeneity of the variances 
was evaluated using the Levene test, and the differences in mean values of the results 
observed in cultures with different treatments were evaluated by the Student’s t-test.  For 
non normal variables the Mann-Whitney test was used. All analyses were performed with 




3.3. Results and Discussion 
The association of oxidative stress with several pathologies supports the development 
of polyfunctional antioxidants, such as MnTM-4-PyP. Despite the extensive research with 
this SODm, cell-based studies focused on oxidant models that exert their toxicity through 
distinct mechanisms are still required. In this context, this Chapter is focused on three 
oxidant systems: XXO, an extracellular O2
•–
 generator; TBHP that generates ROO
•
 radicals 




3.3.1. Effects of MnTM-4-PyP 
To properly study the XXO, TBHP and Dox oxidant models in the presence of 
MnTM-4-PyP, the effects induced by this compound per se were firstly evaluated in V79 
cells. In the MTT reduction assay (Fig. 3.7A – white bars), after a 24 h-incubation period 
with MnTM-4-PyP, no cytotoxic effects were observed at lower concentrations (1, 10 and 
50 μM). However, a decrease of ~12% in the MTT reduction was noticed at 100 μM (P < 
0.05). 
 
Fig. 3.7 - Effect of MnTM-4-PyP on the cytotoxicity induced by xanthine (240 M) plus 
xanthine oxidase (20 U/L) in V79 cells - grey bars. Cells were incubated with increasing 
concentrations of MnTM-4-PyP in the presence of XXO for 24 h, and then submitted to the 
MTT (A) or to the CV (B) assays. (*P < 0.05 and **P < 0.01, when compared with XXO-
treated cells without MnTM-4-PyP). The white bars present the cytotoxicity of MnTM-4-
PyP per se. (
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The toxicity of MnTM-4-PyP (100 μM, 24 h) was confirmed by the CV method (Fig. 
3.7B – white bars), where a ~16% decrease in cell viability was found. These results are in 
accordance to those reported by Kim et al [33], who have also observed a decrease in cell 
proliferation with MnTM-4-PyP. 
The MI was evaluated as a measure of cell division and proliferation. This endpoint 
gives information on the possible cell cycle arrest induced by a given agent in colchicine-
treated viable cells. The results are presented in Table III.1. Control cells presented a MI 
value of 9.0%, which was reduced to 7.8% by MnTM-4-PyP (2.5 and 100 µM). 
  
Table III.1 – Mitotic indices presented by V79 cells treated with the oxidants 
under study, in the absence or presence of MnTM-4-PyP. 
Treatment [MnTM-4-PyP] (µM) Mitotic Index
a
 
Negative control 0 9.0 ± 1.0 
MnTM-4-PyP 
2.5 7.8 ± 2.5 
100 7.8 ± 2.7 
Xanthine (240 µM) + XO (40 U/L) 
0 2.9 ± 0.1 
###
 
100 3.4 ± 1.1 
TBHP (50 µM) 
0 4.1 ± 0.5 
##
 
2.5 3.7 ± 0.3 
Dox (50 nM) 
0 5.5 ± 0.4 
##
 
100 5.2 ± 0.4 
a
 These results are mean values ± SD from two to four independent experiments. Cells were 
exposed to the compounds for 15 h before colchicine treatment. At least 1000 cells were 
scored for each sample in each independent experiment (
##
P < 0.01 and 
### 
P ≤ 0.001, when 




The exposure of V79 cells to MnTM-4-PyP (100 µM) for a 3 h-period resulted in a 
decrease of the levels of intracellular ROS (P < 0.05), as depicted in Fig. 3.8 (white bars). 
Decreases in the hydroxyethidium fluorescence were also observed by other authors using 
different mammalian cell lines exposed to MnTM-4-PyP [32] or other MnPs [34]. 
Although the DHE assay was performed using a shorter incubation period than the cell 
viability and MI assays, the abrogation of basal ROS herein observed may contribute to 
explain the decrease in those parameters, since ROS can act as signalling molecules in cell 
proliferation [1]. However, other mechanisms may be involved since it has been reported 
that MnPs could interfere with biological structures like DNA [35, 36] or lipid membranes 
[37]. 
 
Fig. 3.8 - Effect of MnTM-4-PyP on the intracellular superoxide anion levels, in the 
absence (white bars) or presence (grey bars) of xanthine (240 M) plus xanthine oxidase 
(100 or 200 U/L), as evaluated by the oxidation of DHE. Values (mean ± SD) represent 
relative fluorescence units (RFU) and are expressed as percentages of the control cells. (
#
P 
< 0.05 when compared with non-treated control cells; **P < 0.01 and ***P < 0.001 when 
compared with XXO-treated cells without MnTM-4-PyP). 
 
3.3.2. Effects of MnTM-4-PyP in XXO-treated cells 
XXO has been extensively used to study the antioxidant profile of a given compound 
[2, 3]. However, scarce information is available concerning the role of SODm, and 
especially MnTM-4-PyP on the modulation of the toxicity induced by this system. When 
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viability was observed (P < 0.05), both in the MTT and in the CV assays (Fig. 3.7 – grey 
bars). The addition of MnTM-4-PyP to XXO exposed cells led to a pronounced protective 
effect. As shown in the MTT results (Fig. 3.7A – grey bars), the protection was dose-
dependent and for concentrations of 5 µM and higher the effect of MnTM-4-PyP against 
the XXO-induced toxicity was statistically significant (P < 0.05). A maximum protection 
was achieved with 100 µM of MnTM-4-PyP, which allowed the cell survival to increase 
from ~50% to ~90% (P < 0.01). In the CV assay, a significant effect (P < 0.05) was also 
observed for concentrations of 50 µM and 100 µM of MnTM-4-PyP, as depicted in Fig. 
3.7B – grey bars. Thus, the 100 µM concentration of MnTM-4-PyP was selected for the 
DHE and MI assays. These protective effects can be explained by the SOD-like activity of 
MnTM-4-PyP. Since XXO is an extracellular generator of superoxide, the dismutation of 
this radical by MnTM-4-PyP in the extracellular medium is likely to contribute to the 
protection observed. It is also important to mention that a control experiment was 
performed in order to exclude the possibility of a direct inhibition of XO by MnTM-4-PyP 
(data not shown). While xanthine is oxidized by XO, concomitantly to the production of 
O2
•–
, uric acid is produced (Fig. 3.1) and its production can be monitored at 293 nm [5, 38]. 
As it was also previously shown by Faulkner et al [21] using different experimental 
conditions, MnTM-4-PyP did not decrease the production of uric acid by XXO, confirming 
that the generation O2
•–
 by XXO was not inhibited. Therefore, the effects observed in the 
biological assays are effectively due to the disproportionation of the superoxide anion and 
not a consequence of an inhibition of the O2
•–
 generation. 
In the DHE assay, V79 cells were incubated for 3 h with xanthine (240 µM) plus XO 
(100 and 200 U/L). Despite the fact that XXO produces superoxide in the extracellular 
medium, our results indicate that also the intracellular level of ROS is increased after an 
exposure to this oxidant system (Fig. 3.8 – grey bars). This is in accordance with other 
authors that using different mammalian cell lines also found increases in the intracellular 
ROS in XXO-treated cells [39, 40]. Some authors pointed out that the XXO system can 
produce H2O2 along with superoxide [6]. Since the DHE probe is considered to be quite 
insensitive to H2O2 [31] superoxide appears to be the major species involved in the DHE 
fluorescence in cells treated with XXO. The exposure of XXO-treated cells to MnTM-4-
PyP (100 µM) led to a decrease in the fluorescence intensity to values lower than those 
presented by the non-treated control cells (Fig. 3.8); this reduction can be explained by the 
dismutation of superoxide by MnTM-4-PyP.  
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The exposure of V79 cells to X (240 μM)/XO (40 U/L) resulted in a pronounced 
reduction of the MI value, from 9.0% to 2.9% (P ≤ 0.001) (Table III.1). In fact, many 
oxidative agents are known to impair cell division, dramatically reducing the MI and other 
proliferation indices [41, 42]. The concomitant incubation with MnTM-4-PyP only led to a 
slight and non-significant increase of the MI, to a value of 3.4 %, indicating a negligible 
effect of MnTM-4-PyP at the cell division level. 
 
3.3.3. Effects of MnTM-4-PyP in TBHP-treated cells 
Despite the extensive use of TBHP as an oxidant model, few studies to assess the 
effect of MnPs towards this agent are available. Figs. 3.9 and 3.10 show the effect of 
MnTM-4-PyP against the cytotoxicity induced by TBHP.  
 
Fig. 3.9 - Effect of MnTM-4-PyP on the cytotoxicity induced by TBHP (100 M) in V79 
cells. Cells were incubated with increasing concentrations of MnTM-4-PyP in the presence 
of TBHP for 24 h, and then submitted to the MTT (A) or to the CV (B) assays. 
(* P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001, when compared with TBHP-treated cells 
without MnTM-4-PyP). 
 
The exposure of V79 cells to TBHP (100 µM) resulted in a considerable decrease in 
the MTT reduction (P < 0.001), as well as in the CV staining (P < 0.05). When the effect 
of MnTM-4-PyP against TBHP-induced cytotoxicity was studied using the MTT assay, a 
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concentrations of MnTM-4-PyP ≥ 1 µM. MnTM-4-PyP (2.5 and 5 µM) has also shown a 
significant protection (P ≤ 0.05) using the CV assay (Fig. 3.9B).  
To further characterize this profile of protection, studies were performed with a range 
of TBHP concentrations (25 - 200 µM), using the MTT assay. The results are depicted in 
Fig. 3.10 and confirm that low concentrations of MnTM-4-PyP (2.5, 5 and 10 µM) can be 
effective in the reduction of TBHP-induced cytotoxicity. Concentrations of MnTM-4-PyP 
of 2.5 and 5 µM were therefore chosen for the MI evaluation and the DHE assay. 
 
 
Fig. 3.10 - Effect of MnTM-4-PyP on the cytotoxicity induced by TBHP in V79 cells, as 
evaluated by the MTT assay. Cells were incubated with increasing concentrations of 
MnTM-4-PyP (2.5-10 M) in the presence of different concentrations of TBHP (25-200 
M) for 24 h. (**P < 0.01 and ***P < 0.001, when compared with cells treated with the 
same concentration of TBHP in the absence of MnTM-4-PyP). 









































As shown by the DHE assay, the exposure to TBHP (1.0 and 2.0 mM, 3 h) led to a 
significant increase in the intracellular level of O2
•–
 in V79 cells (Fig. 3.11). An increase in 
the fluorescence intensity was also observed by Scanlon and Reynolds [43] after exposing 
DHE-loaded neurons to TBHP. Additionally, the production of O2
•–
 by TBHP was 
previously reported by Awe et al [10]. In the present experiments, MnTM-4-PyP (5.0 µM) 
completely abolished the effect of TBHP (P < 0.05, Fig. 3.11), suggesting that the 
scavenging of ROS, including superoxide anion may be involved in the protection afforded 
by this SODm. In addition, MnTM-4-PyP has previously shown the capacity to inhibit 
lipid peroxidation [44]. The ability of MnTM-4-PyP to decompose peroxyl radicals may 
therefore be a relevant mechanism for the abrogation of the TBHP toxicity. 
 
Fig. 3.11 - Effect of MnTM-4-PyP on the intracellular superoxide anion levels in cells 
treated with TBHP (1.0 or 2.0 mM), as evaluated by the oxidation of DHE. Values (mean ± 
SD) represent relative fluorescence units (RFU) and are expressed as percentages of the 
control cells. (*P < 0.05 when compared with TBHP-treated cells without MnTM-4-PyP). 
 
The exposure of V79 cells to TBHP (50 μM) led to a reduction of the MI value from 
9.0% to 4.1% (P < 0.01). The concomitant incubation with MnTM-4-PyP did not change 
considerably the MI value (Table III.1). This absence of effect by MnTM-4-PyP that was 
also above mentioned for the XXO system may be a consequence of DNA repair. When 
oxidative DNA damage occurs, cell cycle arrest is essential to allow time to deal with the 
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3.3.4. Effects of MnTM-4-PyP in Dox-treated cells 
As aforementioned, Dox can injure cells through different mechanisms, including the 
generation of ROS. The incubation of V79 cells with Dox (2.5 µM) for 24 h resulted in a 
significant inhibition of the MTT reduction (P < 0.01). The treatment with MnTM-4-PyP 
(1 - 100 µM), did not alter the % MTT reduction presented by Dox, as shown in Fig. 
3.12A.  
 
Fig. 3.12 - Effect of MnTM-4-PyP on the cytotoxicity induced by Dox in V79 cells. Cells 
were incubated with increasing concentrations of MnTM-4-PyP in the presence of Dox 
(2.5 M) for 24 h, and then submitted to the MTT assay (A). The panel B represents the 
results obtained with the CV assay for the exposure of V79 cells to MnTM-4-PyP and Dox 
(5 M). 
 
To confirm these data, studies were performed using a range of Dox concentrations 
up to 20 µM. Only slight but non-significant protective effects were observed (Fig. 3.13). 
The CV staining (Fig. 3.12B) was performed for Dox (5 µM) in the presence of MnTM-4-
PyP (50 and 100 µM) and no changes in cell viability were observed. Also, the cell 
division impairment induced by Dox (50 nM), expressed as a decrease in the MI value 
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Fig. 3.13 - Effect of MnTM-4-PyP on the cytotoxicity induced by Dox in V79 cells, 
as evaluated by the MTT assay. Cells were incubated with increasing concentrations of 
MnTM-4-PyP (25-100 M) in the presence of different concentrations of Dox (2.5-20 M) 
for 24 h.  
 
In the DHE assay, the intracellular production of ROS was observed in cells exposed 
to Dox (2.5, 5 and 10 µM) for 3 h (Fig. 3.14). The concomitant incubation with MnTM-4-
PyP (100 µM) resulted in a significant decrease of fluorescence for 2.5 µM of Dox. The 
fluorescence intensity of cells treated with 5 µM of Dox has also decreased in the presence 
of MnTM-4-PyP (non significant), although no effect was observed for the 10 µM 
concentration. At this concentration, we can not rule out that the generation of O2
•–
 can 
somehow overwhelm the activity of MnTM-4-PyP. Further studies using more potent 
ortho-subsituted MnPs, namely MnTM-2-PyP, MnTE-2-PyP or MnTnHex-2-PyP [36, 46] 
could give some additional insight on this matter. Ortho-substituted porphyrins also 
possess different stericity than the para- analogues. Being bulkier, they interact differently 
with biological molecules, what may give additional mechanistic insights particularly in 
relation to Dox. 
 
 


























Fig. 3.14 - Effect of MnTM-4-PyP on the superoxide anion levels in cells treated with Dox 
(2.5, 5 or 10 M), as evaluated by the oxidation of DHE. Values (mean ± SD) represent 
relative fluorescence units (RFU) and are expressed as percentages of the control cells. 
(**P < 0.01 when compared with Dox-treated cells without MnTM-4-PyP). 
 
The results presented here suggest the complexity of mechanisms of action presented 
by Dox. It is usually mentioned that while Dox-induced cardiotoxicity seems to be 
mediated by free radicals formation, the antitumor activity of this drug is mainly due to 
non-radical dependant mechanisms [1, 11, 15]. Cell type specificities may therefore be 
involved in this lack of protection. Konorev et al [47] have reported protective results 
using a different manganese porphyrin – MnTBAP, in Dox-treated cardiomyocytes. It has 
been reported that cardiomyocytes are particularly vulnerable to the oxidative stress 
induced by Dox because of their relatively modest antioxidant defenses [1, 11, 15]. This 
fact may justify the diverse responses to oxidative stress and antioxidants between 
cardiomyocytes and other cell types. To clarify the potential role of MnTM-4-PyP against 




In this Chapter, MnTM-4-PyP presented differential responses, depending on the 
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TBHP, whereas no considerable protection was found for Dox. These results emphasize the 
importance of the mechanisms of toxicity inherent to each oxidant model on the responses 
of MnTM-4-PyP, and reinforce the need to study different models and experimental 
conditions for the adequate evaluation of the potentialities of a catalytic antioxidant. 
Moreover, the data obtained within this Chapter allowed the validation of two models of 
oxidative stress injury, XXO and TBHP, in which the well established SODm MnTM-4-
PyP was a protective antioxidant. These models are useful tools to study novel SODm 
compounds and were applied to study the potential antioxidant effects of macrocyclic 
copper(II) complexes synthesized and developed within the scope of the present thesis 
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This Chapter was adapted from: 
Protective role of ortho-substituted Mn(III) N-alkylpyridylporphyrins against the oxidative 
injury induced by tert-butylhydroperoxide. A.S. Fernandes, J. Gaspar, M.F. Cabral, J. 





This Chapter addresses the role of two ortho-substituted Mn(III) N-alkylpyridylporphyrins, 
alkyl being ethyl in MnTE-2-PyP
5+
 and n-hexyl in MnTnHex-2-PyP
5+
, on the protection 
against the oxidant TBHP. Their protective role was studied in V79 cells using endpoints 
of cell viability (MTT and CV assays), intracellular O2
•–
 generation (DHE assay) and 
glutathione status (DTNB and monochlorobimane assays).  MnPs per se did not show 
cytotoxicity in V79 cells (up to 25 µM, 24 h). The exposure to TBHP resulted in a 
significant decrease in cell viability and in an increase in the intracellular O2
•–
 levels. Also, 
TBHP depleted total and reduced glutathione and increased GSSG. The two MnPs 
counteracted remarkably the effects of TBHP. Even at low concentrations, both MnPs were 
protective in terms of cell viability and abrogated the intracellular O2
•–
 increase in a 
significant way. Also, they augmented markedly the total and reduced glutathione contents 
in TBHP-treated cells, highlighting the multiple mechanisms of protection of these SODm, 












Manganese porphyrins (MnPs) are among the most effective functional catalytic 
antioxidants [1, 2] and have been showing remarkable effects in different models of 
oxidative stress [3]. As stated in Chapter 1 (section 1.2.2), these compounds have the 






 radicals  due to 
their several in vivo easily accessible oxidation states (+2, +3, +4, +5) [3]. Furthermore, the 
mitigation of oxidative damage by MnPs seems to involve the modulation of cellular 
redox-based metabolic pathways (e.g. HIF-1α, NF-kB, and AP-1 transcription factors) [4-
8]. 
In Chapter 3 the ability of the Mn(III) para methylpyridylporphyrin  MnTM-4-PyP, 
to cope with the cytotoxicity induced by XXO, TBHP and Dox was studied, and the 
possibility of evaluating ortho-substituted analogues was raised. Ortho-substituted 
porphyrins have been developed based on structure-activity relationship [1, 9, 10] and 
possess among the highest catalytic rate constants for O2
•–
 dismutation, due to a combined 
effect of inductive, resonance, steric and electrostatic factors [9]. When the positive charge 
is moved from para onto ortho position of the pyridyl groups, i.e. closer to the porphyrin 
ring, the redox potential at the manganese site shifts to around +300 mV vs NHE. This is 
the midway potential between the oxidation and reduction of O2
•–
 which allows equal 
facilitation for both steps of dismutation process, and thus the optimal kcat on 
thermodynamic basis.  Another factor that contributes to the antioxidant potency of the 
ortho isomers is the presence of positive charges close to the porphyrin ring that guide 
negatively charged O2
•–
 to the metal center [1, 11, 12]. It has been further demonstrated 
that kcat for the O2
•–
 dismutation parallels the rate constant for ONOO
-
 reduction. Same 
thermodynamic as well as electrostatic facilitation for the approach of negatively charged 
ONOO
-
 to the Mn site is assured [13]. Finally, and as stated above, the same mechanism of 
action with ROO
•
 as with ONOO
-
 is presumably operative.  When compared to para 
analogues, the ortho isomers are further bulkier and thus do not interact significantly with 
nucleic acids, and are in turn expected to be less toxic [9]. This Chapter studies two ortho-
substituted MnPs, MnTE-2-PyP and MnTnHex-2-PyP (Fig. 4.1). These MnPs are nearly 
identical in terms of O2
•–
 dismuting and ONOO
-
 reducing abilities [1, 13]. However, 
MnTnHex-2-PyP is 13 500-fold more lipophilic than MnTE-2-PyP, and thus more prone to 




Fig. 4.1 - Chemical structures of the Mn(III) porphyrins MnTE-2-PyP and  
MnTnHex-2-PyP. 
 
Ortho-substituted MnPs have already shown remarkable protective effects in in 
vitro and in vivo models of oxidative stress injuries [2, 6, 7]. However, a thorough 
knowledge on the effects at the cellular level is still missing. In Chapter 3, MnTM-4-PyP 
showed to be a potent antioxidant against the toxic effects of TBHP in V79 cells. In the 
present Chapter, the protection afforded by MnTE-2-PyP and MnTnHex-2-PyP against the 
same oxidative stress inducer is evaluated. This work also aims to explore if enhanced 
lipophilicity of the hexyl analogue makes it a more potent compound in this model. 
Recently 6 MnPs, 3 Mn salens and 2 Mn cyclic polyamines in radioprotection of ataxia 
telangiectasia cells were compared, among them MnTE-2-PyP and MnTnHex-2-PyP [16]. 
While MnTnHex-2-PyP was efficacious, the equally potent antioxidant, but hydrophilic  
MnTE-2-PyP was not. The study indicated the critical role of compound bioavailability 
and suggested that the accumulation of the hexyl analogue within mitochondria may be in 
the origin of its efficacy. 
As mentioned in Chapter 3, TBHP is a short chain analogue of lipid hydroperoxides 
that has been often used as a model to investigate the mechanism of cell injury initiated by 
acute oxidative stress in a variety of cells [17-22]. Because of the higher stability and 
presence of the hydrophobic butyl moiety which allows easier membrane penetration, 
TBHP provides a convenient alternative to the natural oxidants hydrogen peroxide and 
lipid hydroperoxide [22]. TBHP penetrates cell membranes [22, 23] and can generate free 



























[23]. Cell injury can consequently occur by different phenomena, including changes in 
mitochondrial permeability [24], oxidative DNA damage, lipid peroxidation [25] and 
apoptosis [21]. Moreover, inside the cell, TBHP can be reduced to t-butanol by GPx [22], 
promoting the depletion of intracellular GSH as reported in hepatocytes and other cell 
types [20, 22, 25-29]. Glutathione is the main nonenzymatic antioxidant defense within the 
cell; the GSH/GSSG ratio reflects the cellular redox state [17, 30]. Since thiol homeostasis 
determines critical aspects of cell function and response [19], an imbalance at this level 
will further contribute to cell injury.  
The present Chapter aims to evaluate and compare the role of optimized MnPs 
MnTE-2-PyP and MnTnHe2-PyP against TBHP-induced cell injury, using a multilevel 
approach. In order to achieve these goals two complementary cell viability assays (MTT 
and CV) were used. ROS generation was assessed using the fluorescence probe DHE. The 
total glutathione (GSHt) and the oxidized glutathione (GSSG) contents were measured by 
the 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) assay. Also, the reduced glutathione, 
expressed as a percentage of the GSH content relatively to non treated control cells was 




4.2. Materials and Methods 
 
4.2.1. Chemicals 
PBS, Ham’s F-10 medium, newborn calf serum, penicillin-streptomycin solution, 
trypsin, MTT, CV, TBHP, 5-sulfosalicylic acid, glutathione reductase from baker's yeast, 
GSH, DTNB, nicotinamide adenine dinucleotide phosphate (NADPH), and glutathione-S-
transferase (GST) from equine liver were obtained from Sigma-Aldrich. A stock solution 
of GST (10 U/mL) was prepared in PBS with 10% glycerol, aliquotized and stored at  
−18 ºC. DMSO and ethanol were purchased from Merck. GSSG and mCB were obtained 
from Fluka. A stock solution of mCB (10 mM) was prepared in ethanol, aliquotized and 
stored at −18 ºC. DHE was purchased from Molecular Probes. MnTE-2-PyP and 
MnTnHex-2-PyP were synthesized at Duke University as previously described [31]. 
 
4.2.2. MTT Reduction assay 
Cytotoxicity assays were carried out in V79 cells, cultured as described in Chapter 
3 (3.2.2). The MTT reduction assay was performed according to the protocol described in 
Chapter 3 (3.2.3.1). V79 cells were treated for 24 h with TBHP (100 – 300 µM) in the 
presence or absence of MnPs (0.1-25 µM). The cytotoxicity induced by the MnPs per se 
was evaluated under the same experimental conditions. After the treatments, the assay was 
carried out as described in the previous Chapter. Three to six independent experiments 
were performed and eight replicate cultures were used for each concentration in each 
independent experiment. 
 
4.2.3. Crystal Violet assay 
The CV assay was performed as described in Chapter 3 (3.2.3.2). Cells were 
exposed for a 24 h period to TBHP (100 µM) with or without the MnPs (1-25 µM). Three 
to seven independent experiments were performed, each one comprising eight replicate 
cultures.  
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4.2.4. DHE fluorimetric assay 
 The DHE assay was performed as described in Chapter 3 (3.2.5), being V79 cells 
exposed for three hours to TBHP (100 µM) in the presence or absence of the MnPs (5 
µM). Five independent experiments were performed, each comprising six replicate cultures 
for each experimental point. 
 
4.2.5. DTNB assay 
The DTNB assay [32-34] was used to quantify the GSHt and GSSG contents. This 
method is simple and convenient, and is based on the reaction of DTNB with GSH, 
generating a product spectrophotometrically detectable at 412 nm (Fig. 4.2) [34]. 
 
Fig. 4.2 – Fundamentals of the DTNB assay (from [34]). GSH reacts with DTNB [5,5’-
dithiobis(2-nitrobenzoic acid)] to form TNB (5-thio-2-nitrobenzoic acid) and the adduct 
GS-TNB. GS-TNB, as well as GSSG, is then reduced to GSH by glutathione reductase 
(GR) in the presence of NADPH. The TNB formed can be measured at 412 nm [34]. 
 
V79 cells were cultured in Petri dishes (~3.0  10
4
 cells/mL of culture medium) and 
incubated for 24 h at 37°C, under a 5% CO2 atmosphere. The culture medium was then 
replaced by fresh medium and cells were treated for a further 24 h period with TBHP  
(100 µM) in the presence or absence of the MnPs (5 µM). After this incubation, cells were 
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carefully washed, scrapped with ice-cold PBS and centrifuged for 10 min at 200 x g. The 
obtained pellet was suspended in PBS and submitted to two freeze-thaw cycles (-80 ºC / 
room temperature). An aliquot of this lysate was saved for the analysis of protein content 
by the Bradford assay and for the mCB assay. Sulfosalicylic acid was added to the 
remaining volume of lysate at a final concentration of 3%, and this suspension was 
centrifuged for 10 min, at 12 000 x g, 4 ºC. The obtained supernatant was divided for the 
quantification of the GSHt and GSSG. GSH and GSSG standard solutions were prepared in 
3% sulfosalicylic acid. For the GSSG quantification, both samples and GSSG standards 
were treated with 2-vinylpyridine (2.5%) to derivatize GSH. The pH was adjusted to ~6 
with triethanolamine and the samples were incubated for 1 h, at 4 ºC before the assay. 
In a 96-well microplate, the GSHt and GSSG samples and standards were mixed with 
a freshly made solution containing glutathione reductase and DTNB, in phosphate buffer 
0.1 M (pH 7.0, containing 1 mM edta). The reaction was started by the addition of 
NADPH. The final concentrations in the reaction mixture were 0.125 U/mL of glutathione 
reductase, 0.028 mg/mL of DTNB and 43 µM of NADPH. The kinetics of the absorbance 
increase at 405 nm was recorded at 4 min intervals over a 20 min period. The glutathione 
concentration in the samples was calculated by comparing the slopes of the sample with 
those of the correspondent standard curve, and the result was expressed in nmol/mg 
protein. At least nine independent experiments were performed for the GSHt content and 
four were performed for the GSSG determination. Each independent experiment comprised 
the analysis of all samples and standards in duplicate. 
 
4.2.6. mCB assay 
The mCB assay was adapted from Kamencic et al [35]. mCB is a probe that reacts 
with GSH generating an adduct (Fig. 4.3) that can be detected by fluorimetry [35, 36]. 
In a black 96-well microplate, PBS was added to 20 µL of the cell lysate (section 
4.2.5), 1 U/mL GST, and 100 µM mCB at a final volume of 100 µL. The reaction 
microplate incubated 30 min in the dark, at 37 ºC, 100 rpm. The mCB–glutathione adduct 
was then measured in a Zenyth 3100 multimode detection microplate reader, using excitation 
= 405 nm and emission = 465 nm. The results were expressed as %GSH of non-treated 
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control cells, after subtracting the background fluorescence and normalizing to the protein 
content. At least five independent experiments were performed, each comprising two 




Fig. 4.3 – Fundamentals of the mCB assay. The reaction of the non-fluorescent 
monochlorobimane (mCB) with reduced glutathione generates the highly fluorescent 
mCB-glutathione conjugate. 
 
4.2.7. Stability of MnPs  
The stability of MnPs under the experimental conditions described in the previous 
assays was evaluated by UV/Vis spectroscopy, using the supernatants of the cell cultures 
incubated for 24 h with MnPs (5 µM) and/or TBHP (100 µM). The supernatant of non-
treated control cultures was used as reference to adjust the baseline. Two independent 
assays were performed.  Both for MnTE-2-PyP and for MnTnHex-2-PyP, the UV/Vis 
spectra of the supernatant of cultures treated with each MnP alone were identical to those 
of cultures treated with “MnP+TBHP”. Therefore, under these experimental conditions, 
MnPs remain stable and no oxidative degradation occurs. 
 
4.2.8. Statistical analysis 




4.3. Results and Discussion 
The most active SODm described so far are among the ortho-substituted MnPs [1, 
2, 37]. However, a thorough knowledge on the effects of these compounds at the cellular 
level is still lacking. In this context, this Chapter studies the effects of two ortho-
substituted MnPs, MnTE-2-PyP and MnTnHex-2-PyP, against the cytotoxic effects 
induced by TBHP in V79 cells. Albeit TBHP is commonly used as an oxidant model, few 
studies to assess the effect of catalytic antioxidants towards this agent are available.  
 
4.3.1. Cytotoxicity profile of MnTE-2-PyP and MnTnHex-2-PyP 
The effects induced by MnTE-2-PyP and MnTnHex-2-PyP per se were firstly 
evaluated in V79 cells, at concentrations up to 25 µM.  After a 24 h-incubation period, no 
cytotoxicity was observed for MnPs, either using the MTT (Fig. 4.4) or the CV assay (data 
not shown). Interestingly, with Escherichia coli toxicity of MnTnHex-2-PyP was observed 
already at > 3 µM levels [15, 37]. 
 
Fig. 4.4 - Cytotoxicity evaluation of MnTE-2-PyP (A) and MnTnHex-2-PyP (B). V79 cells 
were treated with the MnPs for 24 h and then submitted to the MTT assay. 
 
4.3.2. Effects of MnTE-2-PyP and MnTnHex-2-PyP against TBHP-induced cytotoxicity 
Figs. 4.5 and 4.6 show the effect of MnTE-2-PyP against the cytotoxicity induced 
by TBHP. The exposure of V79 cells to TBHP (100 µM) resulted in a considerable 
decrease in the MTT reduction (P < 0.01), as well as in the CV staining (P < 0.001). The 








































reduction when compared with TBHP-treated cells, even for the 0.1 µM concentration 
(Fig. 4.5A). At 5 µM, MnTE-2-PyP was highly protective, reverting the decrease in MTT 
reduction induced by TBHP (P < 0.05). The CV assay confirmed the significant protective 




Fig. 4.5 - Effect of MnTE-2-PyP on the cytotoxicity induced by TBHP (100 M) in V79 
cells. Cells were incubated with increasing concentrations of MnTE-2-PyP in the presence 
of TBHP for 24 h, and then submitted to the MTT (A) or to the CV staining (B) assays. 
(*P ≤ 0.05 and **P ≤ 0.01, when compared with TBHP-treated cells in the absence of 
MnTE-2-PyP). 
 
To assess the effect of MnTE-2-PyP in more severe conditions, experiments using 
higher concentrations of TBHP were performed. As depicted in Fig. 4.6, cultures treated 
for 24 h with 200 and 300 µM of TBHP showed a drastic cell death. The co-incubation 
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Fig. 4.6 - Effect of MnTE-2-PyP on the cytotoxicity induced by TBHP in V79 cells, as 
evaluated by the MTT assay. Cells were incubated with increasing concentrations of 
MnTE-2-PyP (1-25 M) in the presence of different concentrations of TBHP (100-300 
M) for 24 h. (*P ≤ 0.05 and **P < 0.01, when compared with cells treated with the same 
concentration of TBHP in the absence of MnTE-2-PyP). 
 
The effect of MnTnHex-2-PyP against the TBHP-induced cytotoxicity is shown in 
Figs. 4.7 and 4.8. In the MTT assay (Fig. 4.7A) this MnP also exerted a considerable 
protective effect, which was statistically significant (P < 0.05) for concentrations ≥ 1 µM. 
Like MnTE-2-PyP, 5 µM of MnTnHex-2-PyP was the lowest concentration that exhibited 
a maximum reversal of cell viability. Both MnPs have shown remarkable protective effects 
against the cytotoxicity induced by TBHP. The protection afforded by MnPs was lower in 
the CV assay than observed with the MTT assay, what may be attributed to the 




































Fig. 4.7 - Effect of MnTnHex-2-PyP on the cytotoxicity induced by TBHP (100 M) in 
V79 cells. Cells were incubated with increasing concentrations of MnTnHex-2-PyP in the 
presence of TBHP for 24 h, and then submitted to the MTT (A) or to the CV staining (B) 





Fig. 4.8 - Effect of MnTnHex-2-PyP on the cytotoxicity induced by TBHP in V79 cells, as 
evaluated by the MTT assay. Cells were incubated with increasing concentrations of 
MnTnHex-2-PyP (1-25 M) in the presence of different concentrations of TBHP (100-300 
M) for 24 h. (*P ≤ 0.05, **P < 0.01 and ***P < 0.001, when compared with cells treated 
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In Chapter 3, the performance of MnTM-4-PyP, a para-substituted MnP, was 
evaluated in the same oxidative stress model. In the present work, both MnTE-2-PyP and 
MnTnHex-2-PyP were more effective than the para- analogue, showing better 
protectiveness at lower concentrations. This higher performance may be attributed to the 
greater antioxidant potency, since the ortho analogues have higher catalytic rate constant 
for O2
•–
 dismutation and ONOO
-
 reduction, and presumably higher rate constant for the 
reaction with peroxyl radicals than para isomers as well [38, 39]. The reaction with 
peroxyl radical involves formation of O=Mn
IV
P, which is also involved in the reaction with 
ONOO
-
; the reactivity is related to the electron-deficiency of MnP that is similar with all 
ortho substituted alkylpyridylporphyrins; therefore the ability of MnPs to remove both 
ONOO
-
 and peroxyl radical is likely similar also.  
The two MnPs have shown comparable cytoprotection profiles with both CV (Fig. 
4.5B and 4.7B) and MTT assays (Fig. 4.5A, 4.6, 4.7A and 4.8). However, with  
MnTE-2-PyP the significant protective effects were seen at lower concentrations (0.1 µM). 
Furthermore, MnTE-2-PyP led to slightly higher cell viabilities in the CV assay, as well as 
in cultures treated with 200 µM of TBHP. It has been reported that MnTE-2-PyP and 







 [13, 31]. Since MnTnHex-2-PyP is more prone to enter the cell due to its 4 orders of 
magnitude higher lipophilicity [14, 15] one could expect this MnP to be more efficient than 
the ethyl analogue at lower concentrations. However, our results showed a slightly higher 
potency for MnTE-2-PyP. It has been reported that V79 cells have endocytic activity [40]. 
In view of this, it is possible that despite the higher lipophilicity of MnTnHex-2-PyP, both 
MnPs have been uptaken by V79 cells in a similar way. It is also possible that the 
protective effects occurred in extracellular millieu, plasma membrane and cytosolic space, 
rather than in mitochondria. As stated in Introduction (section 4.1), were the effects 






4.3.3. Effects of MnTE-2-PyP and MnTnHex-2-PyP against TBHP-induced ROS 
generation 
The data on the intracellular generation of superoxide anion, as evaluated by the 
DHE assay, are depicted in Fig. 4.9. The exposure of V79 cells to TBHP (100 µM) led to a 
significant increase in the fluorescence intensity (P < 0.01), indicating the intracellular 
production of O2
•–
 by TBHP. The intracellular ROS production has been previously 
reported as an early event in TBHP-induced cytotoxicity [41], what justifies the observed 
increase in a 3 h incubation period. When cells were exposed to TBHP and MnTE-2-PyP 
or MnTnHex-2-PyP (5 µM), the fluorescence intensities returned to values lower than 
those presented by control cells (P < 0.01). 
 
Fig. 4.9 - Effect of MnTE-2-PyP (A) and MnTnHex-2-PyP (B) on the DHE oxidation in 
V79 cells treated with TBHP (100 µM). Values (mean ± SD) represent relative 
fluorescence units (RFU), which approximately reflect the levels of superoxide anion, 
expressed as percentages of the control cells. (
##
P < 0.01, when compared with non-treated 
control cells; **P < 0.01, when compared with cells treated with TBHP in the absence of 
MnP). 
 
The effect of the MnPs on the O2
•–
 levels of cells treated with higher concentrations 
of TBHP (1.0 and 2.0 mM) was also tested. Even in this case, the presence of MnPs 
decreased significantly the fluorescence intensities to values lower than controls (data not 
shown). These results suggest that the scavenging of superoxide anion should be involved 
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activity, the ability of MnPs to decompose peroxyl radicals should also be a relevant 
mechanism for the abrogation of TBHP effects. The two MnPs showed a similar efficiency 
in reducing the intracellular ROS. It is also important to mention that cells treated only 
with the MnPs, either MnTE-2-PyP or MnTnHex-2-PyP, exhibited a considerable 
reduction in the hydroxyethidium fluorescence (P < 0.01) which could be ascribed to the 
abrogation of some level of oxidative stress that cells experience while growing in the 
medium or of the basal cellular ROS content. 
 
4.3.4. Effects of MnTE-2-PyP and MnTnHex-2-PyP on the changes in glutathione status 
induced by TBHP 
Glutathione is the main nonenzymatic antioxidant defense within the cell and its 
content, as well as the GSH/GSSG ratio, reflects the cellular redox state [22, 30, 42]. 
Under normal conditions, reduced GSH is largely predominant over GSSG, while with 
oxidative stress the percentage of GSSG can increase considerably [43]. To evaluate the 
glutathione status of cells submitted to different treatments, we have used two 
complementary approaches. The classical DTNB assay was used to determine the total 
glutathione content and the GSSG concentration, and the fluorimetric mCB assay to assess 
the reduced form of glutathione. The results of the DTNB assay are shown in Table IV.1. 
V79 cells, upon treatment with 100 µM TBHP, exhibited a marked depletion in the 
total glutathione content, that decreased from 7.69 to 2.50 nmol/mg prot (P < 0.001). 
When cells were concomitantly exposed to TBHP and MnTE-2-PyP or MnTnHex-2-PyP, 
the GSHt increased to 16.54 and 19.71 nmol/mg prot, respectively. These increases were 
statistically significant (P < 0.001), when compared to the GSHt content of cells exposed 
only to TBHP. These cells also exhibited GSHt levels significantly above those of non-
treated control cells (P < 0.001). The MnPs per se did not considerably change the GSHt 
content of V79 cells. Similar results were found for the para analogue MnTM-4-PyP. 
While this MnP per se did not alter significantly the GSHt levels, V79 cells co-treated with 
MnTM-4-PyP and TBHP presented a GSHt content of 19.22 ± 4.05 nmol/mg prot, a value 
that is significantly above control cells (P ≤ 0.001) and TBHP-treated cells (P < 0.01) 
(data not shown). 
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 In control cells, as well as in cells treated only with MnTE-2-PyP or MnTnHex-2-
PyP (5 µM), the levels of GSSG were low, having a small contribution for the total 
glutathione content. When V79 cells were treated with 100 µM TBHP, the GSSG level 
increased significantly (P < 0.01), accounting considerably for the GSHt observed in this 
case (Table IV.1). Cells co-treated with TBHP and MnTE-2-PyP or MnTnHex-2-PyP, 
although had very high GSHt contents, did not show remarkable GSSG concentrations. 
 
Table IV.1 - Effect of MnTE-2-PyP and MnTnHex-2-PyP on the changes in glutathione 









Non-treated control cells 7.69 ± 3.07 0.20 ± 0.10 
MnTE-2-PyP 5 µM 8.20 ± 2.20 0.22 ± 0.19 
MnTnHex-2-PyP 5 µM 7.34 ± 3.77 0.18 ± 0.11 
TBHP 100 µM 2.50 ± 2.90 
###
 1.07 ± 0.30 
##
 
TBHP 100 µM + MnTE-2-PyP 5 µM 16.54 ± 4.92 
###, ***
 0.46 ± 0.11 
#, *
 
TBHP 100 µM + MnTnHex-2-PyP 5 µM 19.71 ± 5.53 
###, ***





Values represent mean ± SD of at least nine independent experiments 
b 
Values represent mean ± SD of four independent experiments 
#
P < 0.05, 
##
P < 0.01 and 
###
P < 0.001, when compared with non-treated control cells 
*P < 0.05 and ***P < 0.001, when compared with cells treated with TBHP alone 
 
The data obtained using the mCB assay, which detects the reduced form of 
glutathione (GSH) are depicted in Fig. 4.10. These results are expressed as a percentage of 
the GSH content of non treated control cells, that presented an average fluorescence value 
of 3.1 x 10
4
 RFU/µg prot. The treatment of V79 cells with the MnPs (5 µM) did not alter 
the GSH content. Cells treated with 100 µM TBHP showed a dramatic GSH depletion, 
having only ~22% of the GSH of control cells (P < 0.001). When cells were incubated 
simultaneously with TBHP and MnTE-2-PyP or MnTnHex-2-PyP, their GSH level 
increased markedly, not only restoring the depletion induced by TBHP (P < 0.01), but also 
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Fig. 4.10 - Effect of MnTE-2-PyP and MnTnHex-2-PyP (5 µM) on the GSH depletion 
induced by TBHP (100 µM) in V79 cells, as evaluated by the mCB assay.  Values (mean ± 
SD) represent relative fluorescence units (RFU) expressed as percentages of the control 
cells, after normalizing to the protein content of the lysate. Control cells exhibited an 
average fluorescence value of 3.1 x 10
4
 RFU/µg prot. (
###
P < 0.001, when compared with 
non-treated control cells; **P < 0.01, when compared with cells treated with TBHP in the 
absence of MnP). 
 
Glutathione can reduce different hydroperoxides and radicals, and it has been 
reported to be depleted after an exposure to TBHP [19, 20, 26, 28]. In addition, TBHP was 
previously shown to increase the GSSG level [17, 44-46]. Our results concur with these 
previous reports either in terms of GSH depletion or GSSG increase. 
The intracellular level of GSH is regulated by the γ-glutamylcysteine synthetase (γ-
GCS) activity and by the availability of the precursor cysteine [47]. γ-GCS activity is rate 
limiting in the synthesis of GSH and this enzyme is subject to feedback regulation by the 
concentrations of glutathione [43]. Previous studies have shown that organic peroxides, 
and specifically TBHP, can stimulate the de novo biosynthesis of GSH [45, 47], by up-
regulating the expression of γ-GCS mRNA [44] and by increasing the activity of this 
enzyme [47]. In fact, Ochi [47] reported an increase in γ-GCS activity in V79 cells after a 
1 h-exposure to 100 μM TBHP. It is therefore expectable that TBHP is stimulating this 
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enzyme under the used experimental conditions. However, due to the ROS and lipid 
peroxides that TBHP generates and also due to the glutathione peroxidase activity with this 
peroxide, the GSH formed is extensively consumed, oxidized to GSSG and extruded from 
cells [48-50], resulting in the depletion of GSHt and GSH and in the increase of GSSG. 
Conversely, in the presence of MnPs, an effective increase in the GSHt and GSH contents 
was observed. Along with the possible increase in γ-GCS-related activity, MnPs 
themselves seem to scavenge ROS, including lipid peroxides that are produced by TBHP 
insult, reducing the consumption of GSH. Our results provided herein add to other 
evidences that MnPs, due to their multiple possible oxidation states (+2, +3, +4, +5), are 
both potent ROS/RNS scavengers, and powerful modulators of cellular redox-based 
metabolic pathways [5-7, 51]. In addition, a MnP was previously shown to counteract the 
oxidative inactivation of isocitrate dehydrogenase [52] increasing the cellular supply of 
NADPH, which levels are known to be suppressed in TBHP-treated cells [53, 54]. This 
may be also contributing to the increase in the GSH contents observed in cells treated with 
TBHP and MnPs. 
 
4.3.5. Conclusion 
This Chapter shows that ortho-substituted MnPs are extremely potent antioxidants, 
with the ability to cope with the cellular damage induced by TBHP, even at low 
micromolar concentrations. Their clear protective effect in V79 cells was observed in 
terms of cytotoxicity and intracellular superoxide level. Also, for the first time, the results 
presented here reveal that these MnPs have an important role in enhancing reducing 
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In this Chapter, five macrocyclic copper(II) complexes (CuL1-CuL5) were synthesized 
and evaluated in vitro for their ability to scavenge the O2
•–
 generated by the XXO system, using 
the NBT and the DHE assays. IC50 values in the low micromolar range were found in four out of 
five macrocyclic complexes studied, demonstrating their effective ability to scavenge O2
•–
. 
Spectroscopic and electrochemical studies were performed in order to correlate the structural 
features of the complexes with their O2
•–
 scavenger activity. The complexes did not show 
considerable toxicity in V79 cells (up to 100 µM, 24 h, MTT assay). From the aforementioned 
studies, the complexes CuL3 and CuL4, that exhibited high stability and effective O2
•–
 
scavenging activity, were selected to be evaluated in the oxidative stress models validated in 
Chapter 3 (XXO and TBHP). The ability of the complexes to counteract these oxidants was 
studied using endpoints of cell viability (MTT and CV assays) and intracellular ROS generation 
(DHE assay). CuL3 was slightly protective against TBHP, but it exerted a pro-oxidant effect in 
XXO-treated cells. For CuL4, no considerable effects were observed. The ability of CuL3 and 
CuL4 to generate HO
•
 radical via Fenton reaction was studied by the DNA stand break analysis. 
These complexes can react with H2O2 leading to HO
•
, being this reaction reverted in the presence 
of catalase. The cytotoxicity profile of CuL3 and CuL4 was also studied in human breast 
carcinoma cells (MCF7) and the compounds did not show toxic effects (up to 100 µM, 24 h, 
MTT assay). Their ability to potentiate the anticancer drug Dox was studied in MCF7 cells, 
using the MTT assay, but no significant effects were observed. Although CuL4 exhibited 
promising chemical and biochemical properties in vitro, this complex did not present relevant 
effects in the cell-based experiments performed in this Chapter. For CuL3, a modest effect was 
observed in TBHP-treated cells. Further studies should be performed for a better comprehension 






Copper is an essential element involved in several biological functions, acting as a 
catalytic component of many metalloenzymes, including SOD. Therefore, copper(II) complexes 
can enclose a SOD mimetic activity hindering increased levels of ROS. Biological effects of the 
SODm are related to their structures. High thermodynamic stability constants are required to 
avoid the dissociation of the complex in vivo, what could be achieved by using macrocyclic 
ligands [1]. The macrocyclic nature of the ligand is important for the SOD-like activity of the 
corresponding complexes as well as for their stability in the presence of biological chelators, 
even if the metal ion does not lie inside the cavity [2]. Several macrocyclic copper(II) complexes 
have been reported to scavenge superoxide anion [2-7]. 
Previous studies have demonstrated that chemical modifications in the ring size, donor 
atoms and substituents on the macrocycles, may have profound effects both on the stability and 
the SOD-like activities of the respective complexes [3, 4]. A copper(II) complex which 
possesses SODm activity should have a flexible arrangement of the ligands around the copper(II) 
ion in order to allow an easy reduction to copper(I). In addition, a copper(II) SODm complex 
should enclose a certain stability, avoiding thus dissociation in the acid region and should 
possess an accessible site in order to easily bind the O2
•–
 radical and, hence to give a quick 
reduction to copper(I). Finally, an equatorial field of medium strength is required because strong 
ones do not favour the attack of O2
•–
 to the accessible apical sites [8]. 
Although many copper(II) complexes have been studied, most of them are not 
thermodynamically stable or highly active at the range of physiological pH [9]. For this reason, 
novel complexes with high stability and activity, together with low toxicity, are still needed. 
Another important feature is the solubility of the compounds. Some of the SODm that have been 
developed, despite of their effective catalytic activity, are not water soluble. It is estimated that  
~ 40% of the compounds that enter the development phase fail to reach the market, mainly due 
to poor biopharmaceutical properties, in which low aqueous solubility is included [10]. Hence, 
the water solubility presented by the complexes under study is definitely an important favorable 
characteristic. 
In this Chapter, five low molecular weight copper(II) macrocyclic complexes are 
described, focusing  on their possible application as superoxide scavenging agents. The ability of 
those copper(II) complexes to scavenge O2
•– 
was evaluated and spectroscopic studies were 
performed in order to correlate the structural features of the complexes with their scavenging 
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activity. In addition, the cytotoxicity of these complexes was assessed in V79 cells. From these 
studies, the most promising compounds were selected and additional cell based assays were 
performed in order to further characterize the potential of these complexes as SODm therapeutic 
agents. In Chapter 3, two oxidative stress models, XXO and TBHP, were validated with the well 
established SODm MnTM-4-PyP. Therefore, in the present Chapter, V79 cells were treated with 
these oxidative stress inducers and the capacity of the complexes to abrogate the inflicted 
damage was evaluated. 
As explained in Chapter 1, SODm, while dismutating O2
•–
, may increase the intracellular 
H2O2 concentration. Hence, SODm can have an anticancer activity, either reducing tumor 
growth or potentiating established anticancer agents [11-13], such as Dox. This anthracycline is 
commonly used in breast cancer chemotherapy and exerts its cytotoxic effect by different 
mechanisms, including the interference in DNA synthesis and ROS generation [14-16]. As 
described in Chapter 3, Dox undergoes redox cycling reactions within the cell, leading to the 
generation of O2
•–
 [14]. If a copper(II) complex with SOD-like activity is present, it can 
disproportionate O2
•–
 into H2O2. If this complex reacts with H2O2 to form HO
•
, this can be a 
further advantage in promoting cancer cells’ death [17], as schematized in Fig. 5.1.  
 
Fig. 5.1 – Potential activity of Cu(II) complexes (CuL) with SOD-like activity as boosters of 
Doxorubicin anticancer properties. 
 
In view of this, the potential application in cancer therapy of the most promising 
complexes was addressed in this Chapter. Their capacity to generate HO
•
 was evaluated in vitro 
and the toxicity of the complexes was studied in breast carcinoma cells (MCF7). Furthermore, 
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5.2. Materials and Methods 
5.2.1 Chemicals 
PBS, caffeic acid, xanthine, xanthine oxidase, nitroblue tetrazolium chloride monohydrate 
(NBT), MTT, CV, trypsin, Ham’s F-10 medium, 30% hydrogen peroxide (w/w),  newborn calf 
serum, penicillin-streptomycin solution, Dulbecco’s Modified Eagle’s Medium (DMEM),  foetal 
bovine serum,  insulin solution from bovine pancreas, TBHP, Dox, catalase from bovine liver, 
and Cu,Zn-SOD from human erythrocytes were obtained from Sigma-Aldrich. Cu,Zn-SOD was 
reconstituted in PBS and the concentration of the resultant solution (7.9 M) was calculated 
taking into account a molecular weight for the enzyme of 32,500 [18]. DMSO was obtained from 
Merck. Chelex 100 resin was acquired to Biorad. Copper(II) nitrate-trihydrate, disodium 
ethylenediaminetetracetate (Na2H2edta) and DHE were purchased from Fluka. Pst1 enzyme was 
obtained from Fermentas. 
 
5.2.2. Synthetic procedures  
5.2.2.1. Synthesis of the macrocycles 
The macrocyclic ligands used for the preparation of the copper(II) complexes studied in 
the present work are shown in Scheme 3.1 and were synthesized as previously described [19-21].  
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NMR spectroscopy on a Bruker Avance 400 spectrometer. The references used for the NMR 
measurements were 3-(trimethylsilyl)propionic acid-d4 sodium salt for 
1




As represented in Fig. 5.2, L1 was synthesized by Richman and Atkins’ procedure [22], 
involving the condensation of the disodium salt of 1,4,N,N’-bis(p-toluenesulfonyl)-1,4-
diaminoethane with 1-O,5-O-di(p-toluenesulfonyl)-3-oxapentane-1,5-diol, at 110 ºC in dry 
dimethylformamide (DMF). The protective groups of the ditosylated cyclic amine were removed 
by a reductive cleavage with a mixture of glacial acetic acid, 48% hydrobromic acid and phenol 
during 28 h under reflux [19]. 
1
H NMR (D2O):  (ppm) 3.06 (t, 4 H), 3.34 (s, 4 H), 3.75 (t, 4 H). 
 
 
Fig. 5.2 – Schematic representation of the synthesis of the ligands L1 and L2. 
 
L2 was synthesized by condensation of the parent amine L1, with potassium bromoacetate 
in an aqueous basic solution [19] (Fig. 5.2).  
1
H NMR (D2O):  (ppm) 3.19 (t, 4 H), 3.25 (s, 4 H), 
3.68 (s, 4 H), 3.80 (t, 4 H). 
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L3 was also prepared according to the Richman and Atkins’ method [22], involving the 
condensation of the disodium salt of 3,6,N,N’-tetra(p-toluenesulfonyl)-3,6-diazaoctane-1,8-
diamine with 1-O,5-O-di(p-toluenesulfonyl)-3-oxapentane-1,5-diol, in dry DMF for 6 h. In a 
second step, the protective groups were removed by a reductive cleavage [20, 23], as described 
above (Fig. 5.3). 
1
H NMR (D2O):  (ppm) 3.21 (s, 4 H), 3.29 (m, 8 H), 3.37 (t, 4 H), 3.73 (t, 4 
H). 
13
C NMR (D2O):  42.73, 43.19, 43.87, 46.50, 65.67.  
 
 
Fig. 5.3 – Schematic representation of the synthesis of the ligands L3 and L4. 
 
L4 was synthesized by condensation of the parent amine L3 with potassium bromoacetate 
in an aqueous alkaline solution [21] (Fig. 5.3). 
1
H NMR (D2O):  (ppm) 3.42 (s, 4 H), 3.55 (t, 4 
H), 3.64 (t, 4 H), 3.77 (t, 4 H), 3.85 (s, 4 H), 4.09 (s, 4 H), 4.15 (t, 4 H). 
13
C NMR (D2O):  
50.00, 51.72, 53.23, 54.67 (d), 55.02, 64.89, 168.59, 171.79.  
L5 was prepared by the same method of L3, using 1-O,8-O-di(p-toluenesulfonyl)-3,6-
dioxaoctane-1,8-diol and the disodium salt of 3,N,N’-tri(p-toluenesulfonyl)-3-azapentane-1,5-
diamine [20] (Fig. 5.4). 
1
H NMR (D2O):  (ppm) 3.52 (t, 4 H), 3.69 (m, 8 H), 3.82 (s, 4 H), 3.94 
(t, 4 H).
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Fig. 5.4 – Schematic representation of the synthesis of the ligand L5. 
 
Aqueous macrocycles solutions were prepared at ~2.5  10
-3
 M, and their concentrations 
were determined by potentiometric titrations. 
 
5.2.2.2. Synthesis of the macrocyclic copper(II) complexes 
Copper(II) complexes were prepared by adding an aqueous solution of the nitrate salt (4.0 
mol) previously standardized by titration with Na2H2edta [24] to an aqueous solution of the 
ligands (4.2 mol). After stirring at room temperature, KOH solution was added until pH 7.4. 
The solvent was removed under reduced pressure and the residue was taken up in 2 mL of PBS. 
At micromolar concentrations, water molecules can act as competing ligands for copper(II), 
modifying the species distributions towards less coordinated species. To avoid this problem, 
when copper(II) complexes were prepared, a small excess of ligand was used in order to increase 
the complexation of the copper(II) ions [25].  
The values of the stability constants of Cu(II) with the ligands were previously determined 
from potentiometric titrations, performed at 25.0 ± 0.1°C and 0.10 M ionic strength [19-21]. The 
constants values were calculated by fitting the potentiometric data obtained using the 
SUPERQUAD [26] or HYPERQUAD programs [27]. 
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Species distribution curves were calculated for the aqueous solutions containing Cu(II) and 
each ligand (L1-L5) at a molar ratio of 1:1, using the Hyss program [28]. The species 
concentrations in solution were determined at physiological pH. Simulations of the species 
distribution in the presence of 0.01 M phosphate buffer were also performed. For these 
calculations, the stability constants for copper(II)-hydrogenophosphate [29] as well as the 
protonation constants for phosphoric acid [30] were considered, in order to calculate the 
percentage of each species present at pH 7.4. 
Theoretical calculations on the copper(II) complexes were performed within density 
functional theory [31], by Matxain et al [32]. Structure optimizations were carried out in gas 
phase, using the B3LYP hybrid functional [33] and the 6-31+G(d,p) [34] basis set for C, N, O 
and H, and the Stuttgart pseudopotentials [35] for Cu. Single point calculations using the 6-
311++G(3df,3p) basis set for all atoms, and the integral equation formalism of the polarized 
continuum model (IEFPCM) of Tomasi and co-workers [36] were performed on the optimized 
gas-phase structures to estimate the effects of bulk solvation. All the calculations were 
performed with Gaussian03 software [37]. 
 
5.2.3. Superoxide scavenging activity 
The superoxide scavenging activity of the complexes was studied by using their ability to 
scavenge O2
•–
, generated by the XXO system (Fig. 3.1), trough two different endpoints: the 
reduction of NBT and the oxidation of DHE. Copper(II) and Cu,Zn-SOD from human 
erythrocytes were used as controls. 
 
5.2.3.1 NBT assay 
The NBT assay is a simple and convenient method widely used for superoxide 
quantification and in SODm research [38]. In this assay, while O2
•–
 is generated, NBT is 
reduced, developing a blue formazan colour which is associated with an increase in the 
absorbance at 560 nm [39]. When a scavenger compound is added, it competes with the NBT for 
the oxidation of the generated superoxide anions. Therefore, there is a decrease in the rate of the 
NBT reduction, which leads to lower absorbance increases. The more effective the compound, 
the lower the concentration which inhibits the NBT reduction in 50% (IC50) [2]. 
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The conditions of the NBT assay were adapted from Kovala-Demertzi et al. [39]. The 
reaction system (final volume = 1 mL) contained 0.2 mM of xanthine, 0.6 mM of NBT in 
phosphate buffer 0.1 M, pH 7.8. Each complex (CuL1-CuL5) was added to the reaction mixture 
in different concentrations up to 40 M. The reaction was started by the addition of XO (6 
mU/mL), an activity which allowed to yield the absorbance change between 0.030 and 0.040 per 
minute, at 560 nm, 25 °C. The extent of NBT reduction was followed spectrophotometrically, by 
measuring the increase of the absorbance at 560 nm on a Hitachi U-2001 spectrophotometer, for 
3 min. Each experiment was performed in duplicate and each concentration generated a time 
dependent curve. From its linear domain, the slope (Abs/min) was calculated. The percentage of 
inhibition for each concentration was calculated as follows: [100- (slope/slope control)*100]. 
The IC50 of each compound was defined as the concentration which inhibited 50% of the NBT 
reduction by O2
•–
 produced in the XXO system. 
 
5.2.3.2 DHE assay  
As referred in Chapter 3, DHE is a probe that undergoes oxidation by O2
•–
 giving the 
fluorescent product 2-hydroxyethidium (Fig. 3.6). This probe can be applied either to cell-based 
experiments or to “test tube” assays. In the present section, DHE was used to detect the amount 
of O2
•–
 present in a “test tube” system, allowing the determination of the superoxide scavenging 
activity of the complexes. This assay was performed in 96-well microplates. Each well (200 L) 
contained 0.2 mM of xanthine and phosphate buffer 0.1 M, pH 7.8. The tested compounds 
(CuL1-CuL4), diluted in phosphate buffer pH 7.8, were added to the reaction mixture (10 L). 
Different concentrations up to 80 M were tested for each complex. In what concerns CuL5, 
since it revealed no activity using the NBT assay (see Results and Discussion section), only the 
highest concentration (80 M) was tested. DHE aliquots (10 mM, DMSO) were diluted 1:100 in 
phosphate buffer pH 7.8. DHE was added to each well at a final concentration of 10 M. The 
reaction was started by the addition of XO (5 mU/mL). The reaction was performed at 25 °C, 
and the extent of DHE oxidation was followed by measuring the increase of the fluorescence on 
a Zenyth 3100 microplate reader, for 60 min, using excitation = 485 nm and emission = 595 nm. 
Each experimental point was performed using eight replicates. Two independent experiments 
were performed for each concentration of the different complexes. Each concentration generated 
a time course curve. From its linear domain, the slope was calculated. The percentage of 
inhibition for each concentration was determined as described above (5.2.3.1). The IC50 of each 
 119 
compound was defined as the concentration which inhibited 50% of the DHE oxidation by the 
O2
•–
 produced in the XXO system. 
 
5.2.3.3. Xanthine oxidase inhibition assay 
The possibility of an inhibition of the O2
•–
 generating system XXO by the copper(II) 
complexes under study was also evaluated. This was performed by following at 293 nm, during 
5 min, the uric acid produced after xanthine was oxidized by XO in aerobic conditions 
concomitantly to the production of O2
•–
 (Fig. 3.1). The assay was performed for each complex 
(80 M) at the same experimental conditions described above (5.2.3.1.), with the exception of 
the NBT solution, which was replaced for equal volume of phosphate buffer [40]. Caffeic acid 
(50 M), a recognized XO inhibitor, was used as positive control. Each experiment was 
performed in duplicate. 
 
5.2.4. Structural studies 
5.2.4.1 Spectroscopic studies 
Spectroscopic studies are useful tools that give information on the copper environment in 
a complex, shedding light on its potential SOD-like activity [41]. EPR spectroscopy measures 
the absorption of microwave radiation by an unpaired electron when it is placed in a strong 
magnetic field [42]. The hyperfine coupling constants from EPR spectroscopy, along with the  
d–d transitions from electronic spectra, are parameters that characterize the first coordination 
sphere around the metal [41]. 
The electronic spectra of the complexes were performed using a UNICAM model UV-4 
spectrophotometer. The complexes were prepared in aqueous solutions at 1.20 × 10
-3
 M (1:1 
ratio) in 0.1 M in KNO3. For CuL2, CuL3, CuL4 and CuL5 the solutions’ pH was 7.38, 7.41, 
7.37, and 7.38, respectively. 
EPR spectroscopy measurements of the copper(II) complexes were recorded with a 
Bruker EMX 300 spectrometer equipped with a continuous-flow cryostat for liquid nitrogen, 
operating at X-band. The complexes were prepared at 1.25 × 10
-3
 M (1:1 ratio) in water (1.0 M 
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in NaClO4). The spectra of CuL2, CuL3, CuL4 and CuL5 were recorded at the pH values of 
7.39, 7.35, 7.40 and 7.40, respectively.  
 
5.2.4.2. Electrochemistry 
Cyclic voltammetry is an electroanalytical technique widely used to study redox 
processes. It enables the search of redox couples and offers a rapid location of the redox 
potentials of the electroactive species. This technique was therefore used to characterize the 
electrochemical behavior of the complexes. 
A BAS CV-50W Voltammetric Analyzer connected to a BAS/Windows data acquisition 
software was used for the electrochemical measurements. Cyclic voltammetry experiments were 
performed in a glass cell MF-1082 from BAS in a C-2 cell enclosed in a Faraday cage, at room 
temperature under nitrogen atmosphere. The reference electrode was Ag/AgCl (MF-2079 from 
BAS) and its potential was −44 mV relative to a saturated calomel electrode. The auxiliary 
electrode was a 7.5 cm platinum wire (MW-1032 from BAS) with a gold-plated connector. The 
working electrode was a glassy carbon (MF-2012 from BAS). Between each cyclic voltammetry 
scan the working electrode was electrocleaned by multicycle scanning in the supporting 
electrolyte solution, polished on diamond 1 µm and on alumina 0.3 µm, according to standard 
procedures. The aqueous solutions of the complexes were prepared at 1.20 × 10
-3
 M (1:1 ratio) in 
0.1 M KNO3 (supporting electrolyte). The voltammograms of CuL2, CuL3, CuL4 and CuL5 
were performed at the pH values of 7.39, 7.35, 7.40 and 7.40, respectively. Cyclic 
voltammograms were recorded in the region from +1.0 to -1.0 V versus Ag/AgCl, varying the 
scan rate from 10 to 100 mV s
-1
. The half wave potentials E1/2 were calculated approximately 
from (Epa+ Epc)/2. 
 
5.2.5. Evaluation of the cytotoxicity profile of the macrocyclic copper(II) complexes in V79 cells 
Cytotoxicity assays were performed in V79 cells, cultured as described in Chapter 3 
(3.2.2). The protocol used for the MTT assay is described in Chapter 3 (3.2.3.1). Cells were 
exposed to different concentrations of the macrocyclic copper(II) complexes (1, 10, 50 and  
100 M) dissolved in PBS, during a 24 h period. Hydrogen peroxide (10 mM) was used as 
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positive control. Two independent experiments were performed and four replicate cultures were 
used for each complex concentration in each independent experiment.  
 
5.2.6. Evaluation of the potential protective effect of CuL3 and CuL4 against the oxidative injury 
induced by XXO and by TBHP 
From the results of the previous assays, CuL3 and CuL4 were selected to be further 
studied in cell-based experiments. The potential antioxidant activity of these copper(II) 
complexes was studied in V79 cells, using XXO and TBHP as oxidative stress inducers. 
 
5.2.6.1 MTT Reduction assay 
The MTT assay was performed as described in Chapter 3 (3.2.3.1).  At t=24 h, the cells 
were treated for a further 24 h-period with each of the oxidants, X (240 µM)/XO (20 U/L) or 
TBHP (100 µM), in the absence or presence of each complex (5, 25, 50, and 100 µM). Two to 
four independent experiments were performed as described above and eight replicate cultures 
were used for each complex concentration in each independent experiment.  
 
5.2.6.2 Crystal Violet assay 
Since CuL3 has shown some protection against the TBHP-induced cytotoxicity in the MTT 
assay, a second cell viability method – the CV staining, was carried out as a confirmatory assay. 
As in the MTT assay, the cells were grown for 24 h and then exposed to TBHP (100 µM) with or 
without CuL3 (5, 25, 50 and 100 µM) for a 24 h period. The CV assay was carried out as 
described in Chapter 3 (3.2.3.2). Five independent experiments were performed, each one 






5.2.6.3. DHE fluorimetric assay 
To assess whether the protective effect against TBHP observed for CuL3 was related to the 
superoxide scavenging activity of this complex, the DHE assay was used. This cell permeable 
probe was used to detect the intracellular levels of O2
•–
 as described in Chapter 3 (3.2.5). V79 
cells were exposed for 3 h to TBHP (100 µM) and/or CuL3 (100 µM) and to DHE (10 M). Five 
independent experiments were performed, each comprising six replicate cultures for each 
experimental point.  
 
5.2.7. DNA strand break analysis 
The generation of HO
• 
radical by the copper(II) complexes CuL3 and CuL4 was 
evaluated by the DNA strand break analysis. The underlying principle of this method is 
schematized in Fig. 5.5. 
 
 
Fig. 5.5 – Fundamentals of the DNA strand break analysis. The disproportionation of O2
•–
 by the 
copper(II) complexes originates H2O2. If the complex undergoes Fenton chemistry, HO
• 
radical 
is generated in the system. This radical attacks the phosphodiester backbone of supercoiled 
plasmid DNA producing relaxed circular DNA [43]. This relaxed circular molecule migrates 
more slowly than the supercoiled form during gel electrophoresis (XO, xanthine oxidase; SC, 

















 Escherichia coli strain DH5α containing plasmid pUC 18 was kindly provided by Dr. 
Michel Kranendonk. Plasmid pUC 18 DNA was amplified in the host strain and extracted using 
a Qiagen plasmid kit. To confirm that the extracted DNA corresponded to pUC 18, a restriction 
assay was performed. The enzyme used was Pst1, since pUC18 DNA has one recognition site for 
this enzyme. The protocol for digestion was carried out according to the manufacturer’s 
instructions. As expected, the agarose gel revealed a single band that corresponded to the size of 
pUC 18 DNA (2686 base pairs). It is also important to mention that a gel electrophoresis of the 
extracted DNA has shown that ~100% of the DNA was in the supercoiled form, thus assuring its 
quality. 
Plasmid DNA was incubated with the reaction mixtures, in 5 mM sodium phosphate 
buffer pH 7.4 pre-treated with chelex 100 resin. Superoxide anion was generated from 5 U/L of 
XO plus 200 M xanthine. XXO plus copper(II) (6.7 M) were used as a positive control for the 
generation of HO
•
 radical. The effects of catalase (221 U/mL) and SOD (0.04 µM) on the 
reversion of the plasmid cleavage were studied and heat-inactivated enzymes were used as 
controls. CuL3 and CuL4 were tested at 100 M. After a 2 h incubation, in the dark, at 37ºC, 
loading buffer was added to the samples and they were analysed by electrophoresis at 150 V in 
1% agarose gel in Tris-Borate-edta buffer. The gels were stained with ethidium bromide. The 
approximate fluorescence of the bands was estimated by densitometry, using the LabWorks 
software. The optical density of supercoiled DNA was corrected by a factor of 1.4 because, when 
stained with ethidium bromide, the relaxed circular form gives a fluorescence intensity 1.4-fold 
higher than the supercoiled form [44]. At least two independent experiments were performed, 
each including three gel lanes for sample.  
 
5.2.8. Evaluation of the cytotoxicity profile of the macrocyclic copper(II) complexes CuL3 and 
CuL4 in MCF7 cells 
5.2.8.1. MCF7 Cells culture  
MCF7 cells, a human breast carcinoma cell line, were purchased from DSMZ. MCF7 
cells were cultured in DMEM supplemented with 10% foetal bovine serum, 1% antibiotic 
solution (penicillin-streptomycin) and 0.01 mg/mL insulin. Cells were kept at 37°C, under an 
atmosphere containing 5% CO2. 
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5.2.8.2 MTT Reduction assay 
The toxicity of CuL3 and CuL4 was evaluated in MCF7 cells, using the MTT assay. 
Briefly, ~6.5  10
3 
cells were cultured in 200 L of culture medium per well in 96-well plates 
and incubated at 37°C under a 5% CO2 atmosphere. The cells were grown for 48 h and then 
exposed to different concentrations of the macrocyclic copper(II) complexes (1, 10, 25, 50 and 
100 µM) during a 24 h-period. The MTT assay was then performed as described in Chapter 3 
(3.2.3.1). At least two independent experiments were performed and at least four 4 individual 
cultures were used for each complex concentration in each independent experiment. 
 
5.2.9. Evaluation of the possible role of the macrocyclic copper(II) complexes CuL3 and CuL4 
on the potentiation of Dox cytotoxicity in MCF7 cells 
The studies on the modulation of the cytotoxicity of Dox were also carried out in MCF7 
cells using the aforementioned MTT protocol. After growing for 48 h, cells were exposed to Dox 
(50, 100, 500, 1000 and 5000 nM) in the absence or presence of 100 M CuL3 or CuL4, for 24 
h. Two to five independent experiments were performed, each comprising at least 4 individual 
cultures. 
 
5.2.10. Statistical analysis 
The results obtained in points 5.2.6 and 5.2.9 were submitted to a statistical analysis as 
described in Chapter 3 (3.2.6). 
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5.3. Results and Discussion 
Macrocycles and their metal complexes have been suggested as promising agents for the 
diagnosis and treatment of different diseases and toxicological conditions [45-47]. In addition, 
some macrocyclic complexes have been suggested as a potential class of SOD mimics, mainly 
because of their high thermodynamic stability [1, 2]. 
Most of the catalytic antioxidants have a redox-active metal center [1, 48], but only a few 
metal ions have the ability to catalyze the dismutation of O2
•– 
to hydrogen peroxide and oxygen. 
It is well known that copper(II) aqueous ion is a very potent superoxide scavenger [1]. The low 
IC50 values found using Cu(NO3)2 in this work are consistent with the values found for other 
Cu(II) salts [2] and show the efficacy of Cu(II) in the disproportionation of O2
•–
. 
Human serum albumin has a high-affinity site for copper(II) [49] precluding the use of 
free copper(II) as a therapeutic SOD mimetic. In fact, in blood plasma, albumin exists in very 
high concentration, binding to the non-ceruloplasmin copper fraction and acting thus as a copper 
transport protein [9, 49]. Therefore, if free Cu(II) ions were administered, they would be 
immediately complexed by serum albumin, losing their ability to dismutate the O2
•–
 [2]. Within 
mammalian cells, the binding of Cu(II) by cellular components also occurs, and copper 
chaperones, glutathione and metallothioneins, among other proteins, may be involved [50]. Since 
the intracellular milieu has an extraordinary overcapacity for chelation of copper(II), free copper 
availability is extremely restricted, even when cells are exposed to an elevation of the medium’s 
copper concentration [51]. In view of this, copper(II) must be enclosed in a stable ligand, which 
protects it from being chelated by serum and cellular components. Additionally, this ligand must 
allow copper(II) to switch its redox state and dismutate O2
•–
. It has been described that if the 
ligand is a macrocycle, the metal complex may have higher biological stability [1, 2].  
 
5.3.1. Chemical characterization and superoxide scavenging activity of the complexes 
The knowledge of the stability constants’ values for the copper(II) complexes is a very 
important issue for the prediction of their behaviour in vivo. High stability constants are required 
to avoid dissociation of the complex in in vivo systems. The stability constants values of the 
macrocyclic copper(II) complexes under study were determined in previous works [19-21] and 
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are shown in Table V.1. All complexes, except CuL1, showed reasonably high values of stability 
constants (log KML > 13). L3 and L4 have indeed shown the highest values (log KML = ~20).  
 
Table V.1 – Stepwise stability constants (log K) for the copper(II) complexes of L1-L5.  











[CuL]/[Cu][L] 10.80 13.37 20.34 19.23 15.72 
[CuHL]/[CuL][H] - - - 4.38 - 
[Cu2L]/[Cu][CuL] - - - 4.56 - 
[CuL2]/[CuL][L] 8.80 - - - - 
[CuL]/[CuLOH][H] - - 10.4 (8.1) 8.87 
a)
 I = 0.10 M KNO3; T = 25.0 ºC [19] 
b)
 I = 0.10 M KNO3; T = 25.0 ºC [20] 
c)
 I = 0.10 M N(CH3)4NO3 T = 25.0 ºC [21] 
 
To properly evaluate the SOD-like activity of a copper(II) complex, it is crucial to know its 
species distribution. The concentration of the different species in solution can be calculated by a 
simulation approach, based on the knowledge of the stability constants of the different complex 
species. A correct speciation will allow the identification the species formed in particular 
conditions, which may be responsible for the O2
•–
 scavenger activity [52]. Speciation studies also 
provide information on the absence or presence of non-complexed copper(II). Since free Cu(II) 
ion is known to be an efficient catalyst of O2
•–
, its presence would lead to the misinterpretation of 
the results of the SOD-like activity assays [8]. The species distribution diagrams and the pCu 
values were therefore obtained from the values of the stability constants of the macrocyclic 
copper(II) complexes, using the Hyss program [28]. The concentration used in these simulations 
was 10 M of Cu(II) at a molar ratio 1:1 with L1-L5. This value was chosen because it is in the 
range of IC50 values of the active superoxide scavenging complexes. The results obtained under 
these conditions and at physiological pH (7.4) are shown in Table V.2. In these simulations, no 
free copper(II) ions are likely to be found in solution for the copper(II) macrocyclic complexes, 
except in the case of L1 (~ 5.1% of aqueous copper(II) ion). This can be explained by the fact 
that under these conditions (molar ratio 1:1) the complexation of L1 with copper(II) is not 
fulfilled. EPR spectra confirmed the absence copper(II) impurities in the CuL2-CuL5 solutions. 
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Table V.2 - Species distribution and pCu values calculated for an aqueous solution containing 
Cu(II) (10 µM) and each ligand (10.5 µM) at a molar ratio of 1:1 (charges on metal ions and 
complexes were omitted for simplicity). 
Ligand Species (% relative to the total amount of Cu(II)) pCu 
L1* 79.8% CuL + 12.4% CuL2 + 5.1% Cu + 2.6% CuOH + 0.1% Cu(OH)2 6.29 
L2** 100.0% CuL 8.90 
L3 99.9% CuL + 0.1% CuOH  15.39 
L4 0.1% CuHL + 83.3% CuL + 16.6% CuLOH 13.44 
L5 96.7% CuL + 3.3% CuLOH 11.22 
* 12.8% CuL + 41.2% CuL2 + 27.2% CuHPO4 + 17.6% Cu(HPO4)2 + 1.1% Cu(HPO4)3, in  
0.01 M phosphate buffer, pH 7.4. 
** 93.9% CuL + 3.6% CuHPO4 + 2.3% Cu(HPO4)2 + 0.2% Cu(HPO4)3, in 0.01 M phosphate buffer,  
pH 7.4. 
 
The copper(II) complexes were initially redissolved in PBS and this solution was used in 
both the biochemical and cytotoxicity assays. In order to give an even more accurate speciation 
in the used conditions, the possible competition between the phosphate species present in high 
levels in the buffer and the copper(II) complexes under study was considered. Having this in 
mind, the species concentrations at pH 7.4 were recalculated. Using this approach, no changes 
were found for the species in solution at pH 7.4 for CuL3, CuL4 and CuL5. In what concerns to 
CuL1 and, in a lesser extent to CuL2, the presence of high phosphate concentration derived in 
some differences in the species in solution, giving rise to the appearance of CuHPO4, Cu(HPO4)2 
and Cu(HPO4)3 at pH 7.4 (Table V.2 - footnote). 
The superoxide scavenging effects of the macrocyclic copper(II) complexes determined by 
both the NBT and DHE methods, are depicted in Fig. 5.6. The correspondent IC50 values 
determined for the complexes under study, as well as for Cu(II), are presented in Table V.3. A 
very good correlation between the NBT and DHE assays was found (r = 0.979). The IC50 values 
obtained for the macrocyclic copper(II) complexes using the NBT assay, were consistently 
higher, approximately 3-fold, than those obtained with the DHE assay (Table V.3). The DHE 
fluorimetric method was previously reported as a more sensitive and specific assay for O2
•– when 
compared to the NBT assay [53], what may somehow explain these results. However, other 
authors have pointed out that DHE could enhance the rate of superoxide dismutation [54]. 
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Fig. 5.6 - Effect of the macrocyclic copper(II) complexes CuL1- CuL5 on the inhibition of the 
NBT reduction (A) and DHE oxidation (B) by the XXO generated superoxide.  
 
 
Table V.3 - Superoxide scavenging activity for the copper(II) compounds and native 
Cu,Zn-SOD. 
Compound 
IC50 ( M) 
NBT assay DHE assay 
CuL1 6.86 1.07 
CuL2 18.84 5.03 
CuL3 30.82 11.78 
CuL4 13.94 4.66 
CuL5 N.D. N.D. 
Cu(II) 0.28 0.11 
Cu,Zn-SOD 0.017 0.001 
N.D., Not Determined 
 
Since both NBT and DHE methods involve the activity of XO it is of utmost importance to 
ascertain that the results obtained are in fact due to a SOD-like activity and not a consequence of 
the inhibition of XO. The monitoring of the production of uric acid revealed that the active 
copper complexes (CuL1, CuL2, CuL3, and CuL4), at 80 µM, did not inhibit XO. Caffeic acid at 
the same experimental conditions inhibited 47.0% and 59.8% of uric acid production at 180 and 


















































concentrations [55]. However, in our experimental conditions, using 80 M of Cu(NO3)2, that 
inhibition did not occur. 
For both assays and for all the complexes studied, the native human Cu,Zn-SOD was used 
as a positive control. As expected, a dose-dependent inhibition was found both for NBT 
reduction and DHE oxidation (data not shown). The IC50 values for the enzyme were determined 
in the same experimental conditions used for the study of the complexes and revealed to be 
extremely low, in the nM range (Table V.3). 
Four of the five macrocyclic copper(II) complexes studied (CuL1, CuL2, CuL3 and CuL4) 
have an effective ability to scavenge the O2
•–
 with IC50 in the low micromolar range (Fig. 5.6, 
Table V.3). The most active was CuL1 followed by CuL4, CuL2 and finally by CuL3. In what 
concerns to CuL5, no IC50 value was calculated because no superoxide scavenging activity was 
found using the NBT assay (Fig. 5.6A). Using the DHE method an inhibition of < 40% was 
found at 80 M, which may be considered as a low superoxide scavenging activity (Fig. 5.6B).  
The superoxide scavenging activities of the complexes under study are in the same range 
of those reported for other metal complexes [56-58]. However, compounds with higher activity 
(e.g. some Mn salens and MnPs) have also been described [56, 59, 60], despite some of them are 
not readily water soluble. Nevertheless, focusing on the previously reported macrocyclic 
copper(II) complexes, which are more similar to the presented compounds, it is noticeable that 
the complexes under study are generally more active, having lower IC50 values [3, 6]. 
In what concerns the four active macrocyclic copper(II) complexes and regardless the 
analytical method, we can observe that CuL1 is the most effective compound for O2
•– 
scavenging 
(Fig. 5.6, Table V.3). However, as it was aforementioned in this discussion, at physiological pH 
and in the molar ratio used, the complexation of L1 with copper(II) is not complete (Table V.2), 
a consequence of the low stability constant of L1 for copper (log KML= 10.8). Thus, we can not 
rule out that the presence of free copper in the reaction system could contribute to the low IC50 
found for the complex of L1. Moreover, in the presence of phosphate buffer, the percent Cu(II) 
complexed with L1 markedly decreased with a concomitant increase of Cu(II) complexed with 
hydrogenophosphate (Table V.2 - footnote). For CuL2 this problem is not so relevant, although 
we should not disregard the presence of Cu(II) complexed with hydrogenophosphate, which may 
contribute in some extent to the dismutation of O2
•– 
[52]. For the complexes CuL3, CuL4 and 
CuL5, this question is not applicable. 
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In an attempt to find out a structural-O2
•– 
scavenging activity correlation for the complexes 
with higher thermodynamically stability (CuL2-CuL5), Visible and EPR spectroscopic studies, 
as well as theoretical calculations, were performed. In addition, the electrochemical behaviour of 
the complexes was studied by cyclic voltammetry. 
The SOD-like activity is known to depend on structural features, namely on the 
conformation of the active site. Too stable square-planar geometries may not be favourable for 
the O2
•– 
dismutation [3], while more distorted arrangements lead to higher SOD activity [61]. 
The EPR parameters provide data on the copper(II) environment in the complex, giving insights 
on its geometry. According to the ligand field theory [62-64], the gz value increases and the Az 
value decreases as the planar ligand field becomes weaker or as the axial ligand field becomes 
stronger and this occurs with the simultaneous red-shift of the d-d absorption bands in the 
electronic spectra. This sequence, in principle, parallels the degree of distortion from square-
planar to square pyramidal, C4v, and then to octahedral (Oh) or tetragonal (D4h) geometries. The 
EPR parameters for copper(II) complexes are determined by the chemical composition and the 
physical constraints on the atoms nearest to the metal ion. On the basis of the Peisach and 
Blumberg approach [65], which accounts for the close relationship between g|| and A|| for 
equatorially coordinated S = ½ paramagnetic metal complexes some important properties of the 
copper(II) complexes may be determined. In this case, the actual composition of the equatorial 
atom donor set may be evaluated from the EPR data using the diagrams of g|| and A|| values 
compiled by the authors for a series of model compounds. The quotient g||/A|| is an empirical 
measure for the degree of tetrahedral distortion, being a relevant parameter to understand the 
SOD-like activity of the complexes [41]. This quotient ranges from ~ 105 to 135 cm for square-
planar structures and increases markedly on the introduction of tetrahedral distortion [66]. 
Spectroscopic visible data and EPR parameters for Cu(II) complexes in water solution are 


















; g||/A||  cm 
  gz gy  gz Ax Ay Az g||/A||
*
 
CuL2 638 (100) 2.041 2.053 2.225 18.1 22.9 190.7 117 
CuL3 580 (141) 2.042 2.046 2.192 30.0 27.9 199.4 110 
CuL4-1   
674 (86) 
2.036 2.104 2.295 4.5 30.2 158.6 145 
CuL4-2  2.037 2.076 2.239 1.7 13.4 176.2 127 
CuL5  634 (111) 2.044 2.049 2.228 26.6 27.7 183.4 122 
Cu,Zn-SOD [67] 680 (150)     -                - 2.271   -    - 140 162 
* Considering gz as g|| and Az as A||. 
 
 
Fig. 5.7 - EPR X-band spectra of the Cu(II) complexes of L2-L5 in 1:1 ratio at the pH = 7.39 for 
CuL2 (a), pH = 7.35 for  CuL3 (b), pH = 7.40 for CuL4 (c) and pH = 7.40 for CuL5 (d) in 1.0 M 
NaClO4. The spectra were recorded at 116 K, microwave power of 2.0 mW and modulation 
amplitude of 1.0 mT. The frequency ( ) was of 9.41 GHz. The simulated spectra are below of 
the experimental ones (grey line).  
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The simulation of the spectra [68] indicates three different principal values of g, showing 
that the Cu(II) ion in these complexes is in a rhombically-distorted ligand field. All the complex 
species show parameters which are characteristic of rhombic symmetry with elongation of the 
axial bonds and a d
x y2 2
 ground state. Elongated rhombic-octahedral, rhombic square-coplanar 
or distorted square pyramidal stereochemistries would be consistent with these data, but 
trigonal-bipyramidal or tetragonal geometries involving compression of axial bonds should be 
excluded [21, 69]. It is important to mention that the structures obtained by the theoretical 
calculations were consistent with those proposed based on the spectroscopic data [32]. 
The spectrum of CuL2 (Fig. 5.7a) exhibits the presence of one species. The g|| value 
(considering gz as g||) and A|| value (considering Az as A||) parameters are according with two 
nitrogen and two oxygen donor atoms coordinated to the metal center in the equatorial plane. 
These parameters, as well as the value of the maximum of the visible band (Table V.4) and the 
B3LYP optimized geometry (Fig. 5.8), suggest a square-pyramidal structure where the equatorial 
plane is determined by the two nitrogen and two oxygen atoms and one oxygen atom is in the 
apical position. 
 
 Fig. 5.8 - B3LYP Optimized geometry of CuL2 
complex (yellow = copper(II), blue = N, red = O, 
orange = C, white = H). 
 
 
The data obtained for CuL3 spectrum, together with the position of the d-d absorption 
band (Fig. 5.7b and Table V.4) point out to a square-pyramidal structure where the equatorial 
plane is determined by the four nitrogen atoms and one oxygen atom is in the apical position 
(Fig. 5.9). Although this complex has an effective O2
•–
 scavenging activity, it presents higher 
IC50 values. The reason for this behavior can be related to the strong equatorial ligand field 
which does not favour the attack of O2
•–





Fig. 5.9 - B3LYP Optimized geometry of CuL3 
complex (yellow = copper(II), blue = N, red = O, orange 
= C, white = H). 
 
 
The spectrum of CuL4 is shown in Fig. 5.7c and exhibits the presence of two species 
(CuL4-1 and CuL4-2). The EPR parameters and electronic spectrum determined in this work 
(Table V.4) are in agreement to those published before [21]. In CuL4-1, copper(II) is in a 
distorted octahedral environment having two nitrogen and two oxygen atoms coordinated 
directly to the metal ion. Two oxygen atoms accomplish the octahedral geometry. In terms of the 
factor g||/A||, CuL4-1 appears to have some tetrahedral distortion of the copper(II) arrangement, 
being the complex structurally most similar to Cu,Zn-SOD [67] (Table V.4). In what concerns to 
the CuL4-2 species the EPR parameters are completely different, having lower g|| and higher A|| 
values, indicating a stronger equatorial field. An octahedral distorted geometry is also proposed 
but having three nitrogen and one oxygen atoms in the equatorial plane and two oxygen atoms in 
axial positions (Fig. 5.10).  
 
 
Fig. 5.10 - B3LYP Optimized geometry of 
CuL4 complex (yellow = copper(II), blue = 
N, red = O, orange = C, white = H). 
 
 
Fig. 5.7d presents the spectrum of CuL5 and Table V.4 lists the spectral parameters 
obtained. The values of g|| and A|| are consistent with two nitrogen and two oxygen donor atoms 
coordinated to the metal center in the equatorial plane. These parameters and also the value of 
the maximum of the visible band (Table V.4) indicate penta- or hexacoordination environments 
for the Cu(II). Although no X-ray structure analysis of this copper(II) complex is available, the 
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literature reports an X-ray structure for a dimer of the same macrocycle with Ni
2+
. The crystal 




 complex cations. The 
coordination environment for each metal is octahedral, determined by three nitrogen and two 
oxygen atoms of the ligand and completed by secondary species from the medium (Cl
-
 and 
water, respectively) [70]. It is important to mention that in this structure one nitrogen atom is in 
an axial position. Considering this X-ray structure, the data from the theoretical calculations and 
the results of the spectroscopic studies, we may propose that in the case of CuL5, the same 
octahedral environment seems probable. The absence of scavenging activity of CuL5 may be 
justified by the presence of an N atom of the macrocyclic backbone at the axial position (Fig. 





Fig. 5.11 - B3LYP Optimized geometry of CuL5 
complex (yellow = copper(II), blue = N, red = O, 




The redox behaviour of CuL2-CuL5 in aqueous solutions was studied by cyclic 
voltammetry. All of the complexes exhibited irreversible waves, except CuL3. This may suggest 
that the SOD-like activity exhibited by the complexes CuL2 and CuL4 is due to a stoichiometric 
scavenging activity. The copper(II) complex of L3 displays a single quasi-reversible one-
electron (ipa/ipc = 1.3; Epa = -0.528 V; Epc = -0.617 V; Ep = 89 mV) reduction wave at -0.573 V 
versus Ag/AgCl, which is assigned to Cu(II)/Cu(I). This may suggest a catalytic behaviour. 
However, the value of E1/2 for CuL3 is more negative than those reported for SOD mimetic 
compounds. Also, the value of Ep is lower than those reported for SODm compounds (from 
114 to 121 mV) [71], which might explain the mild activity exhibited by this complex on the 
biochemical assays.  
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5.3.2. Cytotoxicity profile of the complexes 
While some of these compounds have shown to be effective scavengers of the O2
•–
, they 
may also be toxic to mammalian cells. In fact, cytotoxicity is a common limitation for the 
pharmaceutical use of new compounds. Therefore, we measured the cytotoxic effects of 
macrocyclic copper(II) complexes using the MTT test in V79 cells. Cell survival was evaluated 
using a standard 24 h incubation with the copper(II) complexes. The concentrations evaluated 
were in the range of those tested in the superoxide scavenging assays. In general, the 
macrocyclic complexes showed only a slight cytotoxic effect of approximately 5 to 15% and no 
dose-response effects were observed. Interestingly, CuL5, the complex that did not show a 
superoxide scavenging activity, revealed the highest cytotoxicity (Fig. 5.12). Despite of the 
potential cytotoxicity of Cu(II), due to its ability to generate hydroxyl radical and to displace 
other metal co-factors from metalloenzymes [50], in our experiments Cu(II) ions did not exhibit 
notable cytotoxic effects, in the range of concentrations studied (Fig. 5.12).  
 
Fig. 5.12 - Cell viability of V79 cells treated with different concentrations of the macrocyclic 
copper(II) complexes CuL1-CuL5 and Cu(II), for 24 h. Values (mean  SD) are percentages 























5.3.3. Studies on CuL3 and CuL4 as potential antioxidants 
From the results above described, CuL3 and CuL4 gather a number of favourable 
characteristics and were therefore selected to be further evaluated. In fact, these complexes have 
high stability constant and pCu values, being less prone to undergo dissociation in vivo, an 
important requisite for a bioactive metal complex. Moreover, CuL3 and CuL4 have shown an 
effective O2
•–
 scavenging activity and exhibited low cytotoxicity in the range of concentrations 
tested (up to 100 µM). The antioxidant effect of these complexes was therefore evaluated in the 
oxidative stress models established in Chapter 3 and validated for the recognized SODm MnTM-
4-PyP. The first oxidant used was the XXO system, that generates O2
•–
 extracellularly. The 
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Fig. 5.13 - Effect of CuL3 and CuL4 on the cytotoxicity induced by xanthine (240 M) plus 
xanthine oxidase (20 U/L) in V79 cells. Cells were incubated with increasing concentrations of 
the complexes in the presence of XXO for 24 h, and then submitted to the MTT assay (*P < 
0.05, when compared with cells treated with XXO alone). 
 
As depicted in Fig. 5.13, when V79 cells were exposed for 24 h to X (240 µM)/XO (20 
U/L), a significant decrease in cell survival was observed (P < 0.05). The addition of CuL3 did 
not afford protection to XXO-exposed cells. On the contrary, this complex exhibited a dose-
dependent pro-oxidant effect (Fig. 5.13A). Concentrations of 50 and 100 µM of CuL3 have 
indeed significantly reduced the cellular viability (P < 0.05). A pro-oxidant action was also 
reported for other SODm compounds [72, 73]. Pérez et al [73] have in fact demonstrated that a 
SODm can exert different actions in cells, either scavenging or producing free radicals, 
depending upon the prevailing redox pathways. The pro-oxidant effect of CuL3 may also be 
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explained by the possible occurrence of Fenton chemistry. A loss of copper from the complex 
during the redox cycling could occur, whereby “free” Cu would give rise to highly oxidizing 
HO
• 
species. Fenton chemistry may be also operative at reduced copper still bound to the ligand 
[72]. In what concerns to CuL4, the addition of this complex (up to 100 µM), did not alter the % 
MTT reduction presented by XXO-treated cells (Fig. 5.13B). 
TBHP, an analogue of lipid hydroperoxides, was used as a second model of oxidative 
stress to further evaluate the potential effects of CuL3 and CuL4. The exposure of V79 cells to 
TBHP (100 µM) resulted in a considerable decrease in cell viability (P < 0.05). The 
simultaneous exposure to CuL3 led to a mild increase in the MTT reduction (Fig. 5.14A), 
although this protective effect was not statistically significant. It is also important to mention that 
a high variability was observed in these experiments. To confirm this antioxidant activity of 
CuL3, a second cell viability method was used – the CV assay. The results are depicted in Fig. 
5.14B. Using this assay, only a minor effect was observed (~5% increase in cell viability, N.S.), 
and only for the highest concentration of CuL3 (100 µM). 
 
Fig. 5.14 - Effect of CuL3 on the cytotoxicity induced by TBHP (100 M) in V79 cells. Cells 
were incubated with increasing concentrations of the complex in the presence of TBHP for 24 h, 
and then submitted to the MTT (A) or to the CV (B) assay. 
 
 
To assess whether the protective effect of CuL3 is related to its O2
•–
 scavenging activity, 
the intracellular production of this free radical was evaluated using the DHE assay. As depicted 
in Fig. 5.15, CuL3 (100 µM) per se did not alter the intracellular levels of O2
•–
. On the contrary, 
cells exposed to 100 µM of TBHP exhibited a significant increase in O2
•–
 production (P < 0.01). 
In cells co-treated with CuL3 and TBHP, the intracellular O2
•–
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presented by control cells (P<0.01 versus TBHP alone). These results indicate that the 
scavenging of O2
•–
 by CuL3 is occurring in this oxidative stress model, being probably 
accounting for the slight increase in cell viability observed. Other mechanisms may also be 
involved in this effect. This protection of CuL3 in terms of intracellular O2
•–
 levels also suggests 
that this complex is cell-permeable in V79 cells. 
 
Fig. 5.15 - Effect of CuL3 on the DHE oxidation in V79 cells treated with TBHP (100 µM). 
Values (mean ± SD) represent relative fluorescence units (RFU), which approximately reflect the 
levels of O2
•–
, expressed as percentages of the control cells (
##
P < 0.01, when compared with 
non-treated control cells; **P < 0.01, when compared with cells treated with TBHP in the 
absence of CuL3). 
 
The potential effect of CuL4 against TBHP-induced toxicity was also studied and the 
obtained results are depicted in Fig. 5.16. This complex, up to 100 M, did not significantly alter 
the decrease in MTT reduction induced by TBHP. Although CuL4 has shown an efficient O2
•–
 
scavenging in vitro, with a low IC50 value, this complex failed to protect cells exposed to the 
oxidative stress inducers XXO and TBHP. This absence of antioxidant activity of CuL4 in cell-
based experiments may be assigned to a possible insufficient catalytic rate of the reaction 
between the complex and O2
•–
. It is possible that O2
•–
 reacts faster with a biological target than 
with CuL4. If that is so, the presence of CuL4 will not counteract the oxidative damage induced 
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Fig. 5.16 - Effect of CuL4 on the cytotoxicity induced by TBHP (100 M) in V79 cells. Cells 
were incubated with increasing concentrations of the complex in the presence of TBHP for 24 h, 





 radical generation by CuL3 and CuL4 
CuL3 and CuL4 were also evaluated for their capacity to generate HO
•
 radical. This 
information is useful to explain the eventual toxic and pro-oxidant effects of the complexes 
under some conditions, as well as to give some insight on the possibilities of these complexes as 
anticancer agents. In the DNA strand break analysis, the generation of HO
•
 radical leads to an 
attack in plasmid DNA, resulting in a decrease of the percentages of DNA in the supercoiled 
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Fig. 5.17 – Validation of the DNA strand break analysis protocol. Results are expressed as 
percentages of DNA in the supercoiled form (CAT, catalase; XXO, xanthine-xanthine oxidase; 
iCAT, heat-inactivated catalase; SOD, superoxide dismutase; iSOD, heat-inactivated superoxide 
dismutase). 
 
As shown in Fig. 5.17A, Cu(II), CAT and XXO, per se, did not decrease the % of  
supercoiled (SC) DNA. However, the incubation of pUC18 with XXO plus Cu(II) resulted in a 
considerable DNA breakage, indicating the generation of HO
•





 radicals may be generated either by Haber-Weiss or Fenton reactions: 
 
Cu(II) + O2
•–    
→ Cu(I) + O2 
Cu(I) + H2O2
    


















































































The reversion of this effect in the presence of CAT indicates that H2O2 is an intermediate 
in HO
•
 generation. The absence of effect of heat-inactivated CAT confirms that is the catalytic 
degradation of H2O2 that is avoiding the formation of HO
•
, and not an unspecific reaction such as 
HO
•
 trapping by the protein. The results obtained with SOD (Fig. 5.17B) support the major role 
of H2O2, but not of O2
•–
, as an intermediate in HO
•
 generation and, therefore, in DNA cleavage. 
The results obtained with CuL3 and CuL4 are shown in Fig. 5.18. 
 
Fig. 5.18 – Evaluation of HO
•
 generation by CuL3 (A) and CuL4 (B), by the DNA strand break 
analysis. Results are expressed as % DNA in the supercoiled form (XXO, xanthine-xanthine 
oxidase; CAT, catalase). 
 
As depicted in Fig. 5.18A, CuL3 per se, reduced the % SC DNA to values of ~84%. 











































activity. Other macrocyclic copper(II) complexes have previously shown the capacity to interact 
with DNA by intercalation, hydrogen bonding, van der Waals forces, hydrophobic interaction or 
coordination between the Cu(II) in the complex and the base nitrogen in DNA. Some 
macrocyclic copper(II) complexes have indeed been developed as artificial restriction enzymes 
[74]. Also, SODm of other classes, namely MnPs, have been previously reported to interact with 
nucleic acids [75] and to degrade those [76]. Although CuL3 has shown to have nucleasic 
activity in vitro, it may not attack DNA in vivo. CuL3 may not enter the nucleus. Furthermore, 
nuclear DNA is organized in a complex supramolecular structure, being less prone to be cleaved. 
The absence of considerable toxicity in cells treated with CuL3 suggests that DNA damage 
should not occur in cells at a considerable extent. When pUC18 was incubated with XXO and 
CuL3, a marked decrease in the % SC DNA was observed. This result indicates that CuL3 reacts 
with H2O2 by Fenton chemistry, and that this complex is devoid of catalasic activity. In the 
presence of CAT, the % SC DNA returned to ~85%, confirming the involvement of H2O2 in HO
• 
generation. 
In what concerns to CuL4 (Fig. 5.18B), no nucleasic activity was found. Although it is 
structurally related with CuL3, it presents a more distorted structure, which may difficult the 
interaction with nucleic acids [75]. CuL4, as observed with CuL3, has the ability to generate HO
•
 
in the presence of O2
•–
 and possess no CAT-like activity. The reversion of the effect in the 
presence of CAT confirms again the participation of H2O2 in the formation of HO
•
. Also, the 
capacity of CAT to inhibit the HO
•
 generation suggests that this reaction may not occur in cells 
with an efficient enzymatic antioxidant system. However, when the enzymatic defenses are 
depleted or the ROS level is increased (e.g. in cancer cells), the detoxification capacities of CAT 
and GPx enzymes can be overwhelmed. In these cases, the production of HO
•
 by CuL3 and 
CuL4 may constitute a strategy to potentiate cell death.  
 
5.3.5. Studies on CuL3 and CuL4 as potential anticancer agents 
Since CuL3 and CuL4 have both superoxide scavenging activity and the ability to 
generate HO
•
, their potential application in cancer therapy was studied. These studies were 
performed in MCF7 human breast carcinoma cells, since it was previously demonstrated that the 
overexpression of SOD in these cells suppressed their proliferation, being H2O2 the mediator of 
the effect [77]. The toxicity of CuL3 and CuL4 (up to 100 µM, 24 h) was evaluated using the 
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MTT assay. As presented in Fig. 5.19, these complexes were not cytotoxic in the range of 







Fig. 5.19 - Cell viability of MCF7 cells treated with different concentrations of CuL3 and CuL4, 
for 24 h, as evaluated by the MTT assay. Values (mean  SD) are percentages relative to non-
treated control cells. 
 
The ability of CuL3 and CuL4 to modulate the toxic effects of Dox was also studied. As 
shown in Fig. 5.20, Dox (50 nM -5 µM) reduced the viability of MCF7 cells in a dose-dependent 
way. The addition of CuL3 or CuL4 to Dox-treated cells did not significantly alter their viability.  
 
Fig. 5.20 - Effect of CuL3 and CuL4 on the cell viability of MCF7 cells treated with doxorubicin 
(Dox), as evaluated by the MTT assay.  Cells were incubated with increasing concentrations of 
Dox in the absence (darker bars) or presence of 100 µM of each complex, for 24 h. Values (mean 
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Different reasons can be proposed to explain the absence of toxicity of CuL3 and CuL4 
in MCF7 cells, as well as the lack of potentiation of Dox effects. One possibility is that the 
uptake of these macrocyclic copper(II) complexes by MCF7 cells may not be sufficient to reach 
an effective intracellular concentration. It is also possible that the catalytic rate of the reaction of 
the complexes with O2
•–
 may not be high enough to afford an extra SOD-like activity to the cell 
and, therefore, the O2
•–
/H2O2 balance will not be altered. Other hypothesis is that, although the 
complexes may be dismutating O2
•–
 into H2O2, the increase in H2O2 concentration is not 
sufficient to overwhelm the detoxification capacities of CAT and GPx enzymes. If cells can 
efficiently detoxify H2O2, no Fenton chemistry is likely to occur. Since Dox has different 
mechanisms of cytotoxity, including an important role at the DNA level [15, 16], it is also 
possible that an eventual increase in H2O2 and even in HO
•
, may not account considerably for the 
overall cytotoxicity of this drug. 
 
5.3.6. Conclusion 
In this Chapter, five macrocyclic copper(II) complexes were synthesized and 
characterized. Four of them exhibited SOD-like activity and, among those, CuL3 and CuL4 were 
selected for biological studies due to their higher thermodynamic stability. However, CuL4 did 
not show biological activity in the cellular models studied. In what concerns to CuL3, 
differential effects were observed according to the model. This complex exhibited pro-oxidant 
effects in XXO-treated V79 cells and slight antioxidant properties against TBHP, while it was 
ineffective in the studies performed with MCF7 cells. These results illustrate the dual nature of 
SODm compounds that may exert either antioxidant or pro-oxidant actions in cells [73]. The 
redox modulation of cellular pathways is therefore a complex issue and different models must be 
studied in order to find out the potential of a SODm for therapeutic purposes. 
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In this Chapter, four pyridine-containing aza-macrocyclic copper(II) complexes (CuL6-
CuL9) were prepared, varying in their ring size (14 to 16 atoms) and/or in the 
substituents. Studies were performed on their thermodynamic stability (potentiometric 
titrations), structural features (Vis spectroscopy and EPR), electrochemical properties 
(cyclic voltammetry), and superoxide scavenging activity (NBT and DHE assays). Two 
out of four complexes (CuL6 and CuL8) were effective superoxide scavengers, with 
IC50 values in the micromolar range. The cytotoxicity profile of the four complexes was 
studied by the MTT assay, in V79 cells, as well as in non-tumoral (MCF10A) and 
tumoral (MCF7) human mammary cells. All the complexes with the exception of CuL7 
were devoid of considerable toxic effects. The potential antioxidant of CuL8, the most 
promising complex, was studied in V79 cells exposed to XXO and TBHP. However, no 
protective effects were found in these models. Using the DNA strand break analysis, 
CuL8 was shown to generate hydroxyl radical. Hence, this complex was studied as a 
redox modulator of Dox and oxaliplatin effects in tumoral (MCF7) and non-tumoral 
(MCF10A) human mammary cells, by the MTT assay. The obtained results showed that 
CuL8 can indeed enhance the therapeutic index of Dox, and specially of oxaliplatin, in 
mammary cells, by both protecting normal cells and increasing the antitumoral effect in 
breast carcinoma cells. CuL8 is thus a promising compound to be further studied as a 









Metal complexes with macrocyclic ligands have been designed as chemical 
models of metalloenzymes [1, 2]. Among those, macrocyclic copper(II) complexes have 
been developed as mimics of SOD [3-6]. Aza-macrocyclic ligands received 
considerable attention during the last decade due to their relationship to biomimetic and 
catalytic systems, because many coordination compounds with aza-macrocycles are 
electrocatalytically active in redox reactions [1]. To be used as a redox drug, 
macrocyclic complexes with high kinetic and thermodynamic stabilities towards metal 
release are required. In the previous Chapter, five macrocyclic copper(II) complexes 
were synthesised and studied as O2
•–
 scavengers. In this Chapter, ligands containing a 
pyridine ring in the macrocyclic backbone were studied. The presence of coordination 
sites belonging to nitrogen heteroaromatic rings seems to be important for a SOD-like 
activity not affected by biological chelators [4]. In addition, it was also previously 
pointed out that the π-electrons in the pyridine ring may favourably respond to the 
Cu(II)-O2
•–
 interaction [5, 7]. Another advantage of macrocycles incorporating a 
pyridine is the faster kinetics of complex formation [8]. 
The N-functionalization of aza-macrocycles may enhance their metal-ion 
selectivity and the stability of metal complexes depending on the coordination 
properties of the pendant arms [1]. The attachment of coordinating groups to the donor 
atoms of the macrocycle may change the geometry of the complex and its redox 
properties [9]. Non-coordinating n-alkyl pendant arms may also participate in various 
equilibria and may have practical applications on the modulation of the hydrophobic 
properties, metal selectivity and redox properties [1, 10, 11]. 
In this Chapter, four water soluble pyridine-containing macrocyclic copper(II) 
complexes were synthesized and studied. Besides the studies on the antioxidant 
properties of the complexes, the compounds were assessed towards a possible 
application as chemotherapy adjuvants. 
As described in Chapter 1 (section 1.2.3), chemotherapy is a field in which the 
therapeutic redox modulation by SODm may have promising clinical applications. Most 
anticancer drugs exert their activity at least in part though the generation of ROS [12]. 
Also, many adverse effects of chemotherapy are related to oxidative stress [13-16]. 
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SODm may therefore be promising antioxidants for the protection of non-tumoral 
tissues from chemotherapy adverse effects. As mentioned in Chapter 1, ROS can exert 
different effects in cell proliferation, either promoting or reducing it, according to their 
nature and to their intracellular level [12]. Tumor cells are usually under higher 
oxidative stress than normal cells [12] and are nearly always low in SOD and catalase 
activities [17]. While in non-tumoral cells, the basal level of H2O2 is low and its 
increase is associated with cell proliferation, the intracellular level of H2O2 in tumor 
cells is close to the threshold of toxicity. In this case, a further increase in H2O2 
concentration will trigger cell death [18]. SODm compounds can increase the H2O2 
concentration as a result of O2
•– 
dismutation, and may thus reduce tumor growth or 
potentiate anticancer agents [12, 18, 19]. Furthermore, as mentioned in Chapters 1 and 
5, if a SODm can react with H2O2 generating hydroxyl radical, it can have an additional 
advantage in promoting cancer cells’ death. For this purpose, copper complexes are 
advantageous over manganese-containing SODm since they are prone to undergo 
Fenton chemistry. In view of this, one of the goals of this Chapter was to develop 
macrocyclic copper(II) complexes with SOD-like activity as chemotherapy adjuvants in 
breast cancer treatment. Breast cancer was chosen, since it has been reported that breast 
tumor tissue have higher levels of oxidative stress than normal breast tissue [20]. 
Furthermore, it was previously shown that MnSOD overexpression leads to a 
suppression in the proliferation of human breast carcinoma MCF-7 cells, being H2O2 the 
mediator of the effect [21]. Similar results were found for the overexpression of Cu,Zn-
SOD [22]. 
Two well established anticancer drugs were studied: Dox and oxaliplatin. The 
anticancer drug Dox is commonly used in a variety of tumors, and is an essential 
component of breast cancer treatment [23, 24]. The mechanisms of Dox cytotoxicity 
were previously described in Chapters 3 and 5, and include the interference in DNA 
synthesis and the generation of ROS, namely O2
•–
 [24-26]. As depicted in Fig. 5.1 
(Chapter 5), if a copper(II) complex with SOD-like activity is present, it can 
disproportionate O2
•–
 into H2O2. If this complex reacts with H2O2 to form HO
•
, this will 
further potentiate tumor cells’ death [27]. On the other hand, non-tumoral cells would 





























Fig. 6.1 – Potential activity of Cu(II) complexes with SOD-like activity as redox 
modulators of oxaliplatin cytotoxicity. (CuL = copper(II) complex; ROS = reactive 
oxygen species; CAT = catalase; GPx = glutathione peroxidase) 
 
Oxaliplatin (Fig. 6.1) is a platinum-based chemotherapy drug that forms mainly 
intra-strand links between two adjacent guanine residues or a guanine and an adenine, 
disrupting DNA replication [28]. Oxaliplatin is commonly used in combination with 5-
fluorouracil/leucovorin to treat advanced colorectal cancer, but recent reports have 
suggested the use of this drug in metastatic breast cancer. In fact, clinical trials have 
shown promising results for oxaliplatin in breast cancer, either in monotherapy [29] or 
in combination protocols [30-35], especially in anthracycline- and taxane-pretreated 
metastatic breast cancer patients. Although the mechanism of action of oxaliplatin is 
mostly at the DNA level, this drug can also increase oxidative stress. Kim et al [36] 
have shown an intracellular accumulation of ROS in human renal carcinoma cells 
treated with oxaliplatin, using the fluorescent probe 2’,7’-dichlorodihydrofluorescein 





 markedly increased in a dose-dependent way. Also, a small 
increase in H2O2 and a decrease in GSH were reported. An increase in O2
•–
 and H2O2 
was also described in normal leukocytes and in CT26 colon carcinoma cells upon 
treatment with oxaliplatin [19]. The involvement of O2
•–
 in oxaliplatin toxicity justifies 
the study of SODm as possible chemotherapy adjuvants. The rational basis underlying 
this hypothesis is analogous to that aforementioned for Dox, and is schematized in Fig. 
6.1. In fact, Laurent et al [12] have previously shown that in oxaliplatin-treated tumor 
cells, an increase in ROS production associated with a decrease in proliferation was 
observed upon addition of the catalytic antioxidants MnTBAP and CuDIPS. These 
authors also demonstrated that the DNA damage caused by oxaliplatin in vitro was 
increased by the H2O2 generated by the SODm [12]. Alexandre et al [19] have also 
reported a potentiation of oxaliplatin cytotoxicity by mangafodipir, MnTBAP and 
CuDIPS in colon carcinoma cells. Furthermore, the SODm mangafodipir protected 
normal leukocytes from the cytotoxicity of oxaliplatin, while CuDIPS and MnTBAP 




6.2. Materials and Methods 
 
6.2.1 Chemicals 
 The starting compounds used for the synthesis of the macrocycles were 
purchased from Aldrich. 2,6-Pyridinedicarbaldehyde was prepared by published 
methods [37]. All the commercially available chemicals were of reagent grade and used 
as supplied without further purification. Organic solvents were purified or dried by 
standard procedures [38]. PBS, xanthine, xanthine oxidase, NBT, caffeic acid, trypsin, 
DMEM, DMEM/Nutrient Mixture F-12 Ham (DMEM/F12), penicillin-streptomycin 
solution, foetal bovine serum, horse serum, insulin solution from bovine pancreas, 
hydrocortisone, cholera toxin, human epidermal growth factor, Dox, oxaliplatin, MTT, 
and Cu,Zn-SOD from human erythrocytes were obtained from Sigma-Aldrich. 
Copper(II) nitrate-trihydrate and DHE were purchased from Fluka. DMSO was obtained 
from Merck. Chelex 100 resin was acquired to Biorad. 
 
6.2.2. Synthesis of the macrocycles 
The macrocyclic ligands used for the preparation of the copper(II) complexes 


























L6 L7 L8 - n = 1
L9 - n = 2
n = 1, 2
160 
 
All the compounds were obtained in good yield and were characterized by 




C NMR spectroscopy. The NMR spectra were recorded on 
a Bruker Avance-400 spectrometer and were performed in CDCl3 or D2O. The reference 
used for the 
1
H NMR measurements in D2O was 3-(trimethylsilyl)propionic acid-d4-
sodium salt and in CDCl3 the solvent itself. For 
13
C NMR spectra 1,4-dioxane was used 
as internal reference. 
L6 was synthesized by previously reported procedures [37], using Cu(II) as the 
template metal ion (Fig. 6.2). Briefly, 3,3‘-diamino-N-methyldipropylamine was added 
to a solution of 2,6-pyridinedicarbaldehyde and copper nitrate (in a mixture of 
ethanol/water, 1:l v/v). The copper(II) diimine complex formed was reduced by sodium 
borohydride, and the copper was removed by precipitation of its sulfide [37]. Yield: 




H NMR (CDCl3): δ (ppm) 1.63 (m, 4H), 1.96 (s, 3H), 2.27 (t, 4H), 
2.44 (t, 4H), 3.14 (br s, 2H), 3.77 (s, 4H), 6.90 (d, 2H), 7.43 (t, lH). 
13
C NMR(CDC13): 


































Fig. 6.2 – Schematic representation of the synthesis of the ligand L6. 
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L7 as prepared from the parent amine 3,7,11,17-
tetraazabicycle[11,3,1]heptadeca-1(17),13,15-triene. This amine was obtained by a 
templated method similar to L6 but using 3,3’-diaminodipropylamine instead of 3,3‘-
diamino-N-methyldipropylamine [37]. This amine was then submitted to a condensation 
of the with ethyl bromoacetate under basic conditions [8]. The resulting ester was 
hydrolysed under acid conditions (Fig. 6.3). Then the solvent was evaporated and 
methanol added. The formed inorganic salts were filtered off and the filtrate passed 
through an anionic resin in the formate form [8]. Yield: 85%. Mp 249–251 ºC. 
1
H NMR 
(D2O, pD 5.0): δ (ppm) 2.38 (q, 4 H), 3.30 (t, 4 H), 3.45 (t, 4 H), 3.77 (s, 2 H), 3.80 (s, 4 
H), 4.64 (s, 4 H), 7.59 (d, 2 H), 7.80 (t, 1 Ht). 
13
C NMR (D2O, pD 5.0): δ (ppm) 18.00, 
48.71,  51.28, 56.20, 56.86, 57.63, 126.17, 140.25, 149.41, 169.40, 169.54. 
 
Fig. 6.3 – Schematic representation of the synthesis of the ligand L7. 

















































 L8 was synthesized by [1:1] condensation of 2,6-pyridinedicarboxaldehyde and 
N,N´-bis(2-aminoethyl)ethane-1,2-diamine (triethylenetetramine), using Pb
2+
 as the 
template ion, followed by the reduction of the resulting tetraimine with sodium 
borohydride (Fig. 6.4). The pure product was obtained as a salt by precipitation with 




H NMR (D2O, pD = 5.10):  (ppm) 
3.21 (s, 4 H), 3.41 (t, 4 H), 3.51 (t, 4 H), 4.57 (s, 4 H), 7.53 (d, 2 H), 7.99 (t, 1 H)  
13
C 
NMR (D2O, pD = 5.10):  (ppm) 43.92, 45.64, 46.33, 49.92, 124.07, 140.33, 150.94.  
 
 




























L8 -  n = 1
L9 -  n = 2
2+
+
n = 1, 2
n = 1, 2
n = 1, 2n = 1, 2
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 L9 was obtained by a procedure analogous to that for L8, replacing the N,N´-
bis(2-aminoethyl)ethane-1,2-diamine by N,N´-bis(2-aminoethyl)1,3-propanediamine 




H NMR (D2O, pD = 2.55):  (ppm) 
2.21 (q, 2 H), 3.37 (t, 4 H) 3.65 (t, 4 H), 3.71 (t, 4 H), 4.63 (s, 4 H), 7.56 (d, 2 H), 8.00 
(t, 1 H).
 13
C NMR (D2O, pD = 2.55):  (ppm) 21.30, 42.25, 43.20, 44.14, 51.35, 124.50, 
140.45, 150.68. 
 
6.2.3. Synthesis of the macrocyclic copper(II) complexes 
Aqueous macrocycles’ solutions were prepared at ~2.5  10
-3
 M, and their 
concentrations were determined by potentiometric titrations. Copper(II) complexes were 
prepared as described in Chapter 5 (5.2.2.2). 
The values of the stability constants of Cu(II) with the ligands L6 and L7 were 
previously determined from potentiometric titrations, performed at 25.0 ± 0.1°C and 
0.10 M ionic strength [8, 37]. For L8 and L9, the stability constants for Cu(II) were 
determined by potentiometric measurements, performed at 25.0 ± 0.1°C and with an 
ionic strength of 0.10  0.01 mol dm
-3
 with KNO3. For L7, L8 and L9, the ML species 
were completely formed right from the beginning of the titration and the concentration 
of the free copper(II) was too small to allow the determination of reliable values for the 
constants. Therefore, a competition technique using edta as the reference ligand [39] 
was performed. The constants values were calculated by fitting the potentiometric data 
obtained using the SUPERQUAD [40] or HYPERQUAD programs [41]. 
 
6.2.4. Species distribution curves  
 Species distribution diagrams were plotted from the calculated constants with the 
HYSS program [42]. These simulations, as well as the pCu values, were determined for 
the aqueous solutions containing Cu(II) (10 µM) and each ligand (L6-L9; 10.5 µM) at a 
molar ratio of 1:1, at physiological pH. This concentration was chosen because it is in 
same order of magnitude of the IC50 values of the active superoxide scavenging 
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complexes. Simulations of the species distribution in the presence of 0.01 M phosphate 
buffer were also performed, as described in Chapter 5 (5.2.2.2). 
 
6.2.5. Structural studies 
6.2.5.1 Spectroscopic studies 
Electronic spectra (visible range) were recorded with a UNICAM model UV-4 
spectrophotometer. The aqueous solutions of the Cu(II) complexes (1:1 ratio) were 




, at a pH value corresponding to total formation of the 
metal complex.  
EPR spectroscopy measurements were previously recorded for CuL6 (in DMF) 
[43] and for CuL7 (in a 1 mol dm
-3
 NaClO4 aqueous solution) [8], in a Bruker ESP 380 
spectrometer. The EPR spectra of CuL8 and CuL9 were recorded with a Bruker EMX 
300 spectrometer, equipped with a continuous-flow cryostat for liquid nitrogen, 
operating at X-band. These complexes were prepared in a 1 mol dm
-3
 NaClO4 aqueous 




 (pH 7.23). 
 
6.2.5.2. Electrochemistry 
Cyclic voltammetry experiments were performed for CuL8 and CuL9, according 












were prepared in 0.1 mol dm
-3
 KNO3 in water. The solutions were deaerated by an 
argon stream prior to all measurements, and were kept under argon during the 
measurements. Cyclic voltammograms with sweep rate ranging from 25 to 1000 mV s
-1
 




6.2.6. Superoxide scavenging activity 
As in Chapter 5, the superoxide scavenging activity of the complexes was 
determined by two different endpoints: the reduction of NBT and the oxidation of DHE, 
using the O2
•–
 generating system XXO.  
 
6.2.6.1 NBT assay 
The NBT assay was performed as described in Chapter 5 (5.2.3.1.). 
 
6.2.6.2 DHE assay  
The DHE assay was carried out according to the protocol described in Chapter 5 
(5.2.3.2.). For CuL7 and CuL8, since they revealed no activity using the NBT assay (see 
Results and Discussion section), only the highest concentration (80 µM) was tested. 
 
6.2.6.3. Xanthine oxidase inhibition assay 
We have evaluated if the generating system XXO could be inhibited by the 
copper(II) complexes by following the production of uric acid at 293 nm, as described 
in Chapter 5 (5.2.3.3).  
 
6.2.7. Cytotoxicity profile of the complexes 
6.2.7.1. Cell culture  
V79 and MCF7 cells were cultured as described in Chapter 3 (3.2.2) and Chapter 
5 (5.2.8.1), respectively. MCF10A cells were purchased from ATCC. These cells were 
cultured in DMEM/F12 medium, containing 5% horse serum, 1% antibiotic solution, 
0.01 mg/mL insulin, 0.5 µg/mL hydrocortisone, 100 ng/mL cholera toxin, and 20 ng/mL 
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human epidermal growth factor. Cells were kept at 37°C, under an atmosphere 
containing 5% CO2.  
 
6.2.7.2. MTT reduction assay 
The toxicity of macrocyclic copper(II) complexes was evaluated in the cell lines 
V79, MCF10A (non-tumoral human mammary cells) and in MCF7 (human breast 
cancer cells), using the MTT assay. For V79 and MCF7 cells, the assay was performed 
as described in Chapter 3 (3.2.3.1) and Chapter 5 (5.2.8.2), respectively. For MCF10A a 
protocol analogous to that of MCF7 cells was used, but the initial number of cells was 
~4  10
3
. The macrocyclic copper(II) complexes were tested at concentrations of 1, 10, 
50 and 100 M, for a  24 h incubation period. H2O2 and Dox were used as positive 
controls. At least two independent experiments were performed and four individual 
cultures were used for each complex concentration in each independent experiment.  
 
6.2.8. Evaluation of the potential protective effect of CuL8 against the oxidative injury 
induced by XXO and by TBHP 
From the results of the previous assays, CuL8 was selected to be further studied 
in cell-based experiments. The potential antioxidant activity of this complex was 
studied in V79 cells, by the MTT method, using XXO and TBHP as oxidative stress 
inducers. These assays were performed as described in Chapter 5 (5.2.6.1). Cells were 
treated with X (240 µM)/XO (20 U/L) or TBHP (100 µM), in the absence or presence 
of CuL8 (5, 25, 50, and 100 µM). Two to three independent experiments were 
performed and eight replicate cultures were used for each complex concentration in 






6.2.9. DNA strand break analysis 
The generation of HO
• 
radical by the copper(II) complex CuL8 was evaluated by 
the DNA strand break analysis, according to the procedure described in Chapter 5 
(5.2.7). 
 
6.2.10. Evaluation of the possible role of CuL8 on the modulation of the cytotoxicity of 
the anticancer drugs Dox and oxaliplatin 
The studies on the modulation of the cytotoxicity of Dox and oxaliplatin were also 
carried out in MCF7 and MCF10A cells using the MTT protocol described above. Cells 
were exposed to Dox (0.5, 1 and 5 M) or to oxaliplatin (20, 50 and 100 M) in the 
absence or presence of 100 M CuL8, for 24 h. Three to eight independent experiments 
were performed, each comprising four individual cultures. 
 
6.2.11. Statistical analysis 
The results obtained in points 6.2.8 and 6.2.10 were submitted to a statistical 
analysis as described in Chapter 3 (3.2.6). 
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6.3. Results and Discussion 
As mentioned in the Introduction section (6.1), macrocycles containing a 
pyridine ring form complexes with copper(II) that appear to have advantages as SODm 
compounds. Hence, in this Chapter, a set of four pyridine-containing macrocyclic 
copper(II) complexes was synthesised, characterised and evaluated in cell-based 
experiments. 
 
6.3.1. Chemical characterization and superoxide scavenging activity of the complexes 
The macrocyclic ring sizes (14 - 16 atoms) were chosen so that the ring could 
encircle the copper(II) ion, taking advantage of the thermodynamic macrocyclic effect 
and therefore, favouring the complex stability [10]. In fact, as shown in Table VI.1, the 
four macrocycles present very high stability constants for copper(II) (logKCuL > 20). The 
direct comparison of stability constants of ligands having different overall basicities can 
lead to erroneous conclusions, because the different competition of metals with the 
proton is not taken into account. To overcome this drawback, the pCu values, defined as 
-log [Cu
2+
], were calculated for all metal complexes at pH 7.4. All complexes presented 
high pCu values (Table VI.1). The data on the stability constants and pCu values clearly 
demonstrate the high thermodynamic stability of the complexes. This is a required 
feature to avoid the dissociation of the complexes in in vivo systems and, therefore, to 
prevent possible toxic effects and losses of activity.  
The simulation of the species distribution in aqueous solution has shown that, for 
the four ligands, the complexation with copper(II) is complete at pH 7.4 (data not 
shown). The study of the species distribution is of utmost importance in the evaluation 
of the SOD-like activity of copper(II) complexes because, since Cu(II) ion is known to 
be an efficient catalyst of superoxide, its presence would lead to misinterpretation of the 
results [44]. The species distribution was also calculated for phosphate buffer solutions 
of the complexes, to consider the possible competition between the phosphate species 
and the copper(II) complexes. The presence of phosphate did not alter the species in 
solution. In fact, at physiological pH, the copper in solution was 100% in the form of 




Table VI.1 – Stepwise stability constants (log K)
 a
 and pCu values for copper(II) 
complexes.  





 23.31(3) 20.86(4) 
[CuHL]/[CuL][H] - 3.67(3)
 c)
 2.31(4) 3.59(6) 
[CuL]/[CuLOH][H] - - 10.06(6) 11.83(7) 
pCu 
d)
 15.30 17.05 18.49 16.27 
a
 Values in parenthesis are standard deviations on the last significant figure. 
b)
 I = 0.10 M KNO3; T = 25.0 ºC [37] 
c)
 I = 0.10 M N(CH3)4NO3; T = 25.0 ºC [8] 
d) 
pCu values calculated for an aqueous solution containing Cu(II) (10 M) and each ligand 
(10.5 M) at pH 7.4. The protonation constants used for the calculations were previously 
reported for L6 and L7 [8, 37]. For L8 the used values (log units) were: K1
H





 = 5.33(2), and K4
H





 = 8.32(3), K3
H
 = 5.56(5), and K4
H
 = 2.37(8). 
 
 
Spectroscopic studies were performed in order to characterize the copper(II) 
environment in the complexes, due to the relevance of this information for the 
understanding of their SOD-like activities [45]. Spectroscopic visible data (λmax), as well 
as the hyperfine coupling constants Ai (i = x, y and z) and g values for the Cu(II) 
complexes obtained by the simulation of the spectra [46], are collected in Table VI.2. 
As mentioned in Chapter 5, EPR parameters may be related to the electronic transitions 
by the factors derived from the ligand field theory [47, 48]: the g values increase and the 
Az value decreases as the planar ligand field becomes weaker or as the axial ligand field 
becomes stronger and this occurs with the simultaneous red-shift of the d-d absorption 
bands in the electronic spectra. Hence, spectroscopic data provide information on the 
degree of distortion of the geometry of a complex. 
All copper(II) complexes exhibited broad bands in the visible region, due to the 
copper d-d transitions (Table VI.2). EPR determinations indicated three different g 
values, that are characteristic of mononuclear Cu(II) complexes in rhombic symmetry 
with elongation of the axial bonds and a d
x y2 2
 ground state. Elongated rhombic-
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octahedral, rhombic square-coplanar or distorted square pyramidal stereochemistries 
would be consistent with these data, but trigonal-bipyramidal or tetragonal geometries 
involving compression of axial bonds should be excluded [49-51]. 
 
Table VI.2 - Spectroscopic data for the Cu
2+
 complexes of L6-L9. 













; g||/A||  cm 
 
  gx gy  gz Ax Ay Az g||/A||
*
 
CuL6 [37] 550 (119) 2.039 2.080 2.201 4.9 14.7 195.9 112 
CuL7 [8] 645 (1560)         A                             2.050 2.066 2.243 2.2 17.6 192.1 117 
                      B                                         2.229 2.110 2.010 142.5 12.1 5.8 3466 
CuL8 610 (150) 2.035 2.070 2.210 26.9 40.0 170.6 130 
CuL9 646 (143) 2.038 2.077 2.222 23.2 33.5 163.8 136 
* Considering gz as g|| and Az as A||. 
 
The redox behaviour of CuL8 and CuL9 was investigated by cyclic 
voltammetry. Since under similar experimental conditions the free ligands revealed no 
electrochemical activity within the scanned potential window, the redox processes are 
assigned to the metal centers only. The electrochemical data obtained for the copper(II) 
complexes are shown in Table VI.3. The complexes exhibited analogous 
electrochemical behaviour showing a single quasi-reversible one-electron transfer 
reduction process at half wave potential values, E1/2, (vs. Ag/AgCl) of –711 mV (Epa-





 couple. Upon repetitive cycling the potential scan, the voltammetric response 
remained essentially unchanged. This feature indicates that the initial copper complexes 
are regenerated during the potential scan. This reversibility is important when a SOD-
like activity is sought, since it means that the complexes may be able to act as catalytic 
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antioxidants rather than stoichiometric scavengers. Despite the redox potentials of CuL8 
and CuL9 are not within the optimal range of values reported for SODm, other authors 
have referred that the redox potentials of the copper(II) complexes are not essentially 
associated with their SOD activities [3, 45]. Furthermore, other electroactive species are 
present in biological milieus, influencing the cellular redox processes. CuL9 yielded a 
E1/2 value that is shifted to less negative (easier reduction to Cu(I)) than the 
corresponding value observed for CuL8. This difference can be rationalized in terms of 
flexibility and the size of the coordination cavity in the complexes, and the geometric 
requirements and the size of the metal ion in different oxidation states. The reduction of 
Cu(II) to Cu(I) involves a drastic increase in the metal radius and a configuration 
change from square planar to tetrahedral. Obviously, the larger and more flexible 16-
membered coordination cavity in L9, compared with the 15-membered one in L8, tends 
to stabilize the copper(I) complex. 
 
Table VI.3 - Cyclic voltammetric data for the copper(II) complexes of L8 and L9
a
 
Complex Epc/mV Epa/mV Ep/mV E1/2/mV 
CuL8 -749 -673 76 -711 
CuL9 -649 -569 80 -609 
a
 Scan rate = 100 mV s
-1
. E1/2 values (vs. Ag/AgCl) were taken as the averages of the anodic 
peak potentials (Epa) and the cathodic peak potentials (Epc). Ep = pcpa EE  . 
 
The superoxide scavenging activity of the four macrocyclic copper(II) 
complexes was assessed using two different methods: the NBT reduction and the DHE 
oxidation. The results obtained in these assays are depicted in Fig. 6.5. The IC50 values 




Fig. 6.5 –Effect of the macrocyclic copper(II) complexes CuL6-CuL9 on the inhibition 
of NBT reduction (A) and DHE oxidation (B) by the XXO generated superoxide. 
 
 
Table VI.4 - Superoxide scavenging activity for the copper(II) 
compounds and native Cu,Zn-SOD. 
Compound 
IC50 (M) 
NBT assay DHE assay 
CuL6 38.07 13.46 
CuL7 N.D. N.D. 
CuL8 14.41 6.56 
CuL9 N.D. N.D. 
Cu(NO3)2 0.28 0.11 
Cu,Zn-SOD 0.017 0.001 
N.D., Not Determined 
 
 Two out of four complexes (CuL6 and CuL8) have shown an effective 
superoxide scavenging effect. In agreement to the results of Chapter 5, the IC50 values 
obtained using both assays were correlated, being the values found using the NBT assay 






































CuL6 CuL7 CuL8 CuL9A B
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Some copper(II) complexes of 14-membered pyridine-containing macrocycles 
were previously tested for the SOD-like activity by Autzen et al [3]. However, those 
compounds did not show remarkable activities. In this Chapter, other two 14-membered 
pyridine-containing macrocyclic copper(II) complexes were studied for their O2
•– 
scavenging activity. It has been reported that non-coordinating n-alkyl pendant arms 
may participate in various equilibria and may have practical applications on the 
modulation of the hydrophobic properties, metal selectivity and redox properties [1, 10, 
11]. Furthermore, the alkylation on secondary amino groups of a 14-membered tetraaza 
macrocyclic copper(II) complex was previously shown to made the reduction to Cu(I) 
easier [11]. The study of CuL6 aimed to test whether the N-methylation of Py[14]aneN4 
could enhance the activity of the correspondent copper(II) complex. CuL6 has indeed 
shown O2
•–
 scavenging activity, having an IC50 value in the micromolar range. 
However, when the production of uric acid by the XXO system was assayed in the 
presence of CuL6, an inhibitory effect was observed. In fact, CuL6 reduced the 
production of uric acid in about 30% at t = 180 sec, although at t = 290 sec there was 
not a statistically significant inhibitory effect. The moderate decrease in urate 
production by CuL6 was, however, far from being comparable to the exceedingly 
efficacy on the extent of the inhibition of NBT reduction seen in Fig. 6.5. CuL6 can thus 
be classified as a mild superoxide scavenger. The EPR data of this complex (Table 
VI.2) indicate a square-planar structure that does not favour SOD-like activity. Also the 
distortion factor (g||/A||) of CuL6 (112 cm) is far from the value reported for the active 
center of the native Cu,Zn-SOD (162 cm) [52], what can contribute to the mild O2
•–
 
scavenging activity exhibited by this complex. 
Another modification on the Py[14]aneN4 ligand studied in the present Chapter 
was the introduction of carboxymethyl groups in the N atoms. The N-functionalization 
of aza-macrocycles with coordinating groups may change the geometry of the complex 
and its redox properties [9]. In Chapter 5, the functionalization of CuL3 with 
CH2COOH pendant arms resulted in a complex (CuL4) more efficient in terms of 
superoxide scavenging activity (lower IC50 value). However, in this Chapter, no 
scavenging effect was detected for CuL7 neither using the NBT assay nor by the DHE 
method. The EPR spectrum of CuL7 presents two isomers for this complex. The data of 
the A isomer is consistent with elongated rhombic octahedral or distorted square-based 
pyramidal stereochemistries. The B isomer is typical of either trigonal-bipyramidal, 
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tetragonal or square pyramidal axially compressed stereochemistries. For both isomers, 
the empirical distortion factor g||/A|| is far from that reported for Cu,Zn-SOD. This 
structural difference may contribute to the absence of SOD-like activity of this complex. 
The geometry of CuL7 was previously proposed by Costa et al [53]. In this complex, 
Cu(II) is encapsulated by the macrocycle in a distorted octahedral environment and the 
four N atoms of the tetraaza ring define the equatorial plan. The six-coordination is 
completed with two oxygen atoms of the appended carboxymethyl arms, one adjacent to 
the pyridine ring and the other opposite to the pyridine moiety. The remaining 
carboxymethyl group is further away from the metal center. It is possible that the 
geometry of this complex does not provide the flexibility of the copper(II) arrangement 
that is required for the O2
•–
 dismutation reaction [7, 44]. Furthermore, the presence of 
three carboxymethyl arms may cause steric hindrance and electrostatic repulsion to the 
approach of superoxide anion.  
The complex of L8 with Mn(II) was previously studied by Riley et al [54] and 
has shown an effective SOD-like activity. However, the thermodynamic stability of the 
Cu(II) complex is much higher than that of the Mn(II) complex (log KMnL = 11.64 [54] 
vs log KCuL = 23.31). In the present work CuL8 has shown the highest O2
•–
 scavenging 
activity, presenting an IC50 value in the low micromolar range (Fig. 6.5, Table VI.4). By 
monitoring the production of uric acid, the possibility of inhibition of xanthine oxidase 
by CuL8 was excluded (data not shown). The EPR parameters of this complex (Table 
VI.2) are consistent with a distorted square pyramidal five-coordinated geometry, as 
also observed in the solid state by crystallography (data not shown). The slightly 
distorted structure of CuL8, along with its quasi-reversible redox behavior (Table VI.3) 
may justify the O2
•–
 scavenging activity observed. 
As described above, CuL8 and CuL9 are quite similar in terms of chemical 
properties. However, in a previous study performed by Kimura et al [5], no SOD-like 
activity was found for CuL9. In the present Chapter, the superoxide scavenging 
activities of CuL8 and CuL9 were evaluated under the same circumstances. In fact, no 
activity was found for CuL9 using the NBT assay (Fig. 6.5A). Using the DHE method, 
only a slight effect (< 40% of inhibition) was observed for CuL9 at 80 M (Fig. 6.5B). 
The redox behaviour of CuL9, as well as the proposed complex geometry, is close to 
that of CuL8. Since the difference of the two complexes remains in the extra methylenic 
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group in the backbone of L9, it seems possible that this group causes steric hindrance, 
blocking the access of superoxide anion to the Cu(II) center. 
 
6.3.2. Cytotoxicity profile of the complexes 
The cytotoxicity pattern of the four macrocycles was studied using the MTT 
assay, in three different cell lines. One of them was the V79 cell line, which was also 
used in the previous Chapters and is widely used in cytotoxicity evaluations. The MCF7 
cells, described in Chapter 5, were used as a breast cancer cell line. The MCF 10A cell 
line (human breast epithelial cells) was used as a model of non-tumoral mammary cells. 
The complexes were evaluated in concentrations from 1 to 100 μM, which are in the 









Fig. 6.6 – Cell viability of V79 cells treated with different concentrations of the 
complexes CuL6-CuL9, as evaluated by the MTT assay. Values (mean ± SD) are 


































Fig. 6.7 – Cell viability of MCF10A cells treated with different concentrations of the 
complexes CuL6-CuL9, as evaluated by the MTT assay. Values (mean ± SD) are 









Fig. 6.8 – Cell viability of MCF7 cells treated with different concentrations of the 
complexes CuL6-CuL9, as evaluated by the MTT assay. Values (mean ± SD) are 
percentages relative to non-treated control cells (100%). 
 
As can be seen in Fig. 6.6, the complexes CuL6, CuL8 and CuL9 did not show 
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notorious toxic effects, decreasing the % MTT reduction to ~35% of that of control cells 
at a concentration of 100 µM. In MCF10A and MCF7 cells (Fig. 6.7 and 6.8), the four 
complexes exhibited only slight decreases in cell survival (up to 10% loss of viability). 
The differences observed for CuL7 may be ascribed to a different sensitivity between 
V79 fibroblasts and mammary cells. Differences in the cellular uptake of this complex 
may also be involved, since V79 cells were previously reported to have endocytic 
activity [55]. Based on these results, toxicity does not seem to be a limiting factor of the 
biological use of the macrocyclic complexes CuL6, CuL8 and CuL9. 
 
6.3.3. Studies on CuL8 as a potential antioxidant 
From the aforementioned studies, CuL8 was selected to be further evaluated in 
cell-based experiments. This complex gathers a number of properties that a SODm 
should present: water solubility, thermodynamic stability (even in the acid region), 
quasi-reversible redox behavior, an effective SOD-like activity with low IC50, and the 
absence of considerable cytotoxicity. The antioxidant properties of CuL8 were therefore 
evaluated in the models XXO and TBHP, validated in Chapter 3. The obtained results 
are depicted in Fig. 6.9. 
As depicted in Fig. 6.9A, when V79 cells were exposed to the O2
•–
 generator 
XXO, a significant decrease in cell survival was observed (P < 0.05). The addition of 
CuL8 (up to 100 M) did not considerably alter the viability of XXO-exposed cells. The 
exposure of V79 cells to the short chain hydroperoxide TBHP (100 µM) also resulted in 
a considerable decrease in cell viability (Fig. 6.9B). CuL8 did not afford protection to 
TBHP-treated cells. On the contrary, a slight and not statistically significant pro-oxidant 
effect was observed in V79 cells simultaneously exposed to TBHP and to the highest 
concentrations of CuL8 (Fig. 6.9B). Although CuL8 is an efficient O2
•–
 scavenger in 
vitro, it did not protect cells exposed to the oxidants XXO and TBHP. The lack of 
antioxidant activity in these cell-based experiments may be ascribed to a possible 
insufficient intracellular concentration of the complex or to an inadequate catalytic rate 






Fig. 6.9 - Effect of CuL8 on the cytotoxicity induced by xanthine (240 M) plus 
xanthine oxidase (20 U/L) (A) or by TBHP (100 M) (B), in V79 cells. Cells were 
incubated with increasing concentrations of the complex in the presence of the oxidants 
for 24 h, and then submitted to the MTT assay. 
 
6.3.4. Studies on CuL8 as a potential anticancer agent 
As mentioned in the Introduction section, SODm may be useful in 
chemotherapy, either protecting non-tumoral tissues from the oxidative damage induced 
by anticancer agents, or potentiating its toxic effects in tumoral cells. In this later case, 
the increase in intracellular H2O2 seems to be a critical factor [12, 18]. If the complex 
reacts with H2O2 originating HO
•
, this could be advantageous to induce cancer cells’ 
death [12, 27]. In view of this, the possibility of hydroxyl radical generation by CuL8 
was evaluated using the DNA strand break analysis. This assay was validated using a 
set of controls as shown in Chapter 5 (Fig. 5.17). The results obtained for CuL8 are 
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Fig. 6.10 – Evaluation of HO
•
 generation by CuL8, by the DNA strand break analysis. 
(A) Representative lanes of one electrophoretic separation showing the cleavages of 
pUC18. (B) Percentages (mean ± SD) of DNA in the supercoiled form. Two 
independent experiments were performed, each comprising three lanes per sample. 
(XXO, xanthine-xanthine oxidase; CAT, catalase). 
 
As can be seen in Fig. 6.10, CuL8 per se does not attack DNA. Although some 
copper(II) complexes have chemical nuclease activity [56], this is not the case of CuL8. 
However, in the presence of superoxide anion generated by XXO, CuL8 led to a 
considerable decrease in the supercoiled DNA and an increase in the relaxed circular 
form (Fig. 6.10). This data show that CuL8 is devoid of catalase-like activity. 
Moreover, CuL8 reacts with H2O2 to generate hydroxyl radical, which attacks DNA. 
The reversion of the DNA cleavage in the presence of CAT confirms that H2O2 is an 
intermediate in the process. In addition, this reversion suggests that, in the cellular 
environment, the production of HO
• 
by CuL8 could be relevant only if the cellular 
antioxidant defences are not enough to degrade the intermediate H2O2. This could be an 
important approach to induce selective cell death between cancer and normal cells, 
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To have some insight on the potential application of CuL8 in chemotherapy, 
studies were performed in human mammary cell lines MCF7 and MCF10A, which 
represent respectively tumor and non-tumor cells. These cell lines vary in their inherent 
antioxidant defences. Weydert et al [22] have reported that MCF-7 cells have lower 
total SOD and MnSOD activities than MCF10A. Catalase activities are similar between 
the two cell lines, but MCF10A contains higher activity of GPx. In terms of total 
antioxidant capacity, MCF-7 cells present a much lower level than MCF-10A cells [20]. 
This pair of cell lines provides thus a useful model to anticipate the effects of CuL8 in 
tumoral and non-tumoral breast tissue. The effects of CuL8 on the modulation of Dox-
induced toxicity were therefore evaluated in MCF10A and MCF7 cells, and the results 
are shown in Fig. 6.11. 
 
Fig. 6.11 – Effect of CuL8 on the cell viability of human mammary cells treated with 
doxorubicin (Dox), as evaluated by the MTT assay.  Cells were incubated with 
increasing concentrations of Dox in the absence (solid line) or presence (dashed line) of 
100 µM CuL8. (A) Non-tumoral MCF10A cells. (B) Breast carcinoma MCF7 cells. (* P 
< 0.05, when compared with Dox-treated cells without CuL8). 
 
As depicted in Fig. 6.11A, the addition of CuL8 to Dox-treated MCF10A cells 
resulted in a small increase in cell viability. This protective effect was statistically 
significant (P < 0.05) for the concentration of 0.5 µM of Dox, in which the presence of 
CuL8 led to an increase in cell viability of ~14%. On the other hand, CuL8 potentiated 











































treated with CuL8 and Dox were consistently lower than those exhibited by cells treated 
only with Dox, although these differences were not statistically significant. 
Since CuL8 has shown a trend to protect non-tumoral breast cells form Dox-
toxicity, while it slightly potentiated the anticancer drug in tumoral cells, a second 
cytotoxic drug was studied. The platinum-based drug oxaliplatin was chosen, since this 
drug was previously shown to increase intracellular ROS, namely superoxide anion [12, 
19]. The effects of CuL8 on the modulation of oxaliplatin were also evaluated in 
MCF10A and MCF7 cells, as shown in Fig. 6.12. 
 
Fig. 6.12 – Effect of CuL8 on the cell viability of human mammary cells treated with 
oxaliplatin, as evaluated by the MTT assay.  Cells were incubated with increasing 
concentrations of oxaliplatin in the absence (solid line) or presence (dashed line) of 100 
µM CuL8. (A) Non-tumoral MCF10A cells. (B) Breast carcinoma MCF7 cells. (* P < 
0.05, when compared with oxaliplatin-treated cells without CuL8). 
 
 
In non-tumoral MCF10A cells, CuL8 reduced the cytotoxicity of oxaliplatin 
(Fig. 6.12A). A protective effect was observed for all concentrations of oxaliplatin 
tested and was statistically significant (P<0.05) at 20 and 50 µM. A maximum 
protection was observed for 50 µM of oxaliplatin, where the co-treatment with CuL8 
increased the absolute cell viability in ~18%. On the other hand, in MCF7 tumor cells 
the incubation of oxaliplatin with 100 µM CuL8 resulted in a considerable potentiation 
of the cytotoxicity of the drug (Fig. 6.12B). This effect was consistent in the three 













































(P<0.05). At these concentrations, decreases in absolute cell viability of 14% and 18%, 
respectively, were found in the presence of CuL8. 
The opposite effects of CuL8 in normal and cancer cells are probably related to 
the differences in basal concentration of ROS and in antioxidant defenses. In MCF10A 
cells, CuL8 presented protective effects against Dox and oxaliplatin. Although different 
mechanisms may be involved in this protection, the results suggest that O2
•–
 production 
is involved in the cytotoxicity induced by the drugs. CuL8 may be dismutating O2
•–
 and 
the generated H2O2 should be efficiently degraded by cellular CAT and peroxidases. 
Since the threshold of toxicity is reached more easily in cancer cells than in non-tumoral 
cells, a further increase in H2O2 due to a combined treatment with O2
•–
-generating drugs 
and CuL8 can induce differential effects in MCF10A and MCF7 cells. While H2O2 
seems to be efficiently degraded in MCF10A cells, it can accumulate in MCF7 cells. 
The subsequent reaction of H2O2 with CuL8 via Fenton reaction may be occurring, 
originating the highly toxic hydroxyl radical. This radical is known to attack cell 
biomolecules like DNA, proteins or lipids [57], promoting MCF7 cells’ death. 
 
6.3.5. Conclusion 
In the present Chapter four pyridine-containing macrocyclic copper(II) 
complexes were prepared and chemically characterized. These complexes were studied 
for their superoxide scavenging activity, as well as for their cytotoxicity profile. Among 
the four complexes, CuL8 was the most active as a superoxide scavenger. In the absence 





. Compounds showing SOD-like activity and Fenton-like reaction were 
previously proposed as a new class of anticancer drugs to induce selective cell death 
between cancer and normal cells [27]. Our results show that CuL8 can indeed enhance 
the therapeutic index of Dox and oxaliplatin in mammary cells, by both protecting 
normal cells and increasing its antitumoral effect in cancer cells. CuL8 is thus a 
promising compound to be further studied as a chemotherapy sensitizer. Moreover, it 
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Free radical toxicology is a multidisciplinary field that underwent a remarkable 
surge in interest during the past three decades, driven by the flood of new data 
associating ROS with the mechanisms of toxicity of several xenobiotics, as well as with 
an ever-expanding list of pathological processes. Superoxide anion is known to be 
implicated in tissue injury and different inflammation processes. By catalyzing the 
conversion of O2
•–
 to H2O2 and O2, SOD enzymes represent the first line of defense 
against the harmful effects of O2
•–
. Although preclinical and clinical studies have 
demonstrated a beneficial role for SOD in a variety of pathological conditions, the 
clinical use of the native enzyme has several drawbacks, as mentioned in Chapter 1. 
Synthetic SOD mimetics with drug-like properties have thus emerged as 
pharmaceutical candidates affording a new and promising approach to treat a variety of 
diseases in which superoxide plays a deleterious role. Moreover, these compounds are 
useful research tools to understand the mechanisms of action of toxic compounds, 
namely to establish whether oxidative stress is involved. A number of researchers and 
companies have been pursuing the development of compounds with SOD-like activity 
in recent years. The relevance of this emergent field is also revealed by the increasingly 
number of publications in the last few years. Complexes of transition metal ions, 
namely complexes of Mn(II), Mn(III), Cu(II) and Fe(III), have shown notable SODm 
activities. Among the metal containing SODm more extensively studied are manganese 
macrocyclic complexes (manganese(III) porphyrins and manganese(II) cyclic 
polyamines), manganese(III) salens, and copper(II) macrocyclic complexes. This thesis 
aims to contribute to the development of the SODm field, especially in two classes of 
macrocyclic complexes: the MnPs and the macrocyclic copper(II) complexes. 
The choice of studying MnPs was based on the fact that this class contains the 
most stable and active SODm developed so far. As described in Chapter 1, several 
studies have been performed on MnPs, showing remarkable protective effects in a 
variety of oxidative stress models. However, a thorough knowledge on the effects of 
MnPs at the cellular level is still lacking. Three MnPs were therefore studied in order to 
contribute to fill this gap. 
In this work, studies on antioxidant protection were performed using the systems 
XXO, TBHP and Dox as oxidative stress inducers. This strategic approach based on 
different types of oxidants was relevant because these systems vary in terms of the ROS 
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involved and in the site of formation of those species, being therefore somehow 
representative of different pathological and toxicological conditions. Increased levels of 
extracellular O2
•–
, along with a reduction in EC-SOD expression, have been reported in 
a variety of pathological conditions. An imbalance of extracellular O2
•–
/EC-SOD in the 
cerebral spinal fluid have been reported in traumatic brain injury, cognitive function 
impairment, and cellular injury following cerebral ischemia. Increased production of 
O2
•–
 and decreased EC-SOD activity in vascular spaces were found in atherosclerosis, 
hypertension, and myocardial infarct. Accumulation of O2
•–
 in the synovial fluid is 
implicated in inflammatory joint diseases. Also, a disequilibrium between O2
•–
 and EC-
SOD in pulmonary extracellular spaces seems to be involved in acute lung injury and 
bleomycin-induced pulmonary fibrosis. The clinical relevance of extracellular O2
•– 
justifies the choice of an extracellular O2
•– 
generator, such as the XXO system. The 
protective effects observed with MnTM-4-PyP against XXO-induced toxicity suggest 
that this MnP may have a therapeutic role in the aforementioned disorders. 
Many studies carried out in this thesis used TBHP as an oxidative stress model. 
This short chain analogue of lipid hydroperoxides is a convenient model of acute 
oxidative stress, which injuries cells by different mechanisms including lipid 
peroxidation, free radicals generation, and glutathione depletion. The protective effects 
of the three studied MnPs, and in a much lesser extent of CuL3, against this peroxide, 
suggest a potential role of these compounds in pathological conditions in which lipid 
peroxidation is involved. In fact, lipid peroxides have been increasingly shown to be 
associated with inflammation, being implicated in a variety of human diseases such as 
Alzheimer disease, chronic obstructive pulmonary disease, spongiform 
encephalopathies, thalassaemia, sickle-cell anemia, ageing, and carcinogenesis 
processes. Furthermore, lipid peroxidation is an important mechanism that contributes 
to the toxicity of a number of xenobiotics (e.g. carbon tetrachloride, aniline, asbestos 
fibres, gentamicin, and nickel). 
The anticancer drug Dox was used as a third oxidative stress inducer. The 
mechanisms of cytotoxicity of Dox are very complex and include, among others, 
hindering of DNA synthesis and ROS generation. Dox is a O2
•–
 generator and was 
chosen mainly due to its clinical relevance. In fact, Dox is commonly used to treat a 
variety of solid tumors and hematological malignancies. However, the occurrence of 
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severe cardiotoxic effects, which are mostly ascribed to oxidative stress phenomena, is a 
major limitation of the clinical use of Dox. 
V79 cells represent a well-established mammalian fibroblast cell line widely 
used in antioxidant research, as shown by the large number of studies published in the 
field that use this cell model. In the present work, V79 cells also showed to be a 
convenient model to assess antioxidant protection against XXO and TBHP. Although 
these cells can also be used to evaluate the role of SODm against Dox-induced damage, 
due to the cell specificity of Dox cardiotoxicity, cell type limitations can not be ruled 
out. In fact, the contribution of the different mechanisms of toxicity of Dox depends 
largely on the cell type and has not yet been completely established for V79 cells. 
Hence, it was not possible to identify whether the absence of considerable protection by 
MnTM-4-PyP is ascribed to an insufficient antioxidant activity of this MnP, or to the 
possibility that O2
•–
 generation is not the limiting mechanism for Dox toxicity in V79 
cells. To clarify this issue, and to better mimic the clinical pitfalls of Dox, future studies 
should be performed in cardiomyocytes. The role of oxidative damage inflicted by Dox 
in these cells is well recognized, what makes cardiomyocytes a more suitable model to 
evaluate the potential protective role of SODm against Dox-induced cardiotoxicity. 
The endpoints used in the studies of antioxidant protection were adequate to give 
more insights on the cellular effects of the MnPs. Two mechanistically different 
methods were used to evaluate cell viability. The assessment of the intracellular levels 
of O2
•–
 was useful to give information on whether the results were related to the O2
•–
 
scavenging activity of the compounds. In what concerns to the MI analysis,  
MnTM-4-PyP did not counteract the cell cycle arrest induced by the oxidants, indicating 
that the effects of this recognized SODm are not observed at the cell division level. 
Therefore, the MI analysis was not included in the subsequent Chapters of this thesis. 
The three MnPs were studied in TBHP-treated V79 cells. As expected, in the 
cell viability assays the ortho-substituted MnPs exhibited notorious protective effects 
with statistical significance at lower concentrations than MnTM-4-PyP. In cells treated 
with high concentrations of TBHP (1 and 2 mM), the ortho-substituted MnPs also 
revealed higher potency in decreasing the intracellular O2
•–
 levels than the para 
analogue. These differences may be ascribed to the higher antioxidant potency of the 
ortho-substituted MnPs. The two ortho analogues, MnTE-2-PyP and MnTnHex-2-PyP, 
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possess identical antioxidant potencies. Since MnTnHex-2-PyP is more lipophilic and 
hence more prone to enter the cell and the mitochondria, it was expected to be more 
efficient than the ethyl analogue at lower concentrations. However, the MnPs presented 
comparable protective effects in the cell viability assays, being MnTE-2-PyP slightly 
more effective. It is possible that, despite the higher lipophilicity of MnTnHex-2-PyP, 
both MnPs have been uptaken by V79 cells in a similar way due to the endocytic 
activity of these cells. Other hypothesis is that the protective effects occurred in 
extracellular millieu, plasma membrane or cytosolic space, rather than in mitochondria. 
Since thiol homeostasis determines critical aspects of cell function and response, 
the effects of the MnPs on the glutathione status were evaluated. The three MnPs have 
shown a remarkable capacity to abrogate the GSHt depletion in TBHP-treated cells, 
what can be very relevant in therapeutics. Glutathione deficiencies have been 
documented in many disorders, namely neurodegenerative conditions (e.g. Parkinson’s 
disease) and respiratory diseases (e.g. chronic obstructive pulmonary disease, idiopathic 
pulmonary fibrosis, acute respiratory distress syndrome, asthma). Moreover, glutathione 
plays a major role in the removal and detoxification of toxicants and carcinogens. The 
reasons underlying the notorious increase in GSHt in cells simultaneously exposed to 
TBHP and MnPs should be explored in futures studies. The observed increases may be 
related, at least partially, to an enhancement of the de novo GSH synthesis. To assess 
this hypothesis, studies on a possible stimulation of the expression and activity of  
γ-GCS, the rate-limiting enzyme in glutathione synthesis, should be performed. MnPs 
may also play a role in providing NADPH to the cell, assuring the function of 
glutathione reductase. This would explain the reduction of GSSG back to GSH and the 
prevention of GSSG release from the cell. The potential effect of MnPs on the activity 
of the enzymes that provide NADPH to the cell, as well as in the cellular pool of this 
cofactor, should also be evaluated. 
The results obtained in this thesis provide a better comprehension of the cellular 
effects of the MnPs. However, there is still very limited data on the protective effects of 
these compounds at the genome level. Previous studies have pointed out a possible 
application of ortho-substituted MnPs in cancer therapy, as radiation protectors. Our 
next step in terms of MnPs research will focus the role of MnTE-2-PyP and  
MnTnHex-2-PyP on the protection of human lymphocytes from radiation-induced 
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genotoxicity. These studies are already ongoing. Human lymphocytes from healthy 
donors have been submitted to low LET radiation (
60
Co-  rays), in the presence or 
absence of the MnPs under study, and genotoxicity is being evaluated using the 
Cytokinesis-Blocked Micronucleus assay. These studies will provide data on the 
usefulness of MnPs as radioprotectors, and will give additional information on the 
genotoxicity of the MnPs per se, which is an issue of utmost importance since these 
SODm have high therapeutical potential. 
The present thesis was also devoted to the development of macrocyclic 
copper(II) complexes. Most of the Cu(II) compounds developed so far are not 
thermodynamically stable or highly active in physiological conditions, and the use of 
macrocyclic ligands has been pointed out as a strategy to overcome these limitations. 
One of the aims of the research group in which this work is integrated has been the 
synthesis and chemical evaluation of macrocyclic compounds. Some of these presented 
thermodynamic and structural properties that could anticipate a possible SOD-like 
activity. As a result of this previous experience, a number of synthetic procedures were 
already optimized, allowing the synthesis of a battery of nine macrocycles within the 
course of this thesis. 
Copper(II) was chosen as the redox active metal ion, since an application of the 
compounds in cancer therapy was sought. Due to its capacity to undergo Fenton 
chemistry, copper has advantages over manganese in boosting anticancer drugs. 
Moreover, the macrocyclic ligands of this thesis are expected to form Mn(II) complexes 
with low thermodynamic stability. In fact, the stability constants of CuL6 and CuL8 for 
Mn(II) were previously reported and are relatively low. As the structures of these 
ligands do not present a considerable hindrance, the kinetic stability of the complexes is 
not expected to compensate the low thermodynamic stability. Conversely, the copper(II) 
complexes are thermodynamically stable, as shown by their stability constants and pCu 
values. 
MnPs and macrocyclic copper(II) complexes cannot be compared 
straightforwardly, since both the ligands and the metal center of the complexes exhibit 
very distinct chemical properties. However, pulling together the data on chemical 
properties and O2
•–
 scavenging activities of the nine macrocyclic copper(II) complexes 
studied, some conclusions may be drawn. In fact, although a number of macrocyclic 
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copper(II) complexes has been previously developed as SODm, few studies have tried 
to correlate the biological activity with electrochemical or spectroscopic data. 
Therefore, this thesis aimed to relate this activity with chemical properties, namely 
thermodynamic stability, structural features and redox potentials.  
The characterization of the thermodynamic stability of the complexes is an issue 
of utmost importance in SODm research. In complexes with low thermodynamic 
stability, the chelation with copper(II) may not be fulfilled at physiological pH, leading 
to erroneous conclusions in the evaluation of their SOD-like activity. Furthermore, the 
release of copper(II) in biological milieus would lead to a loss of activity of the complex 
and to cytotoxicity due to the indiscriminate redox chemistry by free copper(II). The 
size of the macrocyclic cavity deeply influences the thermodynamic stability of the 
complexes. Too small cavities may not properly accommodate copper(II). This was 
observed for CuL1 and CuL2, precluding the interest of these complexes as SODm 
compounds. The effect of the introduction of substituents in the macrocyclic backbone 
was evaluated. Macrocycles with carboxymethyl pendant arms (L2, L4 and L7) were 
studied, since these substituents provide a flexible arrangement of the donor atoms 
around the copper(II) ion. However, differential effects were observed in the SOD-like 
activity of the complexes. Steric hindrance was shown to have profound effects on O2
•–
 
scavenging activity. In fact, the absence of activity of CuL5, CuL7 and CuL9 could be, 
at least partially, attributed to geometries with steric hindrance that would block the 
access of O2
•–
 to the copper(II) center of the complexes. 
Taking into account the data on thermodynamic stability, O2
•–
 scavenging 
activity and cytotoxicity, CuL3, CuL4 and CuL8 were selected to be evaluated in cell-
based assays. The potential of these complexes as antioxidants was studied in the 
cellular models of oxidative stress validated for MnTM-4-PyP (XXO and TBHP). 
However, despite of the promising chemical and biochemical properties of the 
complexes, no relevant antioxidant effects were observed. One hypothesis that may 
contribute to explain this lack of antioxidant activity is that the intracellular 
concentration of the complexes may not be sufficient to afford an extra SOD activity to 
the cell. In addition, it is possible that the catalytic rate of reaction between the 
complexes and O2
•–
 is not high enough. If this is the case, O2
•–
 will react with biological 
targets instead of being dismutated by the complexes, and oxidative damage still occurs. 
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Nevertheless, before excluding a potential role for these complexes as antioxidants, they 
should be evaluated in other oxidative stress models. 
The potential role of CuL3, CuL4 and CuL8 in chemotherapy was also 
evaluated. The three complexes were shown to undergo Fenton chemistry, what can be 
an advantage to promote cancer cells’ death. The studies on the potential effect of the 
complexes as potential chemotherapy sensitizers were performed in breast cell lines, 
since it has been reported that breast cancer tissue has higher levels of oxidative stress 
than normal breast tissue. Furthermore, the overexpression of MnSOD, as well as of 
Cu,Zn-SOD, was previously shown to suppress the proliferation of breast carcinoma 
cells. Human mammary MCF7 and MCF10A cell lines, that represent respectively 
tumor and non-tumor cells, vary in their inherent oxidative stress levels and antioxidant 
defences, being therefore appropriate models to mimic the in vivo situation.  
CuL3 and CuL4 were not toxic to MCF7 carcinoma cells, and failed to 
potentiate the cytotoxicity of Dox. This lack of activity can be related to the intracellular 
concentration of the complexes or to their catalytic rate, as aforementioned. Other 
hypothesis is that, although the complexes may be dismutating O2
•–
 into H2O2, the 
increase in H2O2 concentration is not high enough to overwhelm the detoxification 
capacities of CAT and GPx enzymes. If this is the case, the H2O2 concentration will not 
significantly increase and the threshold of toxicity will not be achieved. Furthermore, if 
cells can efficiently detoxify H2O2, no Fenton chemistry is likely to occur. 
CuL8 has shown a trend to potentiate Dox cytotoxicity in MCF7 cancer cells, 
while it exhibited some protection in Dox-treated MCF10A cells. Due to these 
interesting results, oxaliplatin, other anticancer drug known to generate O2
•–
, was 
studied. Again, CuL8 boosted the anticancer properties of oxaliplatin, while it protected 
non-tumoral cells from the toxicity of this drug. The differential effect of CuL8 in 
normal and cancer cells is probably related to the differences in the basal ROS and 
antioxidant defenses of the two cell lines. Chemotherapy regimens commonly use high 
doses to achieve a substantial reduction in the number of tumor cells, what leads to 
considerable side effects. Novel strategies to allow an effective treatment without the 
side effects of high-dose chemotherapy are thus needed. One such strategy is the 
potentiation of chemotherapy with well tolerated agents that are capable of lowering the 
threshold for chemotherapy-induced cell death in cancer cells. The results obtained for 
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CuL8 suggest a potential role of this complex as a chemotherapy sensitizer for breast 
cancer. By improving the efficacy of a given anticancer drug, CuL8 could eventually 
allow a reduction of its doses and, therefore, a decrease in the occurrence of side effects. 
Furthermore, the sensitization of cancer cells by CuL8 can be an advantageous strategy 
to overcome drug resistance. On the other hand, CuL8 exhibited protective effects in 
non-tumoral mammary epithelial MCF10A cells, what may be a benefit in the reduction 
of chemotherapy side effects. These notable results highlight the therapeutic 
opportunities of copper(II) complexes with SOD-like activity in oncology and support 
the future evaluation of CuL8 and related compounds in cell-based protocols and/or in 
animal experiments, towards an application as chemotherapy sensitizers. Chemotherapy 
will certainly be an area of future research in the SODm field. The rational design of 
novel compounds for this purpose, targeting specific organs and cellular compartments, 
is a pertinent issue. In addition, it is crucial to better understand the mechanisms 
underlying anticancer effects, namely in what concerns to the redox modulation of 
transcription factors that may be involved. 
The understanding the molecular mechanisms related with the effects of SODm 
is a challenging issue not only in chemotherapy, but also in the broad variety of diseases 
in which SODm may have clinical applications. One emergent field in oxidative stress 
research is the unraveling of the signal transduction mechanisms used by O2
•–
 and other 
ROS to modify key components of the inflammatory response. This will undoubtedly 
elucidate on molecular targets that may be modulated by SODm, being crucial to 
propose and clarify pharmacological interventions using these compounds. 
Other area of major interest in SODm research is the rational drug design of 
optimized SODm compounds. In the case of the copper(II) complexes studied in this 
thesis, a number of chemical modifications could be endeavored in order to increase the 
O2
•–
 scavenging activity of the complexes. These would include changes in the 
macrocyclic backbone and/or in the substituents to obtain copper(II) complexes with 
more suitable geometries and redox potentials. In addition, the functionalization of the 
compounds with positively charged pendant arms would provide electrostatic 
facilitation to guide the negatively charged O2
•–
 to the metal center of the complex. 
Along with the catalytic activity, also the pharmacokinetic properties of the complexes 
could be improved. The compounds prepared in this thesis are water soluble, which is 
200 
 
advantageous in terms of biopharmaceutical attributes. However, an increase in 
lipophilicity would enhance cellular uptake, and therefore the biological effectiveness of 
the complexes. Other interesting strategy that could be tested in future studies is the 
attachment of lipophilic groups (e.g. triphenylphosphonium cation) to obtain 
mitochondria-targeted copper(II) complexes. For the generality of the SODm under 
development, the optimization of structures tailored to meet the needs of a particular 
disease would be a plus. By adapting a promising core catalyst structure and/or varying 
functional substituents, it is possible to design a SODm targeting a specific organ or 
subcellular compartment. This strategy will provide compounds with minimal toxicity 
and maximal efficacy, more appropriate for pharmaceutical applications. 
In summary, the broad array of pathological conditions that are, at least partially, 
related to oxidative stress has drawn increasing attention to the therapeutic use of 
antioxidants. Among those, metal macrocyclic complexes with SOD-like activity bring 
promising perspectives that have not been fully explored yet. The original findings 
presented herein add important data to the global scenario of the SODm field. Although 
many questions were raised and dealt along this thesis, additional issues remain 
unsolved. Even so, SODm compounds have already proven their high therapeutical 
potential and future research in this field will certainly push it fast towards their clinical 
use. 
